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Stellingen 
behorende bij het proefschrift "Prognostic microarray studies in 
ovarian cancer: toward patient-tailored therapy" 
1. Overexpressie van de tumorsuppressor p53 of de epidermale groeifactor­
receptoren EGFR en HER2 in de tumor leidt tot een kortere overleving van 
patienten met een ovariumcarcinoom. (Dit proefschrift) 
2. Afwezigheid van de tumorsuppressor PTEN in de tumor leidt tot een langere 
progressievrije overleving van patienten met een ovariumcarcinoom. 
(Dit proefschrift) 
3. Factoranalyse is een efficiente methode om microarraydata te analyseren. 
(Dit proefschrift) 
4. Verschillende microarraystudies in ovariumcarcinomen tonen dezelfde ont­
regelde prognostische intracellulaire routes, hetgeen wijst op de relevantie 
van deze routes. (Dit proefschrift) 
5. De combinatie van CA-125 en IL-7 serumspiegels discrimineert beter tussen 
benigne en maligne ovariumtumoren dan de CA-125 serumspiegel alleen. 
(Dit proefschrift) 
6. Met behulp van een 86-genexpressieprofiel van primaire stadium Ill/IV se­
reuze ovariumcarcinomen is het mogelijk patienten met een slechte en een 
relatief goede overleving te onderscheiden. (Dit proefschrift) 
7. Kwaliteit van leven gescoord door kankerpatienten is een betere voorspeller 
van hun overleving dan de performance status gemeten door artsen. 
(J Clin Oneal 2008;26:1355-1363) 
8. mTOR inhibitie gestart voor aanvang van gefractioneerde radiotherapie ver­
hoogt de radiosensitiviteit van solide tumoren in preklinische modellen. 
(Clin Cancer Res 2008;14:892-900) 
9. Verhoogde fysieke activiteit verlaagt het risico op kanker. (Nature Rev Cancer 
2008;8:205-211) 
10. Met geluk is het net hetzelfde als met gezondheid; als je er niets van merkt, 
betekent dit dat het er is. (lwan Toergenjew) 
11. Een database is de minst efficiente medewerker. 
12. Voor meta-analyses geldt: "rubbish in, rubbish out". 
Anne Crijns, april 2008 
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Introduction ---
nostic value of the tumor suppressor protein p53, detoxification protein glutathione 
S-transferase pi (GST-pi) and the growth factor receptors EGFR (HER-1) and HER-2 for 
ovarian cancer are contradictive. In chapter 2 meta-analyses of prognostic studies on 
these molecular markers are described. Furthermore, the methodological differences 
of the prognostic studies are reviewed. 
Prognostic molecular markers may be good candidates for targeted therapy. In 
chapter 3 an overview of the current status of molecular targeting research in ovar­
ian cancer is presented. Currently, several drugs targeted at key components of 
apoptotic, prosurvival and angiogenesis pathways are in various stages of clinical 
implementation. 
Until recently it was only possible to investigate single pathway components instead 
of complete pathways at one time. However, endeavors such as the Human Genome 
Project and technical advances in molecular biology now allow for the comprehen­
sive screening of tumors at the genetic, genomic and proteomic levels 5. 
In chapters 2 and 3 DNA microarray studies in ovarian cancer are summarized. Par­
ticularly, the challenges of performing prognostic microarray studies are discussed. 
There are several ways of identifying prognostic and/or predictive profiles for patients 
with advanced stage ovarian cancer. In chapter 4 the prognostic value of a number 
of molecular components of prosurvival pathways in ovarian cancer was investigated. 
lmmunohistochemical staining of epidermal growth factor receptor 1 (EGFR/HER-1 ), 
phosphorylated EGFR (pEGFR) , EGFR variant 3 (EGFRvlll, lacks exons 2-7), epidermal 
growth factor receptor 2 (HER-2), tumor suppressor gene PTEN (phosphatase and 
tensin homolog deleted on chromosome 10), oncogene AKT, phosphorylated AKT 
(pAKT ) and phosphorylated MAP kinase ERK (pERK) was performed on 232 primary 
ovarian tumors using the tissue microarray technique and related to clinicopathologic 
characteristics and survival. In addition, the expression of EGFRvlll was determined in 
45 ovarian cancers by reverse transcription-polymerase chain reaction (RT-PCR). 
There are many statistical methods that can be used to analyze microarray data. In 
chapters, factor analysis was applied to the microarray data. Factor analysis is a meth­
od that can be used to make biological contrasts that underlie the many microarray 
data visible by representing the data in a reduced set of factors. Disadvantages of fac­
tor analysis are that biological contrasts do not necessarily coincide with single factors 
and that the biological factors are difficult to recognize. 
We therefore hypothesized that when the microarray hybridization design would 
contain contrasts, biological contrasts would be reflected by single factors that would 
be easy identifiable (as the correlation structure of the factors with the arrays would 
10 
reflect the design). This hypothesis was tested in a study exploring drug-resistance 
markers that might be used to select which patients will benefit from chemotherapy. 
Factor analysis was applied to microarray data obtained by profiling an ovarian cancer 
cell line model for cisplatin-resistance using -18K cDNA microarrays according to a 
hybridization design including "SelfSelf" hybridizations, dye swaps and independent 
replications. 
Three amino-acid loop extension (TALE) homeobox proteins MEIS and PBX are cofac­
tors for HOX proteins, which control growth and differentiation during embryogene­
sis and homeostasis. We showed that MEIS1, MEIS2 and PBX3 expression are related to 
chemoresistance in an ovarian cancer cell line model for cisplatin-resistance (chapter 
5). In addition, the MEIS1 gene has been shown to be amplified and overexpressed 
in ovarian cancers compared to normal ovarian surface epithelium and is part of an 
ovary-specific gene expression profile distinguishing primary lung, colon and ovar­
ian adenocarcinomas 6-8. As protein expression data of the HOX cofactors in ovarian 
cancer are lacking, the aim of the study described in chapter 6 was to investigate 
MEIS1, MEIS2 and PBX protein expression in ovarian cancers of 232 patients arranged 
onto a tissue microarray. Of 44 patients there was also a post-chemotherapy sample 
available on the tissue microarray. The protein expression levels of MEIS1 and 2 and 
PBX were furthermore investigated in the surface epithelium of 15 normal ovaries. 
MEIS and/or PBX expression levels in primary cancers were related to clinicopatho­
logic characteristics and patient survival. Additionally, to compare MEIS and PBX RNA 
expression between normal ovarian surface epithelium and various other normal tis­
sues and between ovarian cancer and various other tumor types, public array data 
sets were studied. 
In chapter 7 it was tried to identify molecular markers underlying acquired plati­
num-resistance in ovarian cancer and to assess the association of pathways and tran­
scription factors with acquired chemoresistance. Tumor samples obtained shortly 
following chemotherapy may well be enriched in resistant cells and/or clones and 
are likely to display the molecular signature associated with acquired chemoresist­
ance. To avoid noise caused by distinct genetic backgrounds of individual patients 
10 paired ovarian cancer samples, obtained before and maximally 6 weeks after 3 or 
6 cycles of first-line platinum-based chemotherapy, were profiled using -35K 70-mer 
oligonucleotide microarrays (-35,000 probes). Paired t-test (p<o.001) was applied to 
identify differentially expressed genes. Furthermore, a functional class scoring analysis 
















In chapter 8 the cytokine bead array was used for the identification of serum cytokine 
levels suitable as diagnostic or prognostic markers in ovarian cancer. Simultaneous­
ly 14 cytokines [interleukin 10 (IL-10), IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-15, granulocyte 
colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor 
(GM-CSF), eotaxin, monocyte chemotactic protein-1 (MCP-1), macrophage inflamma­
tory protein-10 (MIP-10) and IP-10] were analyzed in prospectively collected sera of 
187 ovarian cancer patients with complete clinicopathologic data and follow-up, 45 
patients with benign serous ovarian tumors and 50 healthy controls. Serum levels of 
the well-known tumor marker CA-125 were also routinely measured in all patients. 
The last approach, carried out in chapter 9, to develop a prognostic predictor was to 
profile 157 advanced stage serous ovarian cancers using -35K 70-mer oligonucleotide 
microarrays. A continuous predictor of overall survival was built taking into account 
well-known issues in microarray analysis, such as multiple testing and overfitting. Ad­
ditionally, the association of pathways and transcription factors with overall survival 
was assessed using a functional class scoring analysis. The survival predictor was vali­
dated on a completely independent, publicly available data set of 118 well-defined 
primary serous ovarian cancers 9• Furthermore, the functional class scoring analysis 
was also done on this independent data set and results were compared. 
Finally, the findings in this thesis are summarized and future perspectives are dis­
cussed in chapter 10. 
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Prognostic factors: current evidence and future prospects ---
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I n  ovarian cancer trans lationa l  research on the prog nostic im pact of molecular biolog ical fac­
tors has unti l  now not led to c l inical imp lementation of any of these factors. This is partly due 
to the often confl icting resu lts of d ifferent prognostic factor stud ies on the same molecu lar  
biolog ica l factor. 
Methods 
We have performed meta-ana lyses on stud ies in ovarian cancer on four putative prognos­
tic molecu lar  biolog ica l factors, epiderma l g rowth factor receptor (EGFR), HER-2, g lutathione 
S-transferase pi (GST-pi) and p53. Odds ratios were estimated for i ncrease in death at 1 and s 
years for patients with ovarian cancer, ha rboring aberrant EGFR, HER-2, GST-pi and p53, respec­
tively. 
Results 
Patients with aberrant HER-2 or p53 in their tumors had sign ificantly worse odds of surviving 
1 and s years, respectively. Patients with a berrant EGFR in  their tumors only had a s ign ificantly 
greater risk of morta l ity at s years, whi le there seemed to be a trend for a decreased probabi l ity 
of s-year surviva l for patients with aberrant GST-pi in their tumors. 
Conclusion 
Despite inevitable flaws (such as sma l l  ind ividua l  study sizes, pub l ication bias, etc.) our meta­
ana lys is confirms, that therapeutic d rugs targeted at EGFR, H ER-2, GST-pi and p53 may have 
therapeutic potentia l .  Since ovarian cancer is a relative ly rare d i sease, international col labora­
tion to increase the number of patients to be ana lyzed is critical for progress in trans lational 
research on the prog nostic impact of molecu lar  biologica l factors and on innovative treatment 
in ovarian cancer. I n  addition, it is important to reach consensus about gu idel ines for the de­
sign, conduct and ana lysis of trans lational  stud ies in  ovarian cancer. 
Introduction 
Ovarian cancer is the leading cause of death from gynecologic cancers and the fifth 
most common cause of cancer death in women after lung, breast, colorectal and pan­
creas cancer. It is estimated that 25,400 new ovarian cancer cases will be diagnosed in 
the United States in the year 2003 and that an estimated 14,300 deaths from ovarian can­
cer will occur 1• This high death rate is related to the difficulty of detecting ovarian cancer 
at an early stage as well as the lack of effective therapies for advanced disease. 
Current clinical decision making in ovarian cancer is based on so-called "classic" clin­
icopathologic prognostic factors, such as stage (according to the International Fed­
eration of Gynecology and Obstetrics (FIGO)), differentiation grade and histiotype. 
Critical questions for the clinicians who treat patients with ovarian cancer are (in part) 
different in early stage patients when compared to late stage patients. In early stage 
patients, it is particularly important: first, to identify those patients who will recur after 
macroscopically complete resection of disease, and second, to identify those patients 
with a high chance of recurrence who will benefit from adjuvant chemotherapy 2• In 
late stage ovarian cancer it would be extremely helpful to be able to predict which 
patients would respond to chemotherapy and ideally which type of chemotherapy 
should be given 3• Based on current "classic" clinicopathologic prognostic factors, it is, 
however, not possible to answer these questions. 
Ovarian cancer, like all cancers, is thought to result from an accumulation of genetic 
changes. Ultimately, when the genetic changes that underlie ovarian carcinogenesis 
are better understood, it should be possible to classify early and late stage ovarian 
cancer patients in a more specific way than currently possible. Based on this "mo­
lecular biological" classification, it should also become possible to treat patients more 
efficiently and in a more individualized manner. 
In breast cancer several cell biological prognostic markers have already been identi­
fied and their assessment in combination with therapeutic consequences has been 
implemented in daily clinical practice. For example it has been clearly demonstrated 
that expression of estrogen receptors is required for optimal responses to hormonal 
therapy and, more recently, that breast cancers that overexpress the epidermal growth 
factor receptor (EGFR) type 2 (HER-2) are less sensitive to chemotherapy regimens lack­
ing anthracyclines 4. Trastuzumab, a monoclonal antibody targeting HER-2, potentiates 
the antitumor effect of chemotherapy in patients with metastatic breast cancer 5• 
In ovarian cancer translational research on the prognostic impact of molecular bio­
logical factors has until now not led to clinical implementation of any of these fac­
tors. Among other reasons this is due to the often inconsistent or even contradictory 
results of different prognostic factor studies in ovarian cancer on the same molecular 














Prognostic factors: current evidence and future prospects ---
on studies in ovarian cancer on four putative prognostic molecular biological factors, 
namely EGFR, HER-2, glutathione S-transferase pi (GST-pi) and p53. These four markers 
were selected because of the high numbers of studies that have been performed on 
each of them, their possible role in response to chemotherapy and the availability 
of clinical intervention studies that targeted their expression in tumors from ovarian 
cancer patients. Our aim was to identify the methodological differences between the 
different prognostic studies and to produce a more precise estimate of the prognostic 
significance of these factors. In addition, we will also summarize available studies in 
ovarian cancer that applied the currently rapidly emerging DNA microarray technol­
ogy to identify gene expression profiles that may predict prognosis. Finally, we discuss 
why translational research in ovarian cancer has not yet made any difference on clini­
cal decision making and how future translational research on the prognostic impact 
of molecular biological factors could be performed. 
�eta-analyses 
Search for prognostic studies 
A PubMed search for studies investigating the prognostic significance of EGFR, HER-2, 
GST-pi, and p53 in ovarian cancer was performed listing one of the search terms "EGFR'; 
"HER-2'; "GST-pi'; or "p53" in combination with one or more of the key words "ovary'; 
"ovarian cancer'; "ovarian carcinoma'; "ovarian neoplasm'; "prognosis'; "prognostic fac­
tor'; "survival'; or "response to chemotherapy''. The references of all publications were 
hand-searched in order to identify missing relevant publications. 
�ethodological variability and inclusion criteria 
Performing meta-analyses of prognostic factor studies in ovarian cancer is rather prob­
lematic. There is considerable variability between prognostic studies with respect to 
type of study design, patient inclusion criteria, assays or methods used to determine 
the status of the specific factor, determinations of factor cut-off points, and defini­
tion of study end points for survival and response to chemotherapy. Furthermore, 
frequently no quantitative information beyond a P-value or even just "not significant" 
is provided. Therefore, the minimum criteria for studies to be included in our meta­
analyses were: presence of a clear definition of positivity or negativity of the specific 
factor; availability of quantitative information on overall survival rates at 1 and/or s 
years (reported, or depicted in a graph) in relation to the status of the specific factor. In 
the subgroup of studies in which both mutation analysis as well as expression analysis 
of the specific factor was performed, only data as determined by mutation analysis 
were used, unless more data as determined by expression analysis were available. 
18 
Where a single study had been reported on multiple occasions, only the most recent 
report or the report with most complete data was included in the analysis. 
Statistics 
The power of heterogeneity tests is relatively low. Because the number of studies in­
cluded was limited and the studies overall showed heterogeneity regarding the effect 
estimates, we show the results of the meta-analyses using random effects models. 
Random effects (DerSimonian-Laird) meta-analysis computes the odds ratios of the 
individual studies, the summary, the random effects variance, and heterogeneity. 
Woolf's formula was used for the calculations of the within variance. Studies with zero 
or infinite odds ratio were omitted, as their variance cannot be calculated sensibly. 
The"plot"method that is presented in the figures shows standard meta-analysis plots. 
The 95% confidence interval for each study is given by a horizontal line, and the point 
estimate is given by a square whose height is inversely proportional to the standard 
error of the estimate. The summary odds ratio is drawn as a diamond with horizon­
tal limits at the confidence limits and width inversely proportional to its standard er­
ror. Odds ratios lower than 1 indicate a decreased risk to survive for patients affected 
by ovarian tumors with aberrant EGFR, HER-2, GST-pi or p53 (e.g. an increased risk of 
death) . Meta-analyses were performed using the Rmeta package of the R Project for 
Statistical Computing (Build1.7.o) . 
Results 
The class I family of receptor tyrosine kinases 
The class I family of receptor tyrosine kinases consists of four closely related receptors 
that use kinase activity as the signal transduction trigger: EGFR  (ErbB-1), HER-2 (ErbB-2), 
HER-3 (ErbB-3), and HER-4 (ErbB-4) .These receptors modulate signaling pathways which 
control cell proliferation and differentiation 6• It further has been shown by studies in 
human ovarian cancer cell lines that EGFR and HER-2 overexpression may play a role 
in sensitivity to chemotherapy. In two ovarian cancer cell lines it was demonstrated 
that blockage of EGFR expression by an antibody resulted in an enhanced response 
to platinum-compounds 7-9• However, in one of those cell lines, short exposure to EGF 
also led to an increased response to cisplatin 10•11 • In addition, the effect of reversal of 
HER-2 overexpression in the ovarian cancer cell line SKOV-3 on sensitivity to paclitaxel, 
doxorubicin and cisplatin has been studied. The data regarding sensitivity to paclitaxel 
are conflicting; one study reported an increased and one a decreased sensitivity of 
the SKOV-3 cells to paclitaxel upon reversal of HER-2 overexpression. The sensitivity of 
the ovarian cancer cells to doxorubicin and cisplatin was not altered 12•13• However, it 
was shown in vivo that an anti-HER-2 antibody enhanced the cytotoxicity of cisplatin 
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against the SKOV-3 cell line14. In another ovarian cancer cell line it was also found that 
exposure to an anti-HER-2 antibody increased in vitro sensitivity to cisplatin 15• 
tpidermal growth factor receptor (t«ifR) 
Nineteen studies were identified that investigated whether EGFR status of ovarian 
cancers was related with prognosis (see Table 1 ) .  EGFR status was determined by three 
different methods: a radioligand-binding assay, immunohistochemistry and reverse 
transcription-polymerase chain reaction. EGFR positivity was detected in 12-82% of 
the ovarian cancers. EGFR positivity of ovarian tumors was associated in one study 
with a better and in 8 studies with worse overall survival. In 6 studies no relation be­
tween EGFR positivity of ovarian tumors and overal l  survival was found. 
Thirteen studies were included in the meta-analysis 16-28• The meta-analysis demon­
strated a decrease in survival at 1 and 5 years for patients with EGFR positive ovarian 
tumors with respective summary odds ratios of 0.94 (95% Cl: 0.58-1.51, not significant) 
and 0.38 (0.24-0.59, significant) (see Figures 1 and 2). The x2 with df=10 for survival at 1 
and 5 years was 15.65 (p=o.1101) and 21.08 (p=o.0206), respectively. 
Several agents that block the activation of the EGFR have been developed, including 
small-molecule tyrosine kinase inhibitors (TKls), such as ZD1839 ("lressa") and OSl-774. 
ZD1839 has been evaluated in three phase I trials, including 33 ovarian cancer patients. 
Of these 33 patients, three patients had stable disease during treatment with ZD1839 29• 
A phase II trial of OSl-774 in 34 patients with heavily pretreated ovarian cancer showed 
three patients with partial responses, while 42% of the patients had stable disease 30•31 •  
No data are as yet available on a possible relation between response to OSl-774 and 
EGFR expression levels in the individual tumors. 
ntR-2 (trbB-2) 
Twenty-five studies were identified that evaluated the prognostic value of the HER-2 
status of ovarian cancers (see Table 2). Most studies used immunohistochemistry to 
determine the HER-2 status of the ovarian tumors. HER-2 overexpression and/or am­
plification was observed in 5-66% of ovarian cancers. Nineteen studies were eligible 
for the meta-analysis 19•21•22•2732-46• The meta-analysis showed that ovarian cancer pa­
tients with HER-2 positive tumors had a worse probability of survival at 1 and 5 years 
with respective significant summary odds ratios of 0.52 (0.36-0.76) and 0.61 (0,4-0.92) 
(see Figures 3 and 4). The x2 for survival at 1 and 5 years was 30.6 (p=o.0151) and 25,07 
(p=o.0226), respectively. 
HER-2 overexpression can be inhibited in ovarian cancer cells by repressing the HER-2 
promoter via the adenovirus type 5 E1A gene, which encodes a well-known transcrip­
tion factor. In in vitro and in animal studies this inhibition appeared to abolish the tu­
morigenicity and metastatic capability induced by the HER-2 oncogene. In a phase I 
clinical trial it has been demonstrated that cationic liposome-mediated E1A gene trans-
20 
Table 1 
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so, 1/11/111/IV 82 
78 
40, 1/11/111/IV 40 
80, 1/I1/11I/IV 12 
117, 1/11/111/IV 54 
so, 1/11/111/IV so 
266, 1/11/111/IV 13 
62, I/I1/11I/IV 73 
35, 1/11/111/IV 60 













mAb 2E9 (frozen); 
mAb EGF-R1 
(frozen) 
IHC, mAb 6080-1 
(paraffin) 
















UA, better OS 
(p=o.0004-0.011) 
UA, no relation 
with OS in stage 
I l l/IV 
UA, worse OS 
(p<o.os) 
UA, worse PFS 
(p=o.ooos); MA, 
(p=o.ooos) 
UA, no relation 
with PFS (p>o.3) 
UA, no relation 
with OS (p=o.559) 
MA, worse OS 
(p=o.03) 
UA, worse OS 
(p=o.0022) and PFS 
(p=o.0033); MA, 
(p=o.014), (p=o.03) 
UA, no relation 
with OS (p=o.31) 
UA, no relation 
with OS 
UA, worse OS 
(p=o.007); MA, 
(p=o.1) 
UA, worse OS and 
PFS 
UA, worse OS 





UA, better response 
(p<o.01) 
UA, better response 
(p<o.01) 
UA, no relation 
(p=o.1) 
UA, no relation C 
C 
C 
UA, no relation 
C 
C UA, worse re-sponse in stage 
II-IV {p=o.031); MA, 
(p=o.052) C 
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Goff et a l  120 
Baekelandt 
et al 26 
Skirnisdottir 
et al  27 
Nagai et a l  28 
Ferrandina 
et al 121 
N, FIGO 
stage 
104, 1/11/11 I/IV 
54, I l l/IV 
185, I l l  
106, 1/11 
39, I/II/11I/IV 
















I HC, pAb4 




I HC, 31G7 UA, no relation 
(paraffin) (p=o.44) 
IHC, pAb UA, no relation UA, no relation 
(paraffin) with OS (p=o.0669) (p=o-458) 
IHC, mAb 





UA, no relation 
with OS (p=o.3559); 
125 I-EGF 
MA, (p=o.6840) 
IHC, mAb 108 
UA, no relation 
(paraffin) 
IHC, immunohistochemistry; mAb, monoclonal antibody; pAb, polyclonal antibody; RT-PCR, reverse tran-
scription-polymerase chain reaction; UA, univariate analysis; MA, multivariate analysis; OS, overall survival; 
PFS, progression free survival. 
fer in patients with HER-2 overexpressing breast and ovarian cancers was feasible 47• 
In addition, anti-HER-2 monoclonal antibodies (mAbs) have been designed to spe­
cifically antagonize the function of the HER-2 receptor in HER-2 positive tumors (e.g. 
trastuzumab). A phase II trial with single agent trastuzumab in patients with recur­
rent or refractory ovarian or primary peritoneal cancer with overexpression of HER-2 
showed a low frequency of HER-2 overexpression and low rate of objective response 
among patients with HER-2 overexpression 48• Currently, two trials are ongoing, using 
trastuzumab in combination with weekly paclitaxel and carboplatin, one in patients 
with newly diagnosed, advanced stage ovarian cancer, and the other in patients with 
platinum-sensitive recurrent epithelial ovarian cancer 49. 
(ilutathione ((i8n) / (ilutathione 8-transferase pi ((i8T-pi) 
Glutathione (GSH) is a non-protein thiol, which is most abundantly present in the cyto­
plasm 50. GSH synthesis depends on the formation of precursors by the enzyme gam­
ma-glutamyl transpeptidase (GGT), and the successive actions of cytosolic enzymes 
such as gamma-glutamylcysteine synthetase (GCS) and glutathione synthetase 51•52. 
22 
J a: 
volgens mij moeten de figuren nu goed zijn, maar wil je het ajb 
nog een keer nakijken? 
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Odds ratios and 95% confidence inter­
vals of survival at 1 year for patients 
with EGFR positive tumors. Individual 
odds ratios; squares whose height are 
inversely proportional to the standard 
error of the estimate, and their respec­
tive confidence intervals; horizontal 
lines. Summary odds ratio; diamond 
with horizontal limits at the confidence 
limits and width inversely related to its 
standard error. Odds ratios lower than 
1 indicate a decreased risk to survive for 
patients affected by EGFR positive ovar­
ian tumors. 
Figure 2 
Odds ratios and 95% confidence inter­
vals of survival at s years for patients 
with EGFR positive tumors (symbols as 
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Table 2 
Prognostic significance of HER-2 positivity in ovarian cancer 
Author N, FIGO 
(Ref. no.} stage 
Slamon 
et al 32 120 
Berchuck 73, I l l/IV 
et al 33 
Kacinski 72, 1/II/III/IV 
et al 34 
Scambia 
et al 35 
94, I l l/IV 
Rubin et al 36 105, I l l/IV 
Singleton 
56, I l l/IV 
et al 37 
Rubin et al is 40, 1/11 
Dam et al 19 
Makar 
et al 122 
Devitt et a I 21 
Meden 
et al :u 
Felip et al 39 
Fajac et al 40 
Zee van der 
et al 78 
80, 1/I1/III/IV 
74, I/I1/II I/IV 
61, I/II/11 1/IV 
266, 1/II/II1/IV 
106, 1/I1/111/IV 


























IHC, mAb TA1 UA, worse OS 
(frozen) (p<0.001) 
I HC, mAb-1 UA, no relation 
(paraffin) with OS or RFS 
IHC, mAb UA, no relation 
(paraffin) 
with OS (p=o.86) 
or PFS (p=o.63) 
IHC, mAb 9G6 UA, no relation 
(frozen) 
with OS; MA, 
(p=o.09) 
IHC, mAb-1 
UA, stainabil ity 
was not related (paraffin) 
with OS (p=o.37) 
IHC, mAb 9G6 UA, no relation 
(frozen) with OS or RFS 
IHC, mAb UA; MA, no 
NEU3 (frozen) relation with OS 
IHC, mAb NCL- UA, no relation 
CB11 (paraffin) with OS 
IHC, mAb 4D5 UA, worse OS 
(paraffin) (p<o.05) 




IHC, mAb CB11 
UA, worse OS in 
stage I l l/IV; MA, 
(paraffin) (p<o.001) 
Southern 




I HC, mAb CB11 UA, no relation 





UA, worse response 
(p<o.05) 
No relation 
UA, no relation 
UA, worse response 
(p=o.0043) 
No relation 




et al 123 
Medi et al 4' 
Tanner 
et al 41 
Goff et a I 120 
Beckmann 
et al 43 
Meden 
et al "" 
Ross et al 124 
Hengstler 
et al �5 
Seki et al 46 
Skirnisdottir 
et al 27 
Ferrandina 





























Technique response to 
with survival 
chemotherapy 
Differential UA, no relation 
PCR 
Quantitative UA, no relation 
PCR with OS (p=o.67) 
UA, no relation 
S1 nuclease 
with OS in stage 
I-IV (p=o.7), worse 
assay OS in stage I l l/IV 
(p=o.04) 
IHC, Ab-3 UA, no relation 
(paraffin) (p=o.19) 
FdPCR 
UA, worse OS and 
RFS (p<o.05) 
Significant dose-
IHC, mAb 9G6 UA, worse OS 
response effect in 
(paraffin) (p=o.0003) 




UA; MA, no 
relation with OS 
S1 nuclease 




Differential UA, no relation 
PCR with OS 
UA, no relation 
IHC, (paraffin) with OS 
(p=o.5872) 
IHC, mAb 
300G9 UA, no relation 
(paraffin) 
IHC, immunohistochemistry; mAb, monoclonal antibody; pAb, polyclonal antibody; PCR, polymerase chain 
reaction; FdPCR, fluorescent differential PCR; FISH, fluorescence in situ hybridization; UA, univariate analysis; 
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Odds ratios and 95% confidence intervals 
of survival at 1 year for patients with HER-2 
positive tumors (symbols as in Figure 1). 
Figure 4 
Odds ratios and 95% confidence intervals 
of survival at s years for patients with HER-
2 positive tumors (symbols as in Figure 1). 
GSH plays an important role in the cellular detoxification of various xenobiotics, such as 
platinum-drugs 50• GSH can bind cisplatin (or alkylating agents) in a glutathione-cispla­
tin chelate complex. This complex is eliminated from tumor cells by a cell membrane­
bound export pump, thereby preventing the formation of drug-DNA adducts 53•54• 
Apart from a direct binding of platinum-compounds to GSH, binding of platinum­
compounds to GSH may also occur by conjugation, mediated by gluthatione S-trans­
ferases (GSTs). Currently, five isozymes of GST have been identified; alpha, mu, pi, theta 
and zeta, of which GST-pi appears to be the predominant GST isozyme in ovarian can­
cers ss-ss_ However, in two different panels of ovarian cancer cell lines no association 
was found between GST levels and resistance to platinum-compounds 59•60. 
Twenty-one studies were identified which have analyzed the predictive value of GST­
pi in ovarian cancer with respect to survival and/or response to chemotherapy (see 
Table 3). With immunohistochemistry GST-pi was detected in 25-1000/o of ovarian can­
cers. Only eight studies could be included in our meta-analysis 61-68. The meta-analysis 
illustrated that patients with GST-pi positive tumors had an increase in mortality at 1 
and 5 years with respective summary odds ratios of o.s6 (0.24-1.31 , not significant) and 
0.57 (0.3-1 .07, not significant) (see Figures 5 and 6). The x,2 for survival at 1 and 5 years 
was 22.26 (p=o.0011 )  and 26.3 (p=o.0004), respectively. 
Cellular GSH can be depleted by buthionine sulfoximine, a selective inhibitor of y­
glutamylcysteine synthetase. Phase I and II clinical trials have been performed in ovar­
ian cancer with buthionine sulfoximine in conjunction with melphalan. Only results of 
the phase I study are available. A progressive decline of cellular GSH was found in pe­
ripheral mononuclear cells, while GSH was depleted in sequential tumor biopsies to a 
variable extent, but with a similar time course 69• In addition, a phase II clinical trial of 
TLK286, a GST-pi activated glutathione analog, has been performed in 21 patients with 
platinum-resistant ovarian cancer. Of the 15 patients that were evaluable for response 
to TLK286, 5 patients had stable disease and one patient had a partial response. No 
data are available on the GST-pi status of the ovarian tumors 70. 
p53 
p53 is a human tumor suppressor gene with in normal cells a key role in coordinat­
ing cell cycle arrest, DNA repair and apoptosis in response to DNA damage (caused 
by radiotherapy, DNA alkylating chemotherapy, or foreign DNA synthesis). In cancer 
cells the loss of wild-type p53 function (via different mechanisms such as mutation, 
protein degradation or sequestration) can lead to more aggressive tumor growth and 
worse response to chemotherapy. Fifty-three studies were identified that examined 
the prognostic impact of the p53 status in ovarian cancers (see Table 4) . p53 over­
expression was detected in 14-790/o of the ovarian cancers. Thirty-two studies were 
eligible for the meta-analysis 67•71-101 . The meta-analysis demonstrated that patients with 
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Table 3 




a l 56 
Zee van der 
et al 56 
Green et al 61 
Hamada et 
a l  62 
Zee van der 
et al 78 
Cheng et a l  125 
Hirazono 
et al 63 
Ghazal-Aswad 




et al 128 
Tanner et al 64 
Codegoni 
et al 129 
Ferrandina 




17, I l l  
86, I/II/II 1/IV 
61, 1/II/11I/IV 
89, 1/11/111/IV 





121, 1/II/II I/IV 





GST activity assay 
HPLC 
99 (38, +; 
53, ++; IHC, (paraffin) 
8, +++) 
54 IHC, (paraffin) 
89 IHC, pAb (paraffin) 
Western blot 
analysis 
57 IHC, pAb (paraffin) 
87 IHC, pAb (paraffin) 

















UA, no relation 
(p=o.653) 
UA, no relation 
UA, stainabi l ity was UA, stainabil ity is 
related with worse related with worse 
OS (p<o.01) response (p=o.003) 
UA, worse OS UA, worse response 
(p<o.005) (p<o.005) 
UA, no relation with UA, no relation 
OS or PFS 
UA, higher levels 
after chemotherapy 
are related with 
resistance (p<o.05) 
UA, worse OS 
(p<o.05-0.001) 
UA, no relation 
(p>o.05) 
UA, no relation (over-
expression is related 
UA, no relation with to worse response 
OS or PFS to combination 
chemotherapy 
(p=o.025)) 
UA, no relation 
(p=o.708) 
UA, no relation with 
OS (p=o.14) 
UA, no relation with UA, no relation 
OS (p=o.085) (p=o.276) 
UA, better OS UA, better response 
(p=o.043) and PFS 
in stage I I/I I 1/IV 
(p=o.037); MA, in (p=o.014); MA, stage I l l/IV (p=o.057), 
(p=o.013) 
(p=o.008) 
Table 3 continued 
Author 
(Ref. no.) 
Silvestrin i  
et a l  130 
Kase et al 131 
Joncourt 
et al 132 
Kigawa et al 133 
Musa et al 66 
Yokoyama 
et a l  13-4 
Mayr et a l  61 
Satoh et al 68 
N, FIGO 
stage 
168, I l l/IV 
87, 1/11/111/lV 
























IHC, pAb NCL-GST- chance of 3-year UA, no relation 
pi (paraffin) OS after cisplatin 
treatment 
IHC, mAb (paraffin) 
UA, worse response 
(p<o.01) 
GST-pi activity UA, no relation UA, no relation 
assay with OS 
IHC, mAb (paraf- UA, no relation with 
fin); Western blot response to second-
analysis line chemotherapy 
IHC, (paraffin) 
UA, worse OS 
(p=o.0337) 
UA, worse DFS 
UA, worse response 
IHC, pAb (paraffin) (p<o.os) (p<o.os); MA, 
(p=oms) 
UA, worse OS in 
UA, worse response 
IHC, pAb (paraffin) stage Ill (p<o.03); 
MA, (p=o.093) (p<o.027) 
UA, stainabil ity was 
IHC, mAb (paraffin) related with worse 
OS (p<o.01-0.os) 
IHC, immunohistochemistry; mAb, monoclonal antibody; pAb, polyc/onal antibody; HPLC, high performance 
liquid chromatography; VA, univariate analysis; MA, multivariate analysis; OS, overall survival; PFS, progres­
sion free survival; DFS, disease free survival. 
spective summary odds ratios of 0.61 (o.s-0.75, significant) and 0.39 (0.3-0.s, significant) 
(see Figures 7 and 8). The x,2 for survival at 1 and s years was 19.1 (p=o.832) and 51.33 
(p=o.0006), respectively. 
The adenovirus dl1520 (ONYX-015) has been attenuated by deletion of its E1B ss-kd 
gene region, the protein product of which is known to bind and inactivate p53 and 
thereby allows continued DNA synthesis and viral replication. Mutants such as dlis20 
lacking this early gene product are severely deficient in their ability to replicate in nor­
mal cells. Yet, ONYX-015 selectively replicates in and destroys cancer cells lacking p53 
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Odds ratios and 95% confidence 
intervals of survival at 1 year for pa­
tients with GST-pi positive tumors 
(symbols as in Figure 1). 
Figure 6 
Odds ratios and 95% confidence in­
tervals of survival at s years for pa­
tients with GST-pi positive tumors 
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Figure 1 
Odds ratios and 95% confidence intervals 
of survival at 1 year for patients with p53 
positive tumors (symbols as in Figure 1). 
Figure B 
Odds ratios and 95% confidence intervals 
of survival at s years for patients with p53 
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Table 4 
Prognostic significance of p53 positivity in ovarian cancer 
Author 
(Ref. no.) 
Marks et al 71 
Kohler et al 72 
Bosari et al 73 
Hartmann 
et a l  74 
Sheridan 
et al 135 
N iwa et al 75 
Niwa et a l  75 
Henriksen 
et al 76 
Renninson 
et al 136 
Levesque 
et a l  77 
Zee van der 
et a l  78 
Klemi et al 79 






107, 1/II/II1/IV so 
52, 1/11 29 
98, 1/I1/III/IV 45 
284, 1/I1/1 1 1/IV 62 
93, I/I1/III/IV 47 
31, 1/II/111/IV 42 
36 33 
ss, 1/I1/II 1/IV 44 
so, I/II/II1/IV 56 
90, 1/I1/II 1/IV 43 
89, 1/11/I11/IV 35 
136, 1/I I/I 1 1/IV 44 




IHC, mAb PAb1801 
UA, no relation 
(frozen) 
with OS in stage 
I l l/IV (p>o.2) 
IHC, mAb PAb1801 UA, no relation 
(paraffin) with OS or DFS 
IHC, mAb PAb1801 
UA, worse OS 
(paraffin) 
(p=o.0025) and DFS 
(p=o.0011) 
IHC, mAb PAb1801 UA, worse OS 
(paraffin) (p=o.04); MA, (NS) 
I HC, mAb D07 MA, no relation 
(paraffin) with OS (p=o.286) 
PCR-SSCP analysis + UA, no relation 
sequencing with OS (p>o.s) 
PCR-SSCP analysis + 
sequencing 
IHC, mAb PAb1801 UA, worse OS 
(frozen) (p=o.002) 
IHC, pAb CM1 
(paraffin) 
lmmunofluoro- UA, worse OS 
metric assay, mAb (p=o.06) and DFS 
PAb240 + pAb CM1 (p=o.03); MA, 
(frozen) (p=o.72), (p=o.63) 
IHC, pAb CM1 
UA, worse OS 
(paraffin) 
(p<o.0001) and PFS 
(p<o.001) 
IHC, mAb DAKO-p53 




I HC, mAb D07 
(paraffin); PCR-SSCP 






UA, no relation 
(p=o.23) 
UA, no relation 
(p>o-4) 
UA, no relation 
(p=o-33) 






Table 4 continued 
Author 
(Ref. no.) 
Allan et al 80 
Diebold et a l  81 
Reles et al 82 
Herod et al 138 
McMenamin 
et al 139 
Geisler et al ""' 
Viale et al 83 
Dong et al 84 
Rohlke et al 85 
Eltabbakh 
et al 86 
Buttitta et a l  141 
Goff et a l  120 



































IHC, mAb PAb240, 
mAb PAb1801 UA, no relation 
(frozen), pAb CM1 with OS (p=o.095) 
(paraffin) + PCR- or DFS (p=o.340); 
SSCP analysis + MA, (NS) 
sequencing 
UA, worse OS 
IHC, mAb D01 (p=o.0001); MA, in 
C (paraffin) stage 1/11 (p<o.005), in stage I l l/IV (p<o.0001) 
IHC, mAb Do1 UA, no relation C (paraffin) with OS (p=o.12) or DFS (p=o.26) 
IHC, mAb PAb1801 
UA, no relation 
UA, no relation C (paraffin) with OS (p=o45); (p=o.69) MA, (p=o.05) 
IHC, mAb Do7 UA, no relation 0 (paraffin) with OS 
IHC, mAb PAb1801 MA, worse OS 
0 (frozen) (p=o.044) UA, worse OS 
IHC, mAb PAb1801 
(paraffin) (p=o.0004); MA, 
UA, no relation 
0 (NS) 
IHC, mAb Do7 
UA, stainabil ity was UA, worse response 
(paraffin) 
related with worse 
(p<o.05) 0 OS (p=o.003) 
IHC, mAb 6 (paraf- UA, worse OS 
(p<o.025); MA, UA, no relation 0 fin) (p=o.023) 
IHC, mAb DAKO-p53 
UA, worse OS 
(p=o.049); MA, 0 (paraffin) (p=o.16) 
PCR-SSCP analysis + UA, worse PFS UA, worse response 
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et a l  130 
Skomedal 
et al 142 
Marx et al 87 
Smith-Sorensen 
et al 143 
Shimizu 
et al 144 
Ferrandina 
et al 88 
Anttila et al 89 
Wen et al 145 
N, FIGO 
stage 
168, I l l/IV 
347, I 
187, 1/II/III/IV 
45, 11/1 1 1  
5 1 ,  1/11 1/IV 
162, 1/I1/III/IV 
316, I/II/III/IV 
105, 1/I1/II 1/IV 
Daponte et al 146 19, I l l  
Shahin et al 90 171, 1/II/111/IV 
Schmider 
106, 1/I1/III/IV 






















IHC, mAb PAb1801 
UA, no relation 
UA, no relation 
with 3-year OS 
IHC, pAb CM1 




IHC, mAb D07 UA, worse OS 
UA, dose response 
(paraffin) (p=o.037); MA, (NS) 
effect in negative 
tumors (p=o.01) 
UA, better RFS in 
pacl itaxel/cisplatin 
Mutation analyses 




IHC, mAb (paraffin) 
MA, no relation 
with OS 
UA, no relation 
UA, related with 
IHC, mAb D07 
with OS or PFS in 
poor response 
(paraffin) (p=o.012); MA, 
stage I l l/IV 
(p=0.022) 
UA, worse OS 
IHC, pAb CM1 
(p<o.00005) and 




MA, worse RFS 
(p=o.013) 
UA, mutation and 
combination of 
IHC, mAb D07 
overexpression and 




with worse OS 
(p=o.049), (p=o.02); 
MA, (NS) 
IHC, mAb D07 + UA, worse OS 
PAb240 (paraffin) (p=o.029) 
UA, worse OS 
PCR-SSCP + se- (p=o.03); MA, mis-
quencing sense mutations 
(p=o.002) 
IHC, mAb D01 + IHC, no relation 
BP53-12-1 (paraffin) with OS (p=o-41) 
34 
Table 4 continued 
Author N, FIGO % p53 Correlation 
Correlation with 





IHC, mAb D07 
UA, worse OS 






PCR-SSCP + se- UA, no relation 
UA, no relation et a l  148 54 quencing with OS or DFS 
Geisler et a l  149 103, 1/11/II1/IV 68 
IHC, mAb PAb1801 MA, worse OS 
(frozen) (p=o.0032) 
UA, better response 
C PCR-SSCP analysis + to platinum/pacli-Lavarino et a l  150 48, I 1/1 1 1/IV 60 taxel-based therapy sequencing 
(p=o.0008); MA, 
(p=o.024) C I HC, mAb D07 UA, worse OS in Mayr et al 67 213, 1/II/III/IV 46 
(paraffin) 
stage Ill (p<o.01); UA, no relation 
MA, (p=o.012) C Gadducci 
38, I l l/IV 
IHC, mAb PAb1801 UA, no relation UA, no relation 
et al 92 63 (frozen) with OS (p=o.1271) (p=o.717-0.956) 
lmmunofluoro- UA, worse OS C Levesque metric Assay, mAb (p<o.01) and DFS UA, worse response 
et al 93 120, 1/II/111/IV so PAb240 + pAb CM1 (p=o.04); MA, (p=o.03) 
(frozen) (p=om), (p=o.os) C 
UA, worse OS Skirnisdottir 
et a l  94 706, 1/11 22 I HC, (paraffin) (p=o.046); MA, C (p=o.37) 
Howells et al 95 81, I/II/III/IV 42 
IHC, mAb D07 UA, no relation 
UA, no relation 
(paraffin) with OS (p=o-45) C UA, overexpression 
and combination 
IHC, mAb D01 of overexpression C Schuyer et al 151 102, 1/11/I11/IV 44 (frozen); PCR-SSCP + and mutation UA, no relation sequencing were related with 
worse OS (p=om), 
C (p=o.008); MA, (NS) 
UA, worse OS 
Reles et al 96 178, 1/II/I I 1/IV 57 PCR-SSCP analysis 
(p=o.015) and PFS 
UA, worse response C (p=o.029); MA, worse OS (p=o-49) 
Fallows et al 97 73, 1/I1/111/IV 44 
PCR-SSCP analysis + UA, no relation 
UA, no relation i!4  sequencing with OS or DFS 
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Table 4 continued 
Author 
(Ref. no.) 
Geisler et al 98 
Skirnisdottir 
et al 99 
Berker et al 100 
Sagarra et al 152 
Kupryjanczyk 
et al 153 
























IHC, mAb PAb1801 MA, worse OS 
(frozen) (p=o.015) 
UA, worse OS 
IHC, Ab (paraffin) (p=o.007); MA, 
(p=o.02) 
IHC, mAb PAb1801 UA, no relation 
(frozen) (p>o.05); MA, (NS) 
IHC, mAb D07 UA; MA, no relation 
(paraffin) with OS, DFS or PFS 
IHC, mAb PAb1801 UA, no relation UA, no relation 
(paraffin) with OS 




IHC, immunohistochemistry; mAb, monoclonal antibody; pAb, polyc/onal antibody; PCR-SSCP, polymer­
ase chain reaction-single strand conformational polymorphism; UA, univariate analysis; MA, multivariate 
analysis; NS, not significant; OS, overall survival; PFS, progression free survival; DFS, disease free survival; 
RFS, relapse free survival. 
therefore resistant to apoptosis, are permissive for replication, leading to virus spread 
and subsequent cytolysis of the cancer cell population 1 02•1 03• In a phase I trial no conclu­
sive proof of viral replication in p53 mutant cancer cells or clear-cut antitumor activity 
could be demonstrated. Before proceeding with studies of intra peritoneal ONYX-015 
in ovarian cancer, either as a single agent or in combination with chemotherapy, it 
will be important to provide evidence of either clear-cut clinical efficacy or at least a 
biological effect (e.g. cancer cell infection) 103• 
SCHsBsoo (rAD/p53) is a replication-deficient adenovirus encoding human, recom­
binant, wild-type p53. A phase 1/ 1 1  clinical trial of SCH58500 gene replacement alone 
and sequentially in combination with platinum-based chemotherapy in heavily pre­
treated recurrent ovarian cancer showed vector-specific transgenic expression in can­
cer by RT-PCR in cells from both ascitic fluid and tissue biopsies, while SCHsBsoo com­
bined with platinum-based chemotherapy was associated with a significant reduction 
of serum CA-125 104• In a subsequent study the long-term follow-up was evaluated of 
the patients who had been enrolled onto the phase 1/ 1 1 trial of SCH58500 gene transfer 
therapy and it appeared that the 12-13-month median survival compared favorably 
to the 16-month median survival for individuals treated with paclitaxel at the time of 
initial recurrence of this disease and is more than double the s-month survival seen 
with palliative radiotherapy or paclitaxel failure 105• Recently, a phase I l l  trial comparing 
carboplatin/paclitaxel against carboplatin/paclitaxel with SCHsBsoo ip. was closed 
prematurely for as yet unspecified reasons. 
�icroarray 
Recently established DNA microarray techniques allow for the simultaneous analysis of 
the expression profiles of thousands of genes in ovarian tumor samples. Technically it 
is now possible to analyze the expression of all known genes and expressed sequence 
tags (ESTs) as described by the Human Genome Project in one experiment 106• However, 
as Simon et al demonstrated, there are several possible pitfalls in the use of micro­
array data for prognostic classification. Experience is needed in the analytical steps 
required to convert tens of thousands of noisy data points into reliable and interpret­
able biological information. In their discussion Simon et al point out that microarray 
studies trying to identify gene expression profiles that will affect clinical decision mak­
ing should be performed with statistical rigor and be reported clearly and with unbi­
ased statistics 107• Until now there are only three studies in ovarian cancer available that 
examined the potential use of DNA microarrays to predict (treatment) outcome. Yet, 
studies using DNA microarrays that tried to identify the molecular determinants of the 
"classic" clinicopathologic factors (stage, grade and histiotype) in ovarian cancer have 
also been presented. The sample size of all of those studies is small, which severely 
affects the statistical reliability of the conclusions. Shridhar et al attempted to iden­
tify molecular differences between early and late stage ovarian carcinomas by cDNA 
microarray and found that the gene expression profiles were very similar 108• Jazaeri et al 
investigated patterns of gene expression in well (N=B) and poorly (N=4) differentiated 
serous papillary ovarian carcinomas and identified 99 genes whose expression was sig­
nificantly different. A disproportionate number of these differentially expressed genes 
were located on the chromosomal regions 20q13 and all exhibited higher expression 
in grade 3 tumors 109• Three studies used DNA microarrays for identifying gene expres­
sion patterns that may predict prognosis (e.g. survival or response to chemotherapy). 
Lancaster et al compared differences in gene expression profiles between short- (dead 
of disease within two years, N=10) and long-term (still alive after seven years, N=B) 
survivors and detected a pattern of gene expression (predictor) that correctly classi­
fied ovarian cancers into either the short- or long-term survival group in 83% (15/18) 
of cases. However, it should be mentioned that these data are still preliminary 110• Wei 
et al profiled methylation alterations of CpG islands in advanced stage ovarian tumors 
(N=19) to identify candidate markers for diagnosis and prognosis of the disease. A high­
er degree of CpG island methylation was associated with early disease recurrence after 
chemotherapy. Also a select group of CpG island loci was identified that may be used 
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gene expression profiles between chemotherapy-sensitive (N=2) and chemotherapy­
resistant (N=2) ovarian tumors and identified six genes that were overexpressed, and 
eight genes that were underexpressed in the chemotherapy-resistant tumors 112• 
Discussion 
During the course of our meta-analyses on studies aimed at determining the prog­
nostic value of EGFR, HER-2, GST-pi and p53, it became more and more clear that the 
methodological variability between the different prognostic studies is considerable. 
As illustrated in our review many of the prognostic studies are especially affected by 
small sample size, which may lead to either over- or underestimation of the relevance 
of the factors under investigation. Only by accepting more or less flexible study inclu­
sion criteria for the meta-analysis did it become possible to combine the results of the 
various prognostic studies regarding a specific factor. Apart from the methodological 
differences between the prognostic studies, another important factor affecting the re­
liability of our meta-analyses is the problem of publication bias. Negative (non-signifi­
cant) findings are seldom written up and much less published. However, despite these 
limitations, the results of the meta-analyses should represent a more precise estimate 
of the prognostic significance of EGFR, HER-2, GST-pi and p53, than the individual stud­
ies by themselves. As illustrated in our meta-analyses patients with aberrant HER-2 or 
p53 in their tumors had significantly worse odds of surviving 1 and s years, respectively. 
Patients with aberrant EGFR in their tumors only had a significantly greater risk of mor­
tality at s years, while there seemed to be only a trend for a decreased probability of 
s-year survival for patients with aberrant GST-pi in their tumors. Therapeutic agents 
targeting these molecular biological factors therefore may have therapeutic potential. 
To evaluate the possible clinical relevance of molecular biological factors, large studies 
examining clinically relevant patient groups are needed, especially when the preva­
lence of the molecular biological factor under investigation is relatively low. To illus­
trate what number of patients is needed for evaluation of the prognostic impact of 
whatever molecular biological factor, we have performed a Log Rank Survival Power 
Analysis (Simple) for early and late stage ovarian cancer separately to calculate the 
sample size needed for a study on the prognostic impact of mutant p53. It was as­
sumed that the prevalence of mutant p53 is approximately 50%, the s-year survival 
rate of early and late stage ovarian cancer is 70% and 20%, respectively, that a survival 
difference of 10% is clinically relevant, and no patients would be lost during follow-up. 
The statistical power achieved had to be 80% at a significance level of 5%. For a study 
on the prognostic impact of mutant p53 in early and late stage ovarian cancer an over­
all sample size of ?11 patients and 295 patients, respectively, is required. None of the 
studies on the prognostic impact of p53 in ovarian cancer have included the number of 
early stage and/or late stage ovarian cancer patients needed according to our calcula­
tions to assure adequate statistical power (see Table 4). 
Due to the relative rarity of ovarian cancer, it is obvious that it will be difficult to include 
sufficient numbers of patients in future studies to obtain statistically reliable results. 
The incidence of ovarian cancer is about 8,4 times lower than the incidence of breast 
cancer 1 • The relative low incidence of ovarian cancer is particularly a problem in prog­
nostic studies in early stage ovarian cancer, since only about 30% of ovarian cancer 
patients have disease that is confined to the pelvis at diagnosis. The inclusion of an 
adequate number of patients is further complicated by the fact that approximately 
36% of the patients with ovarian cancer are seventy years of age or older at the time of 
diagnosis 113• Because of comorbidity older patients with ovarian cancer are often not 
treated according to protocol, whereas (as much as possible) uniformity of treatment 
is important in prognostic studies in ovarian cancer. 
Based on these considerations it is clear that to reach sufficient number of ovarian 
cancer patients in studies on prognostic factors international collaboration is critical 
to ensure progress in translational research. Our power calculations are based on a 
minimal difference in prognosis to be detected of 10 percent. In this respect it is en­
couraging to note that in a recent study by van de Vijver et al microarray analysis on 
295 breast tumors allowed the identification of gene expression signatures in breast 
cancer associated with differences in prognosis much larger than 10 percent 114•1 15• Using 
DNA microarrays, it may therefore also be possible to identify gene expression pro­
files/signatures that can better predict prognosis in ovarian cancer than the current 
"classic" clinicopathologic factors. However, it remains of utmost importance to reach 
consensus about guidelines for the design, conduct and analysis of such studies in 
ovarian cancer. Ideally, future prognostic studies should include ovarian tumor sam­
ples derived from patients treated in clinical trials with identical regimens, follow-up 
and salvage strategies. Hopefully in that way molecular biological factors will be identi­
fied that will make a difference in clinical decision making in ovarian cancer, ultimately 
resulting in effective, individualized targeted therapy. 
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Abstract 
In ova rian cancer the cei l i ng seems to be reached with chemotherapeutic drugs. Therefore, 
a paradigm shift is needed. I n stead of treating a l l  patients accord ing to standard gu idel i nes, 
i nd ivid ua l ized molecular ta rgeted treatment should be aimed for. Th is means that molecu­
lar profi les of the d istinct ova rian cancer subtypes should be estab l i shed. U nt i l  recently, most 
stud ies trying to identify molecular targets were s ing le marker stud ies. The prognostic role 
of key components of apoptotic and prosurviva l pathways such as p53, EGFR, and HER-2 has 
been extensively studied because resistance to chemotherapy is often caused by fa i l u re of 
tumor cel l s  to go i nto apoptosis. However, it is more than l i kely that d ifferent ovarian  cancer 
subtypes with extensive molecular heterogeneity exist. Therefore, exploration of the potentia l  
of specific tumor-targeted therapy, based on expression of a prognostic tumor profi le, may 
be of i nterest. Recently, new profi l ing techn iques, such as DNA and protein  microarrays, have 
enabled h igh-throughput screening of tumors. In this review an overview of the cu rrent status 
of prognostic marker and molecular ta rget ing research in  ovarian cancer, i nc luding microarray 
stud ies, is presented. 
Introduction 
Ovarian cancer is the leading cause of death from gynecologic cancer and the fourth 
most common cause of cancer death in women. In 2005 it is estimated that 22,220 
new ovarian cancer cases will be diagnosed in the United States, and 16,210 deaths 
caused by ovarian cancer will occur 1 • This high death rate is related to the difficulty in 
detecting ovarian cancer at an early stage and the lack of effective therapies for ad­
vanced disease. After surgery, for FIGO stages IC, 1 1B, Ill and IV disease, platinum-based 
chemotherapy is indicated. For patients with FIGO stages I ll/IV disease, this results in 
250/o survival at s years 2• Intrinsic, but especially acquired, resistance to chemothera­
peutic drugs is a major problem. The several newer first-line regimens studied hardly 
improved survival; therefore a paradigm shift is needed. 
Within the current FIGO classification system, ovarian cancer subtypes with d istinct 
cl inical courses are likely to exist, but they have yet to be defined. Unraveli ng the 
molecular pathways of importance in  the different subtypes may allow the develop­
ment of more molecularly targeted therapies based on the biology of the disease. It 
is therefore of great importance to identify new prognostic molecular markers that 
will facilitate the classification of ovarian carcinomas into pathogenetic subtypes with 
distinct clinical courses. 
However, research in ovarian cancer is hampered by the relatively low incidence of 
ovarian cancer; e.g. the incidence of ovarian cancer is about 9.S times lower than the 
incidence of breast cancer 1 • Furthermore, ovarian cancer research is complicated by 
the fact that approximately 360/o of the patients with ovarian cancer is 70 years or older 
at the time of diagnosis 3• Because of comorbidity, elderly patients with ovarian cancer 
are often not treated according to standard guidelines. 
In this review we will present an overview of the available data on molecular path­
ways of potential importance and describe ongoing initiatives to find new prognostic 
markers and new drug targets for ovarian cancer. 
Key components of molecular pathways; 
putative prognostic markers 
The "classic" clinicopathologic prognostic markers for ovarian cancer include age at 
diagnosis, FIGO stage, histiotype and grade of the disease, amount of residual tumor 
after primary debulking surgery, and response to first-line chemotherapy. However, 
these prognostic markers are imperfect predictors of outcome and do not provide 
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Resistance to chemotherapy is considered to be especially due to failure of tumor 
cells to go into programmed cell death (apoptosis). Therefore, especial ly the role of 
apoptotic or prosurvival pathways in ovarian carcinogenesis has been extensively 
studied. Apoptosis can be executed through an "intrinsic" (mitochondria-dependent) 
and "extrinsic" (death receptor-dependent) pathway. The intrinsic apoptotic pathway 
is triggered by diverse stress signals, including withdrawal of growth factors. The ex­
trinsic apoptotic pathway is initiated by activation of death receptors expressed on 
the cell membrane 4• 
The prognostic value of various key components of apoptotic and prosurvival path­
ways has been frequently analyzed. The results of these studies are, however, contra­
dictory. This is because of considerable methodological variability between the dif­
ferent prognostic studies. In addition, many studies were affected by small sample 
size, which may lead to overestimation or underestimation of the relevance of the 
molecular factor. 
We have therefore performed a meta-analysis of prognostic studies on the tumor sup­
pressor gene p53 and the growth factor receptors, EGFR, and HER-2 in ovarian cancer. 
This meta-analysis showed that patients with aberrant p53, EGFR, or HER-2 tumor sta­
tus had significantly lower odds of surviving s years 5• Agents targeting these molecu­
lar biological factors, thus, may have therapeutic potential. Currently, several drugs 
targeted at these and other key components of apoptotic and prosurvival pathways 
are in various stages of development, and those that are clinically being assessed will 
now be discussed. 
Intrinsic apoptotic pathway 
p53 is an important mediator of the intrinsic apoptotic pathway. The p53 network is 
involved in the cellular defense against various stress signals, such as DNA damage, 
oncogene or aberrant growth factor signaling and stress caused by ultraviolet radia­
tion, hypoxia, or chemotherapeutic drugs 6• Upon activation, the p53 protein will act 
as a tumor suppressor through effects on gene expression, resulting in cel l  cycle ar­
rest, apoptosis, senescence, or differentiation 7• For an overview of the intrinsic and 
extrinsic apoptotic pathways, see Figure 1. The involvement of a defective p53 path­
way in carcinogenesis makes it a target for therapeutic intervention. Several strate­
gies have been developed. The adenovirus dl1520 (ONYX-015) has been attenuated by 
deletion of its E1B ss-kd gene region, which encodes a protein product that is known 
to bind and inactivate p53, hereby preventing the p53-mediated activation of the cel­
lular defense mechanism against viral infection. Deletion of this gene region should 
cause the virus only to replicate in p53-defective cells, leading to virus spread and 
subsequent cytolysis of the tumor cel ls  M_ However, although there is evidence of 
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Figure 1 
Apoptotic pathway. The death receptor-initiated apoptosis pathway is referred to as the extrinsic 
apoptosis pathway. The death ligand, TRAIL in this example, binds as a homotrimer to DR4 and 
DRs, which results in homo-trimeriziation of the receptors. This leads to the assembly of a death­
inducing signaling complex. At the death-inducing signaling complex, the adaptor protein FADD 
(Fas- associated death domain) acts as a bridge between the death receptor complex and the 
initiator caspase 8. Upon recruitment by FADD, caspase 8 will be activated by autoc/eavage and 
activate downstream effector caspases such as caspase 3, 6, and 7. Cross-talk exists between the 
extrinsic pathway and the intrinsic or mitochondria-initiated apoptosis pathway through Bid, a 
BH3-only protein member of the Bc/-2 gene superfamily. Activated caspase 8 will cleave Bid, which 
then translocates to the mitochondria to induce cytochrome c release, forming the connection 
between the extrinsic and intrinsic pathway. The intrinsic pathway triggers apoptosis after DNA 
damage, hypoxia, starvation, and many other kinds of severe cellular stress. When the intrinsic 
pathway is activated, proapoptotic members of the Bc/-2-gene family translocate to the mito­
chondria, causing subsequent release of cytochrome c and other mitochondrial factors into the 
cytosol. In the cytosol, cytochrome c binds in the presence of deoxyadenosine triphosphate the 
adaptor protein Apaf-1 and procaspase 9, forming the apoptosome-signaling complex in which 
caspase 9 is activated and can activate on its turn the effector caspases 3, 6, and 7. 
therapeutic efficacy, the virus's mechanism of cellular selectivity is less clear 10• In a 
phase I trial with dlis20, including 16 ovarian cancer patients, it was demonstrated for 
the first time that a selective replication-competent virus can be safely administered 
intraperitoneally. Furthermore, there were signs of continuing viral replication in ovar­
ian cancer cells after dlis20 administration 9• The adenovirus-s E1A protein is able to 
reprogram transcription in tumor cells, thereby reversing the transformed phenotype 
of cancer cells and suppressing tumor growth 11 • Several phase I studies with lipo­
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with intraperitoneal administration of an E1A-lipid complex in patients with recurrent 
epithelial ovarian cancer overexpressing HER-2 showed evidence of safety and gene 
transfer 14• SCHsssoo (rAD/p53) is a replication-deficient adenovirus encoding human, 
recombinant, wild-type p53. The results of a phase 1/ 1 1 trial with SCHsssoo in recurrent 
ovarian cancer showed safety, effective gene transfer, and serum CA-125 reduction 
when combined with platinum-based chemotherapy 15. In a subsequent study the 
long-term follow-up was evaluated of the patients who had been enrolled into the 
phase 1/1 1 trial with SCHsssoo. The median survival was 12-13 months 16• However, a 
phase 1 1/1 1 1  trial, where patients with primary stage Ill ovarian cancer were randomized 
to receive either standard therapy or the same regimen combined with SCHsssoo 
gene therapy, was prematurely closed due to lack of therapeutic effectiveness and 
increased treatment morbidity. The reasons for this failure of gene therapy in ovarian 
cancer are probably numerous and not exclusively limited to problems relating to 
gene therapy itself 17• 
txtrinsic apoptotic pathway 
The extrinsic apoptotic pathway can be executed through death receptors and their 
ligands, which belong to the tumor necrosis factor superfamily. They operate as es­
sential mediators of apoptosis in the immune system, acting in cell-mediated toxicity 
in response to infectious agents, in immune homeostasis, and in antitumor responses 
18• As failure of tumor cells to undergo apoptosis leads to tumor progression and resist­
ance to cancer therapy, induction of apoptosis by targeting the death receptor path­
way offers an attractive strategy in cancer therapy. The ligands TNF and CD95UFasL 
show substantial antitumor effects in vitro. However, systemic administration of FasL 
is limited by severe systemic side effects in mice, and low-dose TNF showed only very 
limited antitumor efficacy in humans 19 21 . 
Tumor necrosis factor related apoptosis inducing ligand (TRAIL) is considered to be 
of special interest for clinical use because of its ability to induce apoptosis in several 
types of cancer cell lines and xenografts regardless of p53 status, without causing tox­
icity to normal cells 22-25_ Administration of T RAIL to non-human primates proved to 
be safe 26• TRAIL can induce apoptosis through two agonistic receptors, death recep­
tor 4 (DR4) and death receptor s (DRs) 27•28• In vitro studies in ovarian cancer cell lines 
show antitumor activity of TRAIL alone or in combination with chemotherapy 29-32• 
lmmunohistochemical staining of ovarian tumors shows that TRAIL and its receptors 
are frequently expressed in ovarian cancer. Most primary and residual ovarian tumors 
express at least one TRAIL death receptor, while in residual tumors following chemo­
therapy, DRs is more frequently expressed 33. Moreover, ovarian cancers show a higher 
TRAI L expression than normal epithelial tissue. Among the tumors studied, those with 
54 
the highest TRAIL expression show a better survival compared to those with a lower 
expression 34. The results stated here show that combining chemotherapeutic drugs 
with biological response modifiers, such as TRAIL or agonisticTRAIL antibodies, seems 
an attractive strategy to prevent or overcome drug-resistance. A phase I study with 
recombinant human (rh)TRAIL has been started. Several phase I and II studies are cur­
rently ongoing with agonistic monoclonal antibodies targeting the death receptors 
DR4, including a phase II study where HGS-ETR1, a monoclonal antibody (mAb) di­
rected at DR4, is administered in combination with carboplatin and paclitaxel. A phase 
I study with a mAb against DRs is ongoing (http://www.hgsi.com). The clinical studies 
that are presently accruing patients are summarized in Table 1 .  
Prosurvival pathways 
f(if receptor family 
The EGFR  family embodies four homologous receptors: the epidermal growth fac­
tor receptor (EGFR/HER-1/ErbB-1), HER-2 (ErbB-2), HER-3 (ErbB-3), and HER-4 (ErbB-4). 
The receptors consist of three main domains: a ligand-binding extracellular domain, a 
transmembrane segment and an intracellular tyrosine kinase domain 35. Activation of 
a monomeric receptor occurs by dimerization between two identical receptors (ho­
modimerization) or between different receptors of the EGFR family (heterodimeriza­
tion) 36. This results in activation of the tyrosine kinase domain with subsequent activa­
tion of interrelated intracellular signaling pathways, such as the phosphatidylinositol 
3-kinase (Pl3K)/ AKT pathway and the MAPK pathway. Activation of these pathways 
can lead to different cellular processes, such as cell division and migration, adhesion, 
differentiation, and apoptosis. The eventual outcome depends on cellular context, the 
ligand causing dimerization, and the receptor dimer formed 37• The normal function 
of HER signaling lies in the mediation of cell-cell interactions in organogenesis and 
adulthood 38• However, dysregulation of HER signaling is associated with malignant 
transformation. This dysregulation can occur through a number of mechanisms such 
as overexpression of a ligand, overexpression of a receptor, activating mutations lead­
ing to constitutively activated receptors, and defective processing of receptors 37• Until 
now, only the EGFR  and HER-2 receptors have been reported to be dysregulated in 
human cancer. A meta-analysis showed aberrant EGFR expression in 12-820/o of ovar­
ian cancer, whereas aberrant HER-2 expression was reported in s-660/o of ovarian car­
cinomas 5• Several strategies targeting EGFR and HER-2 have been developed. mAbs 
targeting the receptors extracellularly or small-molecules targeting the intracellular 
tyrosine kinase domains (tyrosine kinase inhibitors, TKls) have been developed and are 
in various stages of clinical testing in ovarian cancer. Those studies that are currently 
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Table 1 
Ongoing cl inical tria ls with novel molecular agents 
Target Novel agent 




RhTRAIL Phase I Solid tumors 
DR4 
mAbs 
HGS-ETR1 with gemcitabin 
Phase l b  Solid tumors 
and cisplatin 
HGS-ETR1 with carboplatin Phase II Solid tumors 
and pacl itaxel 
DRs 
mAbs HGS-ETR2 Phase I Solid tumors 
HGS-TR2.J Phase I Solid tumors 
EGFR 
TKls Gefitinib and docetaxel Phase I Advanced solid tumors 
Gefitinib and calcitriol with or 
Phase I Advanced solid tumors without dexamethasone 
Advanced ovarian, fal lopian 
Gefitinib ( lressa) Phase I I  (pi lot) tube, primary peritoneal or 
cervical cancer 
Advanced ovarian, non-small 
mAbs Erlotinib Phase 1/11 cell lung, or squamous cel l  car-
cinoma of the head and neck 
Erlotinib with carboplatin and 
Advanced ovarian, fal lopian 
pacl itaxel Phase 1/11 
tube or primary peritoneal 
cancer 
Cetuximab (Erbitux) Phase II 
Persistent or recurrent ovarian 
or primary peritoneal cancer 
Cetuximab with carboplatin Phase II 
Recurrent ovarian or primary 
peritoneal cancer 
HER-2 
mAbs Trastuzumab with erlotinib Phase Advanced solid tumors 
and paclitaxel 
Trastuzumab and imatinib 
Phase I 
Recurrent or metastatic HER-2 
mesylate expressing cancer 
lntegrin avp
3 
mAb Cilengitide Phase I 
Advanced solid tumors 
or lymphoma 
56 
die aparte regel voor Hsp90 kan wel, ik had het niet goed 
begrepen, sorry 
Table 1 continued 
Target Novel agent 




Ovarian or primary peritoneal 
mAb Bevacizumab Phase I I  cancer where doxil or topote-
can has failed 
Bevacizumab and imatinib 
Phase 1/11 
Advanced melanoma or other 
mesylate advanced cancers 
Soluble Relapsed or refractory 
decoy VEGF Trap Phase I advanced solid tumors or 
receptor non-Hodgkin's lymphoma 
Ras-Raf-MAPK and VEGF 
Sorafenib (BAY 43-9006) with Recurrent ovarian, primary 
or without paclitaxel and Phase II peritoneal or fal lopian tube 
carboplatin cancer 
Sorafenib and gemcitabin Phase II 
Recurrent or refractory ovarian 
or primary peritoneal cancer 
Sorafenib and bevacizumab Phase I 
Refractory, metastatic or 
unresectable sol id tumors 
Inhibitors of Farnesyl transferase 
R115777 with topotecan Phase I Advanced solid tumors 
Proteasome 
Platinum- and taxane-resistant 
PS-341 (Bortezomib) Phase I 
recurrent ovarian , primary 
peritoneal, and fal lopian tube 
cancer 
Bortezomib Phase I I  
Persistent or recurrent ovarian 
or primary peritoneal cancer 
Hsp90 
17-AAG Phase I 
Unresectable solid tumors 
or relapsed lymphoma 
17-AAG with cisplatin and Phase I Advanced solid tumors 
gemcitabin 
17-AAg with docetaxel Phase I 
Metastatic or unresectable 
solid tumors 
17-AAg with paclitaxel Phase I 
Metastatic or unresectable 
solid tumors 












3 4  
C 
C 
Prognostic markers: toward patient-tailored therapy ---
The TKI gefitinib, directed at the tyrosine kinase domain of EGFR, has been evaluated 
in three phase I trials, including 33 ovarian cancer patients. Of these 33 patients, 3 had 
stable disease during treatment with gefitinib 39. At this moment a phase II pilot study 
of gefitinib in patients with advanced ovarian cancer is recruiting patients (http:// 
www.clinicaltrials.gov) . Gefitinib has been approved in the United States in 2003 for 
the treatment of patients with non-small cell lung cancer who had failed two or more 
courses of chemotherapy. However, recently the gefitinib Survival Evaluation in Lung 
cancer (ISEL) showed no survival benefit for patients under treatment with gefitinib. It 
should be mentioned that, in non-small cell lung cancer patients, it has been shown 
that only activating mutations in EGFR underlie responsiveness to gefitinib 40. 
Another TKI directed at EGFR, erlotinib, was evaluated in a phase II trial in 34 heav­
ily pretreated ovarian cancer patients. Three patients were reported to have a partial 
response, while 42% experienced stable disease. There was no relation between re­
sponse to erlotinib and EGFR tumor expression 41• Various phase 1/ 1 1  trials are examining 
erlotinib in combination with chemotherapy 42• Preliminary results of a phase I study of 
erlotinib with docetaxel showed stable disease in ovarian cancer patients 43. The data 
of a recently closed phase II trial of erlotinib and carboplatin are being analyzed. 
At this moment cetuximab, a mAb directed at the EGFR, is being evaluated in ovarian 
cancer in phase II clinical trials. A trial with cetuximab in advanced EGFR positive ovar­
ian, fallopian tube, or primary peritoneal cancer is no longer recruiting patients, and its 
results are being evaluated. The results of a phase II clinical trial of EMD-7200, another 
mAb against EGFR, are currently under evaluation as well. Cetuximab is currently reg­
istered for the use in EGFR overexpressing, irinotecan refractory colon carcinomas. 
The anti-HER-2 mAb trastuzumab (Herceptin), registered for the treatment of HER-2 
positive metastatic breast cancer patients, has been designed to specifically antago­
nize the function of the HER-2 receptor in HER-2 positive tumors. A phase II trial with 
trastuzumab in patients with recurrent or refractory ovarian or primary peritoneal can­
cer with overexpression of HER-2 showed a low rate of objective response 44• A phase II 
study of trastuzumab and paclitaxel in patients with HER-2 overexpressing relapsed 
or progressive breast and ovarian carcinomas has been completed. Furthermore, two 
phase I trials, one with interleukin 12 and trastuzumab and one with interleukin 12, 
trastuzumab, and paclitaxel in patients with HER-2 overexpressing solid tumors have 
been completed as well. No results from these studies have been reported yet. Cur­
rently, a clinical trial with trastuzumab in combination with paclitaxel and interleukin 
12 is ongoing. Another mAb targeting the dimerization domain of HER-2, pertuzu­
mab, is currently being clinically evaluated. A trial with pertuzumab in ovarian cancer 
patients pretreated with one or more platinum-based chemotherapy regimens has 
completed enrollment. 
58 
Phosphatidylinositol 3-kinase/ AKT pathway 
The Pl3K/ AKT pathway represents one of the key pathways controlling survival, pro­
liferation, and growth in cells. A dysfunctional Pl3K/AKT pathway is involved in sev­
eral diseases, including cancer. Pl3K can be activated by a diverse array of physiologic 
stimuli, including growth factor receptor signaling, several interleukins and stress, as 
well as by activated Ras proteins 45•49_ Active Pl3K is able to activate AKT at the cell 
membrane via a second messenger. AKT, also known as protein kinase B, exists in 
three closely related isoforms, AKT1, AKT2, and AKT3 49. By phosphorylating numerous 
downstream proteins, activated AKT can control essential cellular processes. For an 
overview of the AKT and ERB/HER pathway, see Figure 2. AKT promotes cell survival 
through several mechanisms, and it downregulates apoptosis through inactivation 
of several proapoptotic proteins 50·53_ Increase of p53 degradation is executed by AKT 
through effects on MDM2, a negative p53 regulator 5455• AKT promotes gene expres­
sion of several prosurvival genes via nuclear factor kappa B 5657• Furthermore, AKT can 
exert effects on cell metabolism and growth through activation of the protein kinase 
"mammalian target of rapamycin" 5859• AKT can also stimulate cell proliferation by ef­
fects on mediators of the cell cycle 55•60. Numerous other AKT targets involved in differ­
ent cellular reactions have been recognized 61 . 
Dysregulation of several key components of the AKT pathway have been described 
in ovarian cancer. Alterations in the tumor suppressor PTEN, which is responsible for 
converting the AKT-activating second messenger to its inactive state, have been re­
ported in ovarian cancer 52-65_ Elevated AKT1 levels and amplification and overexpres­
sion of the isoform AKT2 were described 47•66•67. Amplification of subunits of Pl3K have 
been characterized as well 68.69. Currently, several drugs targeting components of the 
Pl3K/ AKT pathway are in various preclinical stages of development. 
Drugs targeting mammalian target of rapamycin have entered clinical trials in breast 
cancer and renal cancer patients 70• No molecular agents targeting the Pl3K/ AKT path­
way are presently being clinically assessed in ovarian cancer. 
4ngiogenesis pathways 
A solid tumor depends on angiogenesis to grow in size and form metastases. Whereas 
in normal tissue the endothelium is extremely quiescent and angiogenesis occurs as a 
tightly regulated process, the endothelium in tumors proliferates rapidly and contrib­
utes to active angiogenesis. Because of the specific properties of angiogenesis under 
malignant conditions, antiangiogenic agents may represent a promising anticancer 
strategy 71.72• More than 75 antiangiogenic drugs are in the process of being tested in 
clinical trials 71 • Bevacizumab, a recombinant anti-VEGF mAb, has been approved by 
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Figure 2 
Prosurvival pathways; Erb/HER and P/3K/AKT. Dimerization between two growth factor 
receptors causes activation of the receptor tyrosine kinases with subsequent autophos­
phorylation. This leads to activation of the MAP-kinase pathway and of the P/3K/AKT 
pathway. Active P/3K converts phosphatidylinosito/-4,5-biphosphate (PJP2) to the second 
messenger phosphatidylinosito/-3,4,5-triphosphate (PJP3), which is able to recruit pleck­
strin homology (PH) domain containing proteins, such as AKT to the cell membrane with 
subsequent activation of AKT. The tumor suppressor PTEN is responsible for converting 
the second messenger PJP3 to its inactive state PIP2. Active AKT is able to control essen­
tial cellular processes, such as apoptosis, survival, proliferation, and growth by phos­
phorylating downstream proteins. p53 degradation is increased by phosphorylation of 
MDM2. AKT promotes gene expression of several prosurvival genes via nuclear factor 
kappa B (NFkB) and inhibits gene expression of several proapoptotic genes by prevent­
ing forkhead-related transcription factors (FKHR) to enter the nucleus. Furthermore, AKT 
can exert effects on cell metabolism and growth through activation of the protein kinase 
"mammalian target of rapamycin" (mTOR). AKT can also stimulate cell proliferation by 
effects on mediators of the cell cycle. Numerous other AKT targets involved in different 
cellular reactions have been recognized. 
colon cancer. At American Society of Clinical Oncology (ASCO) 2005 two interim re­
ports of phase II clinical trials of bevacizumab in recurrent ovarian or primary perito­
neal cancer were presented. One trial with bevacizumab as monotherapy showed a 
median disease free interval of 6.S months in 62 patients 73• Another report of a trial 
of bevacizumab combined with cyclophophosphamide described encouraging re­
sponse rates in 29 patients (6 partial response (PR), 17 stable disease (SD), 6 progressive 
60 
disease (PD)) and a progression free survival at 6 months of 470/o of the patients 74• At 
ASCO 2005 the Gynecologic Oncology Group proposed a design for a phase I l l  trial of 
combination therapy with or without bevacizumab in persistent or recurrent ovarian 
cancer or primary peritoneal cancer. Numerous agents, ranging from monoclonal an­
tibod ies, TKls, soluble decoy receptors, matrix metal loproteinase inhibitors, and others 
are currently being evaluated in cl inical trials. A phase I trial with VEGF Trap, a soluble 
decoy receptor for VEGF, is now recruiting patients. Cilengitide, a mAb targeting the 
av�3 integrin receptor, which promotes angiogenesis upon binding the l igand basic 
fibroblast growth factor, is currently being evaluated in a phase I tria l . Several smal l­
molecule VEGF receptor TKls have been developed. 
�olecular agents targeting multiple targets 
Given the diversity of molecu lar alterations acquired during mal ignant transforma­
tion, there seems to be no single dominant neoplastic pathway in ovarian carcinomas. 
Therefore, it is unl ikely that targeting a single step in ovarian carcinogenesis wil l  be 
effective in treating this disease, especial ly when the putative target has many down­
stream effectors and redundant or overlapping pathways. To maximize anticancer ef­
ficacy, it seems necessary to intervene s imu ltaneously in mu ltiple pathways. Recently, 
agents that inhibit mu ltiple targets have been developed and many are a l ready being 
eva luated in  cl inica l tria ls. One of the candidates is bortezomib, a reversible inh ibitor 
of the proteasome. The proteasome is the multicatalytic protease complex that plays 
an essential role in the degradation of most intracel lu lar proteins, including those 
control l ing cel l  cycle progression and apoptosis 75• Bortezomib was approved by the 
Food and Drug Admin istartion in 2003 for the treatment of mu ltiple myeloma pro­
gressing on prior therapy. Cl in ical tria ls with bortezomib show promising resu lts in  
numerous other ma lignancies 76• I n  ovarian cancer bortezomib is now being assessed 
as combination therapy with carboplatin in a phase I and as monotherapy in a phase I I  
trial. There is increasing evidence that hypermethylation of  tumor suppressor genes 
contributes to carcinogenesis. Therefore, another candidate is the DNA hypomethyl­
ating agent decitabine. Cl in ical trials with decitabine are ongoing. A phase I trial with 
decitabine and carboplatin in patients with advanced malignancies, including ovarian 
cancer, showed feasibi l ity of the combination therapy 77• I nhibitors of farnesyl trans­
ferase (FTls), the enzyme that cata lyzes a key step in the addition of an a l iphatic iso­
prenoid chain to a number of proteins (including Ras, Rho, PxF and laminins A and B), 
seemed interesting. However, c l in ica l studies evaluating the FTls BMS-214662 and L-
778123 as monotherapy or combined with chemotherapy in solid tumors have been 
stopped because of toxicity. Yet, numerous phase 1/1 1 studies with FTI R115777 are cur­
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antiangiogenic properties by targeting Raf kinase and the receptor tyrosine kinases 
VEGFR-2 and PDGFR, is due to enter phase I l l trials in 2005. I n  ovarian cancer patients, 
BAY 43-9006 combined with different chemotherapy regimes is currently being test­
ed in two phase I I  cl inica l tria ls. 
BAY 43-9006 has shown substantial antitumor effects in patients with metastatic re­
na l cancer 18• I nhibitors of the chaperone protein heat shock protein  90 (Hsp90) are 
presently emerging as targets in cancer therapy. Chaperone proteins are in charge of 
maintain ing correct fold ing, function and stabi lity of certain proteins. Hsp90 seems of 
special importance in mal ignant transformation because of its requirement in chaper­
oning proteins essential in cell signal ing, proliferation, and surviva l, such as AKT. HER-2, 
and c-Raf and in chaperon ing mutated proteins such as mutant p53. The Hsp90 inhibi­
tor 17-al lylamino-17-demethoxygeldanamycin is the first of a class of Hsp90 inhibitors 
that has reached cl in ical trials with successive promising resu lts 79•80• 
(ienetic, genomic and proteomic profiling 
techniques 
In ovarian cancer mu ltip le oncogenic pathways are l ikely to exist. Until recently it was 
only possible to investigate sing le pathway components instead of complete path­
ways. However, endeavors such as the Human Genome Project and technical advanc­
es in molecu lar biology now al low for the comprehensive screening of tumors, at the 
genetic, genomic, and proteomic levels 81• Examples of microarray-based technolo­
gies include DNA arrays for comparative genomic hybridization, sing le-nucleotide 
polymorphisms or expression ana lysis, and (reverse-phase) protein  arrays for protein 
profil ing. Furthermore, tissue microarray technology enables high-throughput tis­
sue ana lyses to eva luate and val idate the cl in ical va lue of the resu lts obtained by the 
microarray-based technologies. 
Successfu l translation of knowledge obtained by these technolog ies may lead to 
more precise and patient-tai lored therapies. Besides profi l ing the ind ividual tumor to 
predict drug-responsiveness, the interindividual variabi l ity in drug-response should 
also be taken into account. This is studied by pharmacogenetics, the field that studies 
the influence of inherited genetic variabi l ity on treatment response 82 84. 
DI\IA rnicroarray &tudie!li in ovarian cancer 
Unti l now quite a large number of studies using DNA microarrays to determine gene 
expression profi les in ovarian cancer have been reported. The specific aims of the sep­
arate studies are summarized in Table 2. Most microarray studies have tried to identify 
diagnostic markers by comparing ovarian carcinomas or ovarian cancer cel l l ines to 
normal ovarian epithe l ium. Furthermore, many microarray stud ies have tried to dis-
62 
Table 2 
DNA microarray studies in ovarian cancer 




Diagnostic markers and/or Normal epithelial tissue or cell lines vs. cancer 22 85,86,88,89,1 17-135 carcinogenesis 
cell lines or carcinomas 
Carcinogenesis Carcinomas 3 87,136-138 
Molecular determinants of"classic" 
clinicopathologic factors (stage, grade, Carcinomas 12 90,91,94,121,139-147 histiotype, (sub)optimal cytoreduction, 
response to chemotherapy) 
Acquired drug-resistance Cancer cell line/tumor 92,139,148-155 resistance model 9 
Drug-action and/or response to Cancer cell lines or 
156-163 chemotherapy xenografts 7 
Effect of overexpression of a particular 
gene on gene expression and/or Cancer cell lines 5 164-168 
drug-response and/or metastasis 
Methylation alterations, genes, or 
profile associated with (progression Carcinomas 4 93,132,169,170 
free) survival 
cover genes associated with "classic" c l in ical prognostic factors or drug-resistance to 
pick up clues to treatment and prognosis. 
Only four microarray studies have tried to identify prognostic factors and/or prognos­
tic profiles for personal ized prediction of disease outcome. 
These microarray studies have provided long l ists of genes associated with ovarian 
carcinogenesis; yet, the importance of these genes for the development and progres­
sion of ovarian cancer has sti l l  to be determined. Additional ly, the cumulative results 
of diagnostic marker microarray studies revealed more than 150 potentia l ly upregu­
lated genes associated with ovarian cancer 85• 
A way to assess the importance of the genes related to ovarian carcinogenesis is to 
try to identify pathways among the genes. Several microarray stud ies have suggested 
pathways to be involved in ovarian carcinogenesis, such as the FAK pathway, the FGF2 
pathway, glucose/insu l in  metabolic pathway, BRCA1 or BRCA2-related pathways, the 
Jak-STAT pathway, and the IGF pathway 86.9'. Samimi et al have identified pathways 
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bosome pathway, the Huntington disease pathway, and the ATP synthesis pathway 91 • 
Currently, the discovery of pathways involved in ovarian carcinogenesis is eased by 
the availabil ity of commercial pathway programs. Donninger et al di scovered by im­
porting the microarray data into such a pathway program that the FAK pathway, as­
sociated with tumor cel l  migration, spread and invasion, was activated in advanced 
stage papil lary serous ovarian cancer 88• Stil l, the importance of these pathways in  
ovarian carcinogenesis has to be further determined. 
Although the microarray studies in ovarian cancer have provided important informa­
tion, they have l imitations, such as sma l l numbers of tumors ana lyzed (see Figure 1), 
exclusive analysis of cel l  lines as opposed to primary tumors and norma l epithel ium, 
as well as a l imited number of features on the microarrays used in  the studies. 
Small sample size is particularly a severe problem for studies that eventual ly a im to 
use tumor gene expression profi l ing as a prognostic tool in ovarian cancer, as it affects 
the statistica l rel iabi l ity of the conclusions. Spentzos et al recently identified a prog­
nostic 115-gene signature by profil ing 68 ovarian carcinomas 93• Furthermore, a three­
gene signature that classifies ovarian tumors according to their resistance to plati­
num-based chemotherapy was recently reported. This was achieved by profil ing 24 
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firmation by reverse transcription-polymerase chain reaction on 92 ovarian tumors 94• 
As is shown in Figu re 3 more and larger microarray studies (including validation stud­
ies) have been performed in breast cancer to identify a prognostic profile 95•103• How­
ever, the value of the prognostic profiles is sti l l  questionable. In breast cancer, the 
prognostic profi les of the different studies only had a few genes in common 98•101,104• 
Ransohoff recently warned for inflated expectations about prognostic microarray stud­
ies, as prognostic profi les may actua l ly be caused by chance and may not be reproduc­
ible. The solution is to assess reproducibi l ity by applying the prognostic profi le derived 
from a "train ing set"to an independent "val idation set" consisting of samples that were 
not used in the "tra in ing set" 105. This requires enough frozen samples for both training 
and validation. In  ovarian cancer, obtaining sufficient samples wi l l  be especial ly hard 
because of the relatively low incidence rates 97•100•102• Furthermore, the cl inical evidence 
of prognostic microarray studies (as wel l  as prognostic studies on single markers) only 
reaches level 3 or 4 evidence (smal l/la rge retrospective studies) on a scale of s ( low) to 
1 (high)106• The prognostic va lue of gene profi l ing in ovarian (and breast) cancer must 
be further eva luated in additional large prospective studies to reach level 2 or 1 c l in ical 
evidence as concluded by Spentzos et a l  and Heileman et a l  93•94• 
I nterestingly, Paik  et al have shown that it is possible to bui ld a prognostic breast can­
cer predictor of 21 (16 cancer-related and s reference) genes prospectively selected 
from publ ished l iterature, genomic databases, and DNA microarray experiments on 
frozen samples. The expression of the 21 genes was determined by reverse transcrip­
tion-polymerase chain reaction in paraffin samples from breast cancer patients en­
rolled in the National Surgica l Adjuvant Breast and Bowel Project c l in ica l trial B-14 107• In 
this way a large (668) prospective prognostic study of level 2 c l in ical evidence cou ld 
be performed. 
Besides genomic microarray studies, genetics and proteomics studies in ovarian can­
cer are a lso giving promising results 108 115• Combining the results of genetics, genom­
ics, and proteomics may speed up translational research in  ovarian cancer. 
Discussion 
The cei l ing seems to be reached with conventional chemotherapeutic drugs. It has 
become clear that ovarian cancer survival rates wi l l  not improve by treating al l  patients 
un iformly according to standard guidelines. There is a need of more patient-ta i lored 
therapy, where specific tumors wi l l  be treated with specific drugs. The present era of 
molecular targeting has generated excitement in the field of anticancer drug devel­
opment. A large number of molecular targeted agents are currently in various stages 
of development and several are a l ready being appl ied in anticancer therapy. However, 
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The "qu ick" translation of target identification and the subsequent development of 
molecular targeted agents are obstructed by the relative rarity of ovarian cancer. This 
impl ies that cl inical ly relevant answers wil l come only from the comparison of differ­
ent experiments and the analysis of large numbers of patients. 
For successful translational research in ovarian cancer, uniform methodological prin­
ciples and the general avai labi l ity of data are requi red. That way studies can be com­
pared and a meta-ana lysis can be performed. In addition, a uniform format for d isplay 
and storage of data wi l l  be helpful. For microarray studies a standard entitled MIAME 
- the Minimum Information About a Microarray Experiment - has been proposed to 
address this problem (http://www.mged.org/Workgroups/MIAME/miame.html) "6• Ef­
forts to standardize new techniques and set up large ovarian tumor banks wi l l  hope­
fu l ly support patient-tai lored therapy in ovarian cancer patients 
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Ovarian cancer is the most frequent cause of death from gynecologic cancer in the Western 
world. Current prognostic factors do not a l low reliable prediction of response to chemotherapy 
and survival for individual ovarian cancer patients. EGFR and HER-2 are frequently expressed in 
ovarian cancer, but their prognostic value remains unclear. I n this study, we investigated the 
expression and prognostic value of EGFR, EGFRvlll, HER-2, and important downstream signal ing 
components in a large series of epithel ia l ovarian cancer patients. 
Methods 
lmmunohistochemical stain ing of EGFR, pEGFR, EGFRvlll, HER-2, PTEN, total and phosphorylat­
ed AKT (pAKT), and phosphorylated ERK (pERK) was performed on 232 primary tumors using 
the tissue microarray technique and related to cl in icopathologic characteristics and survival. In 
addition, the expression of EGFRvlll was determined in 45 tumors by RT-PCR. 
Results 
Negative PTEN immunostaining was associated with stage 1/11 disease (p=o.006), non-se­
rous tumor type (p=o.042) and In multivariate a nalysis with a longer progression free survival 
(p=o.015). Positive pAKT staining was associated with advanced stage d isease (p=o.006). Other 
proteins were expressed only at low levels, and were not associated with any clinicopathologic 
parameter or survival. None of the tumors were positive for EGFRvl l l . 
Conclusion 
Tumors showing negative PTEN staining could represent a subgroup of ovarian carcinomas 
with a relatively favorable prognosis. 
Introduction 
Five-year survival of advanced stage ovarian cancer patients remains only 15-25%, de­
spite intensive surgica l  treatment and combination chemotherapy. Development of 
intrinsic or acqu i red resistance to platinum-containing chemotherapy is the major 
obstacle in the treatment of patients with ovarian cancer 1• Current cl inicopatholog­
ic prognostic factors do not a l low individual ized prediction of response to chemo­
therapy or disease outcome. Identification of molecular biological prognostic factors 
would be of great va lue for more accurate classification of ovarian carcinomas into 
su btypes with a different cl in ical outcome, thereby possibly also enabling individual­
ized treatment strategies 2• 
EGFR and HER-2 are members of the ErbB family of tyrosine kinase receptors. Aberrant 
activity of EGFR and HER-2 has been shown to play an important role in tumor g rowth 
and development. Binding of l igand to the ectodomain of ErbB receptors resu lts in  
receptor autophosphorylation and in itiation of  downstream signaling cascades, such 
as the Pl3K/ AKT pathway and the Ras/Raf/MEK/ERK pathway. Activation of these path­
ways in cancer has been associated with increased angiogenesis, metastasis, dedif­
ferentiation, growth and protection from apoptosis (Figure 1) 3• PTEN (phosphatase 
and tensin homolog deleted on chromosome 10) directly antagonizes the Pl3K/AKT 
pathway by preventing the phosphorylation of AKT 4• 
Several studies have shown that overexpression of HER-2 and EGFR, as well as a ltera­
tions in their downstream targets AKT and ERK are associated with resistance to plati­
num- and taxane-based chemotherapy. Treatment with agents directed against these 
proteins may enhance chemotherapy-induced cel l  death s·0The prognostic significance 
of EGFR and HER-2 has been extensively studied in ovarian cancer, but remains u nclear. 
A recent meta-analysis revealed that abnormal expression of these markers appears to 
be associated with poor five-year survival, but this is not a uniform finding 9• 
The EGFR variant I l l  (EGFRvll l) lacks exons 2-7 of the extracel lu lar domain of the recep­
tor. Although EGFRvll l  is unable to bind l igand, it is constitutively phosphorylated and 
able to activate downstream signal ing pathways '0• EGFRvl l l  expression is thought to 
confer resistance to cisplatin and pacl itaxel 11•12• One study so far investigated the fre­
quency of EGFRvl l l  expression in ovarian cancer, and found positive immunostaining 
in 75% of ovarian tumors '3• 
The a im of the present study was to investigate the prognostic significance of EGFR, 
HER-2, and their downstream targets AKT, ERK and PTEN in a large series of 232 epithe­
l ial ovarian cancer patients using the tissue microarray (TMA) technique. In addition to 
immunostaining, we determined the expression of EGFRvl l l  in more deta i l  in a subset 

























The ErbB signaling pathway. Adapted and modified from Hougardy et al••. Binding of ligand 
to the ectodomain of ErbB receptors results in receptor autophosphorylation and initiation 
of downstream signaling cascades, such as the P/3K/ AKT pathway and the Ras/Raf/MEKIERK 
pathway. Active P/3K converts phosphatidylinosito/-4,5-biphosphate (PIP2) to the second 
messenger phosphatidylinosito/-3,4,s-triphosphate (P/P3), which is able to recruit AKT to the 
cell membrane with subsequent activation of AKT. PTEN (phosphatase and tensin homo/og 
deleted on chromosome 10) directly antagonizes the P/3K/AKT pathway by preventing the 
phosphorylation of AKT; PTEN is responsible for converting the second messenger PIP3 to its 
inactive state PIP2. Activation of the P/3K/AKT pathway and the Ras/Raf/MEK/ERK pathway 
in cancer has been associated with increased angiogenesis, metastasis, dedifferentiation, 
growth and protection from apoptosis. 
Patients and methods 
Patients 
Since 1985 al l clinicopathologic and follow-up data of 329 epithelial ovarian cancer 
patients treated at the University Medical Center Groningen have been prospectively 
stored in a database. All patients gave informed consent for data storage and tumor 
col lection, and stud ies were conducted in accordance with the Declaration of Helsinki 
principles and Institutional Review Board policies. For the current study a l l  consecu­
tive chemonaive ovarian cancer patients for whom sufficient paraffin embedded tu­
mor tissue and complete fol low-up data were avai lable were selected (N""232). 
Bo 
Patients were surgical ly staged according to FIGO (International Federation of Gyne­
cology and Obstetrics) criteria 14• Optimal and suboptimal debulking was defined as 
the largest residual tumor lesions having a diameter of �2 cm or >2 cm, respectively. 
The histology of a l l  carcinomas was determined by a gynecologic pathologist accord­
ing to World Health Organization (WHO) criteria 15• 
Response to chemotherapy was evaluated according to WHO criteria '6• When indi­
cated, intervention surgery was performed after three cycles of chemotherapy, while 
until 1996 second-look surgery was regu larly performed after six cycles of chemo­
therapy. 
T�A construction and immunostaining 
TMAs were constructed as described previously 11. In total, four tissue cores from 232 
primary tumors and 45 paired tumors obtained at second-look surgery or surgery for 
recurrent disease were included on eight TMAs. 
Antigen retrieval methods, primary antibodies and detection techniques are shown 
in Table 1. Sections (4 µm) were deparaffinized in xylene and endogenous peroxidase 
was blocked by incubation in  0.3% hydrogen peroxide for 30 min. After antigen re­
trieva l, sl ides were incubated in normal goat serum (HER-2), horse serum (EGFR, pEG­
FR), bovine serum (pAKT, pERK, PTEN, total AKT) or blocking solution (DAKO, Glostrup, 
Denmark) for EGFR. For pEGFR, pAKT, pERK and PTEN sta in ing, endogenous avid in and 
biotin activity was blocked using Blocking kit (Vector Laboratories, Burl ingame, UK). 
HER-2 staining was performed in a DAKO autostainer (DAKO). Sta ining was visual ized 
by 3,3'-diaminobenzidinetetrahydroch loride and sections were countersta ined with 
hematoxyl in. EGFRvl l l  stain ing was kindly performed by Dr. A Jungbluth, Ludwig I nsti­
tute for Cancer Research, New York, USA. 
Positive controls included separate TMA sl ides containing multiple tumor and normal 
tissues for EGFR and pEGFR, sections from tumors with known marker expression for 
HER-2 and PTEN, ovarian cancer cell l ine A2780 for AKT, pAKT and ERK, and gl ioblas­
toma cel l  line U87 transfected with an EGFRvl l l  plasmid for EGFRvll l  sta ining 18• Nega­
tive controls were obta ined by omission of the primary antibody, and by incubation 
with normal rabbit lgG for tota l AKT. All control experiments gave satisfactory results. 
Antigen preservation was verified by vimentin sta ining, which was positive in all tu­
mor and control samples. 
Eva luation of immunosta in ing was independently performed by two observers (KAH, 
PDG), bl inded to cl in ica l data. The agreement between the two observers was >90%. 
Discordant cases were reviewed with a gynecologic pathologist and were reassigned 
on consensus of opinion. 
HER-2 sta ining was scored according to the Herceptest protocol 19, and was consid­
ered positive when >10% of tumor cel ls showed moderate or strong membrane stain­
















Antibodies used for immunohistochemical staining 
I 
Incubation 
Antigen Antigen retrieval Primary antibody Company Dilution Detection method time 
HER-2 Tris/EDTA (pHB)' NCL-CBE-356 Novocastra' 1:200 3o min DAKO EnVision+ 
EGFR Trypsin digestion 31G7 Zymed• 1:50 6o min DAKO Universal LSAB™ Kit 
pEGFR Citrate (pH 6)' 1H12 Cell Signaling' 1:500 Overnight DAKO Universal LSAB"' Kit 
AKT1/2 Autoclave' N-19 Santa Cruz' 1:100 Overnight DAKO EnVision+ 
pAKT1/2 Citrate (pH 6)' 736E11 Cell signaling' 1:50 Overnight Avid in/Biotin 
pERK1/2 Citrate (pH 6)' 20G11 Cell Signaling1 1:50 Overnight Avidin/Biotin 
PTEN Citrate (pH 6)' 6H2.1 Cascade' 1:50 6o min Avidin/Biotin 
EGFRvlll EDTA (pH 8)' DHB.3 • 1 µg/µI Overnight Powervision HRP Plus System 
' Sections were boiled in a microwave for 15 (HER-2, pEGFR, pAKT, pERK, PTEN) or 45 (EGFRvlll) min; ' 3 times 5 min at 155 °C in blocking reagent (2% block + 0.2% SOS in 
maleic acid, pH 6.o, Boehringer Mannheim, Mannheim, Germany); • Novocastra, Newcastle upon Tyne, UK; ' Zymed, San Francisco, USA; ' Ce/I Signaling, Danvers, USA; 
• Santa Cruz Biotechnology, Santa Cruz, USA; ' Cascade Bioscience, Winchester, USA; • The DHB.3 antibody was kindly provided by Dr. A Jungbluth (Ludwig Institute for 
Cancer Research, New York, USA). 
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considered to show overexpression 20•22• Overexpression of pEGFR was defined as >5% 
granular cytoplasmic staining 23. Tumors were considered positive for AKT or ERK if 
>100/o of tumor cel ls showed positive cytoplasmic and/or nuclear staining 24• PTEN 
staining in tumor sample was scored relative to staining in vascular endothel ium 25.,6, 
and was regarded as negative when stain ing was completely absent in tumor tissue, 
but present in  vascular endothelium. 
l!T-PCI! for f(ifl!vlll 
RT-PCR was performed on a subset of 45 frozen tumor samples, of which 35 showed 
positive immunostaining for (p)EGFR or downstream targets and 10 were completely 
negative. Positive controls included a g l ioblastoma tumor sample expressing both 
the wild-type EGFR (wtEGFR) and EGFRvl l l ,  and a cel l  l ine transfected with an EGFRvl l l  
plasmid (Jurkat.EGFRvlll) •7• 
RNA extraction and cDNA synthesis was performed as previously described 28• RT-PCR 
was performed separately for EGFRvlll and the housekeeping gene GAPDH. Primers 
were 5'-GGGCTCTGGAGGAAAAGAAA-3' and 5'-AGGCCCTTCGCACTTCTTAC-3' for am­
pl ifying EGFRvl l l  and wtEGFR 29, and 5'-CACCCACTCCTCCACCTTTG-3' and 5'-CCAC­
CACCCTGTTGCTGTAG-3' for ampl ifying GAPDH. The protocol was as fol lows: in itial 
denaturation at 95 °C for 10 min, fol lowed by 30 cycles (EGFRvll l) or 25 cycles (GAPDH) 
of ampl ification (1 min at 95 °C, 1 min at 56°C for EGFRvl l l  and at 60 °C for GAPDH, and 
90 sec at 72 °C) and a final extension step at 72 °C for 7 min.  RT-PCR products (128 bp 
for EGFRvlll, 929 bp for wtEGFR and 110 bp for GAPDH) were visual ized by 1 .5% agarose 
gel electrophoresis in 1x Tris-Borate EDTA buffer. 
Statistical analysis 
Statistical analysis was carried out using the SPSS 12.01 software package. Cut-off 
points for positive marker expression were determined a priori. All cases with <2 eva lu­
able cores were excluded from ana lysis. 
Comparisons between paired tumor samples obtained before and after chemothera­
py were made using the Wilcoxon rank sum test. Associations between markers, and 
between markers and cl in icopathologic characteristics were performed using the 
Ch i-square or Fisher's exact test, where appropriate. 
The end points investigated were progression free and disease-specific overal l  sur­
vival (PFS and OS), defined as the time from primary surgery until progression/relapse 
of the disease or death of ovarian cancer, respectively. Response to platinum-based 
chemotherapy could only be eva luated in patients who had measurable disease after 
primary surgery and/or during first- l ine chemotherapy (N=130), and was defined ac­
cording to WHO criteria 16• 
For univariate and multivariate survival analysis Cox proportional hazards model was 
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simultaneously into the multivariate model. Response to chemotherapy was analyzed 
using logistic regression analysis. For this ana lysis, response was entered as a categori­
cal variable (complete and partial response vs. stable and progressive disease). P-val­
ues <0.05 were considered statistically significant. 
Results 
Patients 
A total of 232 patients (median  age 57.8 years, range 22-90) treated at the Groningen 
University Medical Center between 1985 and 2002 were selected for the present study 
(Table 2). Sixty-four (27.6%) patients presented with stage 1/1 1 d isease and 166 (71 .5%) 
patients with stage I l l/IV d isease. Optimal debulking was achieved in 61 (96.8%) stage 
1/11 patients and 48 (31.0%) stage I l l/IV patients. First-l ine chemotherapy regimens were 
platinum-based in 100 (43.1%) patients and platinum- and taxane-based in 72 (31.0%) 
patients. Twenty-five (10.8%) patients were treated with other regimens, and 32 (13.8%) 
patients did not receive chemotherapy because of stage IA disease, comorbidity or 
treatment refusal. 
For stage 1/11 patients, median PFS was 53 (range 0-207) months and median OS was 
58 (range 0-207) months. For stage I l l/IV patients, median PFS was 10 (range 0-149) 
months and median OS was 18 (range 0-213) months. 
lmmunostainlng and l!T-PCI! 
The number of non-eva luable primary tumors due to core loss during stain ing proce­
dures or absence of tumor tissue ranged from 2 (0.9%) for HER-2 sta in ing to 10  (4.3%) 
for pERK staining. Positive sta in ing was present in 6.2% of tumors for EGFR, 5.1% of 
tumors for HER-2, 11 .8% tumors for pEGFR, 100% of tumors for total AKT, 8-3% of tu­
mors for pAKT and 36.9% of tumors for pERK (Table 3; Figu re 2). Sixty-nine out of 224 
tumors (30.8%) showed completely negative PTEN staining. None of the tumor sam­
ples stained positive for EGFRvl l l , nor could EGFRvll l be detected by RT-PCR. Staining 
for pERK was more frequent in tumor samples obta ined after three or six cycles of 
chemotherapy compared to pa ired primary tumor samples (65% vs. 37%, p=o.020). 
For a l l  other proteins, staining patterns in primary tumors were comparable to pai red 
residual or recurrent tumor samples (Table 3). 
Unexpectedly, PTEN staining was positively correlated with pAKT staining (p=o.034). 




All patients (N=232) 
Characteristic N % 
FIGO stage 
Stage I 45 19.4% 
Stage II 19 8.2% 
Stage Ill 133 57.3% 
Stage IV 33 14.2% 
Missing 2 0.9% 
Tumor type C 
Serous 129 55.6% 
Mucinous 27 11.6% C Clear Cell 17 7.3% 
Endometrioid 33 14.2% C Adenocarcinoma NOS 9 3.9% 
Other 17 7.3% C Tumor grade 
Grade , 39 16.8% 
C Grade 2 51 22.0% 
Grade 3 104 44.8% 
Undifferentiated 14 6.0% C 
Missing 24 10.3% 
Residual disease C s2 cm 111 47.8% 
>2 cm 109 47.0% C Missing 12 5.2% 
Type of chemotherapy 
44 No chemotherapy 32 13.8% 
Platinum-based 100 43.1% 
Platinum/taxane-based 72 31.0% C 
Other regimen 25 10.8% 
Missing 3 1 .3% C 
BS 0 
Table 3 
Results of immunostaining - � 
I - � EGFR pEGFR HER-2 pAKT pERK PTEN "'I 
Primary tumors (N=232) Evaluable 228 228 230 228 I (II 222 224 = 
Positive 16 (7.0%) 27 (11.8%) 12 (5.2%) 19 (8.3%) 82 (36.9%) 155 (69.2%) I !. = 
Negative 212 (93.0%) 201 (88.2%) 218 (94,8%) 209 (91.7%) 140 (63.1%) 69 (30.8%) I = 
Second-look (N=26) Evaluable' 22 22 22 21 20 19 I =-i 
I Positive 4 (18.2%) 5 (22.7%) 1 (4.5%) 4 (19,0%) 13 (65,o%) 16 (84.2%) = 00 I � OI Negative 18 (81.8%) 17 (77.3%) 21 (95.5%) 17 (81 .0%) 7 (35,0%) 3 (15,8%) 
� 
P-value' 0,317 0,317 1.000 0.317 0.020 0.655 I = = 
� 
Recurrent disease (N=19) Evaluable' 18 18 18 I = 19 19 19 = � 
Positive 2 (10.5%) 3 (15.8%) 2 (11.1%) 3 (16.7%) 8 (42.1%) 17 (94,4%) I "'I 
Negative 17 (89.5%) 16 (84.2%) 16 (88.9%) 15 (83.3%) 11 (57.9%) 1 (5.6%) 
P-value' 0.317 0,564 0.157 0 317 0317 0.317 
Bold signifies p<o.05. ' Number of evaluable cases (cases with <2 evaluable cores were excluded from the analysis); ' P-value from Wilcoxon rank sum test for 
comparison of protein expression between tumor samples from primary surgery and from second-look; ' P-value from Wilcoxon rank sum test for comparison of 
protein expression between tumor samples from primary surgery and surgery for recurrent disease. 
Table 4 
Relationship between proteins and clinicopathologic characteristics 
HER-2 EGFR pEGFR 
positive positive positive 
Variable No. (%) P* No. (%) P* No. (%) P* 
All patients 12 (5-4%) 16 (7.0%) 27 (11.8%) 
Age 0.14 0-44 0.84 
s58 years 3 (25.0%) 6 (37.5%) 14 (51.9%) 
>58 years 9 (75.0%) 10 (62.5%) 13 (48.1%) 
Stage 1.00 0.77 0-49 
C0 I Early 3 (25.0%) 5 (31.3%) 9 (33.3%) 
Late 9 (75.0%) 11 (68.8%) 18 (66.7%) 
Histology 0.38 0.017 0-43 
Serous 5 (41.7%) 4 (25.0%) 16 (59.3%) 
Non-serous 7 (58.3%) 12 (75.0%) 11 (40.7%) 
Grade 1.00 0.78 0.18 
Grade 1/2 5 (45.5%) 5 (35.7%) 13 (56-5%) 
Grade 3/undiff 6 (54-5%) 9 (64.3%) 10 (43.5%) 
Residual tumor 0.54 1.00 0.84 
s2 cm 4 (36.4%) 7 (46.7%) 12 (46.2%) 
>2 cm 7 (63.6%) 8 {53.3%) 14 (53.8%) 
Bold signifies p<o.05. * Chi-square or Fischer exact test, where appropriate. 
0 0 0 � 0 0 () () () () � 
pAKT 
positive 
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Figure 2 
Results of immunostaining. A. Positive membrane staining for EGFR; 
8. Granular cytoplasmic staining for pEGFR; C. Membrane staining for 
EGFRv//1 (positive control); D. Membrane staining for HER-2; E. Cytoplas­
mic staining for pAKT; F. Nuclear and cytoplasmic staining for pERK; G. 
Nuclear and cytoplasmic staining for total AKT; H. Cytoplasmic staining 
forPTEN. 
Clinlcopathologlc characteristics 
Overexpression of EGFR was more frequent in non-serous tumors (p=o.017; Table 4). 
Stage Il l/IV tumors more often showed overexpression of pAKT (p=o.029). Loss of PTEN 
was related to stage 1/1 1 d isease (p=o.006). Furthermore, negative PTEN immunostain­
ing was associated with non-serous tumor type (p=o.042), occurring in 250/o of serous, 
390/o of endometrioid, 42% of mucinous and 560/o of clear cel l  tumors. No other associa­
tions between protein expression and cl inicopathologic variables were found. 
88 
Table 5 
Results of univariate surviva l analysis 
Univariate Cox regression analysis 














Bold signifies p<o.05. 




























Univariate Cox regression analysis revealed that patients with a PTEN negative tu mor 
had a better PFS and OS (p,0.001 and p=o.037, respectively; Table 5). Subgroup a naly­
sis for stage 1/1 1 and stage I l l/IV patients showed that PTEN predicts PFS only in the 
early stage group (HR 0.29, 95%CI 0.095-0.9, p=o.032 for stage 1/11 patients; HR 0.74, 
95% Cl 0-48-1 .15, p=o.18 for stage I l l/IV patients). I n  mu ltivariate analysis PTEN stain ing 
(p=o.015), FIGO stage (p=o.013) and residual tumor after primary surgery (p<o.001) 
independently predicted PFS (Table 6). Tumor stage (p=o.023) and residual tu mor 
(p<o.001), but not PTEN sta in ing (p=o.833), were s ignificant prognostic factors in mul­
tivariate analysis for OS. Other markers were not associated with survival. Protein  ex­
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Table 6 
Results of multivariate survival analysis 
Multivariate Cox regression analysis 
Progression free survival 
PTEN negative tumor 
Age >58 years 
FIGO stage Ill/IV 
Serous tumor type 
Differentiation grade 3/undiff 
Suboptimal debulking 
Overall survival 
PTEN negative tumor 
Age >58 years 
FIGO stage I l l/IV 
Serous tumor type 
Differentiation grade 3/undiff 
Suboptimal debulk!ng 
Bold signifies p<o.05. 
Discussion 
Hazard 95% confidence 
ratio interval 
0-57 0-36·0 90 
1.09 0.74-1.60 
2.51 1 .21-5.19 
1 .44 0-92-2.24 
1-40 0.89-2.19 




















Our study in a large, wel l-defined series of epithel ia l  ovarian cancer patients shows 
that PTEN negative tumors might represent a subgroup of ovarian carcinomas with 
a relatively favorable prognosis. To our knowledge this is the first study describing a 
relationship between negative PTEN staining and improved survival in ovarian can­
cer. While a relationship between negative PTEN sta in ing and improved survival has 
been described for endometria l  cancer patients, previous studies in  ovarian cancer 
found no or an inverse relationsh ip between PTEN and prognosis 30 33• These contrast-
90 
ing resu lts could be explained by the fact that previous studies either did not have the 
power to eva luate possible relations with survival, or restricted their ana lysis to stage 
I l l/IV ovarian cancer patients, whi le in the current study PTEN sta ining was of prognos­
tic sign ificance mainly in the stage 1/1 1 group. 
We found negative PTEN expression in 30.8% of tumors, which is in agreement with 
previous studies 31•32•34• In ovarian cancer, loss-of-heterozygosity (LOH) at the PTEN lo­
cus (1oq23.3) occurs in 31-45% of tumors, whi le mutations of the second PTEN a l le le 
are relatively rare 24•35•36• Loss of protein expression is therefore a lso thought to a rise via 
other mechanisms, such as DNA methylation 4• 
Interestingly, we showed a high rate of negative PTEN staining in endometrioid and 
clear cel l  tumors. A high rate of PTEN loss in  c lear cel l  and endometrioid carcinomas 
has a lso been shown in previous, much smal ler studies 34•36. Both cancers are thought 
to at least partly arise from endometriosis. Sato et a l  showed that in  three out of five 
ovarian carcinomas associated with endometriosis, LOH at 1oq23.3 occurs in  both the 
carcinoma and in endometriotic lesions, impl icating that LOH is an early event in car­
cinogenesis and that PTEN is involved in the progression from endometriotic precur­
sor lesion to clear cel l  or endometrioid ovarian cancer 37. 
Our results show that negative PTEN staining is strongly associated with early stage 
disease and a non-serous tumor type. Recent studies suggest that ovarian carcino­
mas cou ld be divided in two categories. The fi rst category, ca l led type I, includes low 
grade serous, mucinous, clear cel l and endometrioid tumor with frequent alterations 
in B-Raf, K-Ras and PTEN. Type I tumors are thought to arise from precursor lesions 
such as endometriosis and have a relatively good prognosis. I n  contrast, type II tu­
mors, includ ing high grade serous and und ifferentiated carcinomas characterized by 
p53 mutations and overexpression/ampl ification of HER-2 and AKT2, tend to show a 
highly aggressive behavior 38•39• In the present study, we identified a relationship of 
pAKT expression with late stage disease. Moreover, our previous work showed that 
overexpression of p53 mostly occurs in high grade, late stage, serous carcinomas 17• 
Our combined resu lts therefore support this model of ovarian carcinogenesis. 
We did not observe any association between EGFR and HER-2 immunostaining and 
disease outcome, confirming results of a previous study a lso from our institution 4". 
Previous studies on the relationship between EGFR or H ER-2 overexpression and cl in­
icopathologic characteristics, response to chemotherapy and survival have shown 
conflicting resu lts 20.41 43• One of the most important reasons for these inconclusive 
data is the considerable methodolog ical variabi l ity amongst studies 44• Techniques 
used to determine marker expression, antibodies and scoring systems used for immu­
nostaining vary widely between studies. For the present investigation, we aimed to 
use well-characterized antibodies that have been extensively studied in other tumor 
types, and, if possible, used well-defined scoring criteria that have been shown to 
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prognostic factor studies 45• The use of these gu idelines and of standardized methods 
should aid in increasing transparency and reproducibi l ity of prognostic factor studies 
in ovarian cancer and other tumor types. 
As tumors showing evidence of strong signal ing through a particu lar pathway are 
thought to have a high chance of responding to therapies d irected against this path­
way, the identification of rel iable biomarkers could aid in selecting patients who are 
most l ikely to benefit from targeted therapy 46• Results of d ifferent clinical tria ls show 
that positive immunostaining for HER-2 or EGFR does not rel iably predict response to 
ErbB targeted therapy 47•48• A possible better marker of response to EGFR and HER-2 
targeted therapies is activation or downregulation of downstream pathways. Indeed, 
positive immunosta in ing for pAKT, pERK, PTEN and EGFRvl l l  have been reported to 
predict sensitivity to EGFR tyrosine kinase inh ibitors in non-small cell l ung cancer and 
g l ioblastoma 23A9• The association of pAKT and pERK in relation to response to ErbB 
targeted therapy in ovarian cancer has not been studied yet, but expression of these 
proteins might be used as a marker of responsiveness to targeted therapies. Our re­
sults show that 8.3% and 36.9% of tumors show positive pAKT and pERK sta in ing, 
respectively, indicating that only a subgroup of patients might benefit from agents 
directed against these pathways. 
As pERK is overexpress in approximately one thi rd of primary ovarian tumors and 65% 
of tumor samples from primary chemoresistant tumors obta ined after chemotherapy, 
treatment of patients with Ras/Raf/MEK/ERK targeted agents appears to be an i nter­
esti ng therapeutic option 50• 
Surprisingly, we identified a significant relationship between positive expression of 
AKT and positive expression of PTEN. The role of PTEN as a negative regu lator of AKT 
is well documented in both cel l l ine models and tumor samples 24,2s.m2• However, oth­
ers have also identified a positive correlation between expression of the two proteins 
by immunosta ining 32.B54_ This might mean that in tumors, the regulatory relationship 
between AKT and PTEN is not l inear. 
In contrast to avai lable data in l iterature we did not detect any EGFRvl l l  in this large 
group of ovarian carcinomas. Moscatello et a l  reported that EGFRvl l l is expressed in 
75% of ovarian tumors, but this high percentage could not be confirmed in  subse­
quent studies 1855• We determined EGFRvl l l  status by immunohistochemistry using the 
wel l-defined antibody DH8.3 and verified our resu lts at the RNA level by RT-PCR on a 
subset of 45 tumors showing positive immunostain ing for EGFR or downstream tar­
gets. As EGFRvll l  heterod imerizes with wtEGFR, is constitutively phosphorylated and 
activates AKT and to a lesser extent ERK, we hypothesized that the chance of finding 
EGFRvl l l  positive tumors was largest in this subgroup st>·sa. As we did not detect any 
EGFRvl l l  positivity in this subgroup, nor in ten tumors that did not overexpress any of 
the studied markers, our data strong ly suggest that EGFRvl l l  signa ling does not play a 
major role in ovarian cancer. 
92 
I n  summary, we demonstrated that negative PTEN staining is associated with favo­
rable patient and tumor characteristics, and independently predicts improved PFS. 
Further studies should elucidate the prognostic va lue of PTEN especially in stage 1/1 1 
patients. The importance of pAKT and pERK expression as downstream markers of re­
sponsiveness to receptor tyrosine kinase targeted therapies deserves to be evaluated 
in c l in ical tria ls. A better understand ing of these pathways and their role in ovarian 
cancer will enable us to use targeted drugs more efficiently, and to identify (groups 
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Factor analysis (FA) has been widely appl ied in microarray studies as a data-reduction-tool with­
out any a priori assumption regarding associations between observed data and latent structure 
(exploratory factor analysis). A disadvantage is that the representation of data in a reduced set 
of dimensions can be difficult to interpret, as biological contrasts do not necessarily coincide 
with single dimensions. However, FA can also be applied as an instrument to confirm what is 
expected on the basis of pre-established hypotheses (confirmatory factor analysis, CFA). We 
show that with a hypothesis incorporated in a balanced (orthogonal) design, including "Self­
Self" hybridizations, dye swaps and independent replications, FA can be used to identify the 
latent factors underlying the correlation structure among the observed two-color microarray 
data. An orthogonal design will reflect the principal components associated with each experi­
mental factor. 
Methods 
We applied CFA to a microarray study performed to investigate cisplatin-resistance in four  ovar­
ian cancer cell l ines, which only d iffer in their degree of cisplatin-resistance. 
Results 
Two latent factors, coinciding with principal components, representing the differences in cis­
platin-resistance between the four ovarian cancer cel l lines were easily identified. From these 
two factors 315 genes associated with cisplatin-resistance were selected, 199 genes from the 
first factor (false discovery rate (FDR): 19%) and 152 (FDR: 24%) from the second factor, while 
both gene sets shared 36. The d ifferential expression of 16 genes was validated with reverse 
transcription-polymerase chain reaction. 
Conclusion 
Our results show that FA is an efficient method to analyze two-color microarray data provided 
that there is a predefined hypothesis reflected in an orthogonal design. 
Introduction 
DNA microarrays are often used to identify genes that are differentia l ly expressed 
among different predefined classes of samples. In a two-color microarray system both 
RNA samples are separately labeled with different colors, mixed, and hybridized to­
gether to an array. The ratio of the two-color signal intensities for each spot represents 
a relative measure of gene expression. There are different types of design of two-color 
microarrays for identifying d ifferentia l ly expressed genes, such as the reference design 
(most commonly used), ba lanced block design, and loop design 1 •  
Two-color microarray data analysis general ly consists of two stages. In the first stage, 
microarray data are fi ltered and normal ized, e.g. adjusted for some of the systematic 
and technical variation that affects the measured gene expression levels. There are 
different methods to correct (normal ize) microarray data for systematic and techni­
ca l variation 2 8. I n  the second stage of microarray data ana lysis, statistical methods 
are used to identify the genes that are d ifferentially expressed between the d ifferent 
classes of samples. Most of these statistical methods use s imi lar basic statistics and 
differ mainly in  their determination of the significance threshold. Therefore, when ap­
plied to microarray data they give very simi lar overa l l  results 9·'0. 
Factor ana lysis (FA) can be appl ied as a data-reduction-tool without any a priori as­
sumption regarding associations between observed data and latent structure (explor­
atory factor analysis, EFA). For this purpose FA has been widely appl ied in microarray 
studies 3• A disadvantage of EFA is that the representation of data in a reduced set of 
dimensions can be difficult to interpret. On forehand the interpretation of the ex­
tracted factors is not fixed a nd biological contrasts do not necessarily coincide with 
single d imensions. 
Yet, FA could be very wel l  used for gene selection when it is appl ied as an instrument 
to confirm what is expected on the basis of pre-established hypothesis (confirmatory 
factor analysis, CFA) 11• When two-color microarray experiments are designed such that 
a hypothesis can be defined a priori regarding the latent structure among the ob­
served two-color microarray data, biological ly relevant factors can be easily identified 
from which genes can be selected (as the correlation structures of the biologically 
relevant factors with the arrays should mirror the appl ied design). 
In  this paper we will i l lustrate CFA as a powerful statistical tool to analyze DNA micro­
array data. As a model a microarray study is used in which the differences in gene 
expression related to cisplatin-resistance are measured, using two-color microarrays, 
for four ovarian cancer cell l ines (A2780, CP70, (30 and C200), which only d iffer in their 
degree of cisplatin-resistance. A2780, the parental cel l l ine, is cisplatin-sensitive and its 
subl ines CP70, (30 and C200 are increasingly resistant to cisplatin (5, 75 and 125 times 
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Background methodology 
Confirmatory factor Analysis 
The fundamental idea underlying the factor ana lytic models is that not a l l causative 
variables can be d i rectly observed. These unobserved variables are referred to as latent 
structu re of factors. Information a bout factors can be obtained by inspecting how the 
factor e lements are formed from l inear combinations of the observed variables. In an 
EFA, there is no specified structure of the relationships a mong the variables under 
study. In a confirmatory factor analysis the retrieved factors should reflect contrasts 
that correspond to differences in sample characteristics. There are a priori defined con­
straints on the relationships among the latent factors and the variables under study. It 
is in this sense that the FA is thought of as confirmatory. 
I n  the here i l lustrated model, differences in gene expression between four ovarian can­
cer cel l l ines (A2780, CP70, (30 and (200) are related to their degree of the cisplatin-re­
sistance. The level of cisplatin-resistance can be considered as the latent factor among 
the observed gene expression data. The latent factors, referred to as I;, are depicted as 
a circle at the top of Figure 1. The ( is imperfectly measured by a number of observed 
variables, e.g. two-color microarrays. While it is assumed that the number of observed 
variables in X is greater than the number of latent factors in I;, there is no a priori as­
sumption about the exact number of latent factors. In our example, seven two-color 
microarrays are used, referred to as X1 to X7, and they are indicated by the squares in 
Figure 1. The measurement errors in the observed variables, referred to as ox to 8 , are 1 X7 
depicted as circles at the bottom of the Figure 1. X1 to X7 are said to be effected by or 
load on I;, the level of cisplatin-resistance. The loadings, referred to as Ax, to Ax?' are in­
dicated by the arrows connecting the latent factor to the observed variables. 
In a microarray experiment there are i = 1 ,  . . .  , n performed arrays and j = 1, . . .  , p probed 
genes. Typica l ly,j is in the order of thousands, while i is in the order of 10-100. The gene 
expression measurements of the microarray experiment are represented by a matrix 
X = [x,, . . . ,x) of dimension n x p, with a rrays as columns and genes as rows. Each ele­
ment xiJ corresponds to the gene expression measurement for the jth gene of the ith 
array. The expression level x,
1 
of each gene can be reconstructed by the standard l inear 
equation: 
Th is means that the observed expression for the jth gene of the ith array is the sum 
of its activities in each of s latent factors (contrasts in the levels of cisplatin-resistance 
between the 4 cell l ines), denoted by l;,J' weighted by the activity of this latent factor 

























Confirmatory factor analysis model of the microarray study. The differences in gene expression related to cispla­
tin-resistance are measured, using two-color microarrays, for four ovarian cancer cell lines (A27Bo, CP10, C30 and 
C200), which only differ in their degree of cisplatin-resistance. The latent factors representing level of cisp/atin· 
resistance are depicted as a circle at the top of the figure. The squares represent the observed variables, e.g. the 
microarrays. The arrows connecting the latent factor and the arrays illustrate the loadings of the arrays on the 
latent factor. (In our model the latent factors do not load on the "SelfSelf" hybridization, X1 ()..x1*=0)). The circles 
at the bottom of the picture symbolize the measurement errors. (This design was performed in triplicate with 
three independent cultures of the ovarian cancer cell lines). 
This can be represented in matrix format as: 
X = A; + o  
Where A is the p x p matrix of factor loadings (the correlation structure of each of the 
latent factors s with the arrays 1) and ; is the n x p matrix of factor scores (the levels of 
activity of each gene j within each of the s latent factors) and 6 is the matrix of residu­
als as result of dimension reduction. 
By subtracting the mean from both the observed and latent variables it is possible 
to define the covariance matrix of a vector of variables in terms of expectations of 
vector products. In addition, it is assumed that the latent factors are uncorrelated (i.e. 
orthogonal). For that, in the here-i l lustrated example, we appl ied the method of sin­
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This method assumes that the extracted factors are uncorrelated and orders the fac­
tors according to percentage explained variation (successive factors account for less 
a nd less variation overa l l). The number of extracted factors can maxima l ly be equal to 
the total number of arrays. 
The confirmatory factor model is identified if the constraints have been imposed in such 
a way that there is a unique set of parameters that can generate the covariance structure. 
More specific, if a parameter can be solved for In terms of the variances and covariances 
of the observed variable, it is identified. The constraint that retrieved factors have to be 
orthogonal is appl ied as some patterns underlying the microarray data are expected to 
be correlated with biological processes and others with experimental artifacts. 
After identification has been establ ished, estimation can start. The objective in es­
timating the factor model is to find estimates of the latent factors and errors that 
reproduce the sample matrix of covariances as closely as possible. The fitting function 
used in the here-i l lustrated example, is the unweighted l inear least squares (ULS). The 
problem of scale dependency was solved by performing the analyses on the correla­
tion structure instead of the covariance structure. 
nybridization design 
The hybridization design  of the microarrays was as fol lows (Table 1): 
• The design was ba lanced: the four ovarian cancer cel l  l ines were hybrid ized to 
the microarrays according to a reference design, indicating that a l l  samples were 
hybridized against the cisplatin-sensitive cell l ine A2780 (common reference). The 
microarray data were expressed as Cys/Cy3 ratios for each spot. 
• The design included a "SelfSelf" hybrid ization, X1 in Figu re 1. Note that al l  observed 
microarray data were expected to load on the latent factor �. except for X1 (A"' ==o). 
This is because there should be no biolog ical d ifference between the two-color 
signal intensities of "SelfSelf" experiments and therefore the "SelfSelf" hybrid ization 
was assumed not to load on the latent factor. 
• The design included dye swaps, X2 and Xs, X3 and X6, X4 and X7 in Figure 1 .  CP70, 
(30 and C200 were labeled with Cys and hybridized against Cy3-labeled A2780, X2, 
X3, and X4 in Figure 1, respectively. Then the dyes were swapped: CP70, (30 and 
C200 were labeled with Cy3 and hybrid ized against Cys-labeled A2780, Xs, X6, and 
X7, respectively. The sign of the loadings of X2, X3 and X4 were assumed to be op­
posite to the signs of the loadings of Xs, X6 and X7, as these were the dye swaps. 
The magnitude of the loadings of X2 and Xs, X3 and X6, X4 and X7 were assumed 
to be similar, as the same ovarian cancer cel l l ines were hybrid ized to these arrays. 
Once the latent factors had been identified using their correlation structure with 
the observed varia bles, d ifferences in level of cisplati n-resistance would appear as 
contrasts between simi lar arrays after correction (sign change) for dye swaps. 
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Table 1 
Overview of the balanced reference design* 






























* This design was used for the 3 independent RNA isolations from the ovarian cancer 
cell lines A2780, CP70, C30 and Cioo (3 independent cell cultures). In addition, one extra 
"SelfSe/f" was performed in the second replication of the design, resulting in a total of 
22 hybridizations. 
• The design was performed in tripl icate with three independent cultures of the cel l  
l ines. I t  was expected that replicate arrays, e.g. the two replicates of X1 to X7, would 
show the same loadings. 
Analysis 
First the observed variables were standard ized, i.e. FA was separately appl ied to the 
Cys and Cy3 m icroarray data to subtract the variation all a rrays had in  common. The 
first factor explaining the largest part of the variation, could be considered as  varia­
tion the arrays have in common 3• This factor cou ld be used for array qual ity control, 
as it wou ld have lower or d istinctly d ifferent correlations with arrays of lesser q ua l ity. 
In add ition, plotting the standardized Cys signal intensities against the standardized 
Cy3 signal intensities, a l lowed us to test whether the hybridizations were non-com­
petitive 12• However, from a mathematical point of view there i s  no objection to di­
rectly subjecting Cys/Cy3 ratios to FA 
In  the second step, CFA was performed to uncover which of the factors coincided 
with differences in levels of cisplatin-resistance between the four ovarian cancer cel l  
l ines and to select the genes with the highest loadings on those factors. 
It was assumed that a random process leading to non-normal d istributions wou ld 
l ikely affect al l extracted factors (biological and non-biological) to an equal degree. 
Therefore, it was assumed that the statistical d istribution of the gene expression data 
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sent noise. Because we expected that the biological factors would resu lt i n  genes with 
more extreme scores than those present in the non-biological factors we performed 
the ana lysis on scores with equal rank. First, the elements of each reta ined (biologica l) 
factor were rank-ordered and normal ized to a mean of zero and to a standard devia­
tion of one. Then the elements with the same rank for each of the factors representing 
noise were averaged and renormal ized. Because the distribution affected by biologi­
cal effects has more weight in the tai ls of the d istribution, the elements with the most 
extreme scores wi l l be la rger in absolute value than the elements with the same rank 
from the rank averaged factors. Subsequently, the genes with the same rank with the 
largest difference va lues (::;;-1 and ;;?:1) from the averaged d istribution were selected. 
This happened to resu l t  in selecting the genes with the most extreme scores. The 
threshold below or above (::;;-1 and ;;?:1) genes were selected was used to obtain a fa lse 
discovery rate (FDR) by observing how many elements of the rank  averaged factors 
were below or above this threshold. 
For a script of the appl ied method, the corresponding author can be contacted. 
Results 
first step of the f A procedure: standardization of the 
CyS and Cy3 data 
The first factors from the Cys and Cy3 data explained 85% of the total variation and 
represented variation common to al l a rrays. Figure 2 shows that the correlations be­
tween the Cys and Cy3 data of each array and the first factor were highly simi lar. This 
figure a lso indicates that the qual ity of the a rrays was very comparable. By subtracting 
this common variation from the Cys and Cy3 data a l l  gene specific variation that does 
not contribute to d ifferences between arrays was el iminated (i.e. the Cys and Cy3 data 
were standardized by subtracting the first factor). 
After el imination of the common variation, the standard ized Cys and Cy3 signal in­
tensities of a l l  a rrays combined showed a positive correlation (Figure 3). When Cys 
signal intensities in  a specific array were lower than average, also Cy3 signa l intensi­
ties were lower than average, and reversely, implying that the hybrid izations were 
non-competitive. The phenomenon of non-competitive hybridization as seen in our 
cDNA microarrays was recently a lso described for long-ol igonucleotide m icroarrays 
by 't Hoen and col leagues 12• 
Second step of the f A procedure: identification of the 
biologically relevant factors 
I n the second step, the factors representing d ifferences in cisplatin-resistance between 
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Figure 2 
Correlations between the Cys and Cy3 data from each array, respectively, and the first factor 
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Figure 3 
Scatterplot of the standardized Cys signal intensities against the standardized Cy3 














factor analysis, an efficient method to analyze microarrays ••• 
dye swap 
0 -----------------------









15 - ------------ · -----------1----
20 








Correlations between the standardized Cyslstandardized Cy3 ratios from each array and the first 
factor retained with FA. 
0 
dye swap 
1 - 'Seltself 
- CP70 
- C30 
5 c:::::::J C200 
2 
>, 10 
1 5  
3 
20 
-0,6 -0.4 -0,2 0,0 0.2 0,4 0,6 
Correlation 
Figure s 
Correlations between the standardized Cyslstandardized Cy3 ratios from each array and the second 
factor retained with FA. 
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and second factor) of which the correlation structures with the observed variables, 
e.g. a rrays, reflected the balanced reference design (Figures 4 and 5). 
The first factor explained a considerable part of the remaining variation between ar­
rays (40%). The first factor did not correlate with the "SelfSelf" hybridizations. Further­
more, the sign of the load ing of dye swap experiments on the first factor was opposite 
and replicate experiments showed the same loading (Figure 4). After the sign of the 
dye swaps was changed, a l l  the arrays showed simi lar loadings on the first factor. Thus, 
this factor reflected the contrast between A2780 (used as reference in each array) and 
CP70 + C30 + C200. The microarray data of the more resistant ovarian cancer cel l  l ines 
C30 and C200 had a consistently higher (about 4%) loading on this factor than the 
data of the less resistant cell line CP70. 
The second factor was only associated with a minor amount of variance (11%), but its 
correlation structure with the arrays reflected "SelfSelf" hybridizations, dye swaps and 
replicate experiments. After correction for dye swaps, this factor could be interpreted 
as a contrast between CP70 and C30 + C200 (Figure 5), as the sign of the loading of 
the microarray data of CP70 on the second factor was opposite to the sign of the 
loadi ngs of the data of (30 and C200. The absolute weight of the microarray data of 
(30 (mean: 8%) was much lower than that of the data of C200 (mean: 19%) and CP70 
(mean: 25%), so this factor reflected mainly the difference between the least and most 
cisplatin-resistant cell l ine. 
After the factors coincid ing with biological contrasts (differences in cisplatin-resist­
ance between the cell l i nes) had been identified, the genes responsible for these con­
trasts were selected as the most extreme ones from the first and second factor. From 
the first factor 199 genes (FDR: 19%) were selected and from the second factor 152 
genes (FDR: 24%). Both gene sets had 36 genes in common. 
Of the 199 genes selected from the fi rst factor, the expression of 99 genes was up­
regulated and the expression of 100 genes was downregu lated in CP70 + (30 + C200 
compared to A2780. Of the 152 genes selected from the second factor, the expres­
sion of 24 genes was upregulated and the expression of 128 genes was down regu­
lated in C30 + C200 compa red to CP70. To va l idate the expression of genes selected 
from the biological factors, reverse transcription-polymerase chain reaction (RT-PCR) 
was performed for 16 genes with GAPDH as a control: COL3A1, ENO2, FGF18, JUN, 
LHX2, MEIS1, MEIS2, PBX3, PDGFRL, PRICKLE1, SAT, SHB, TIMP2, TLX1, TOP1 and UACA. 
Figure 6 demonstrates that the differential expression pattern of the 16 genes, as de­
termined with RT-PCR, was comparable to the FA results of the microarray data, con­
firming the rel iabi l ity of our  analysis of the microarray data. Additional ly, in Table 2 is 
shown that there is overlap between our gene l ists and gene l ists from other groups 
who have profi led A2780 and its cisplatin/oxa l iplatin-resistant subl ine(s), confirming 
our results 13 16• Furthermore, FatiGO was used to annotate the genes with Gene On­
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RT-PCR results for 16 genes of the 4 ovarian cancer cell 
lines. F1, up- (t) or down- (,I,) regulated in CP70 + C30 
+ C2oo compared to A21Bo. F2, up- {t) or down- (,I,) 
regulated in C30 + C2oo compared to CP70. 
d istribution of the main GO terms between the gene l ist selected from the fi rst and 
second factor 17• As shown in  Table 3, the d istributions of the main GO terms were not 
s ignificantly d ifferent between the two groups of genes. 
Discussion 
I n genera l  FA, as effected by SVD, is appl ied to two-color mlcroarray data for sum­
marizing, fi ltering and preprocessing data (EFA), a lthough several stud ies have shown 
FA can be used for gene selection '8 29• A weakness of straightforward appl ication of 
FA to microarray data without a ny a priori expectations regarding the latent structure 
among the observed data is that there is no straightforward way of objectively assess­
ing model performance. However, in our microarray study we have shown that rather 
than applying FA directly to the analysis of microarray data, when the structure of the 
relationships among the variables (e.g. arrays) is specified a priori, reflected by the de­
sign of the study, FA is an efficient method to analyze two-color microarray data. 
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Table 2 
Comparison of our gene l ist with gene l ists described in literature 
A2780 vs. CP70 + C30 + C200 CP70 vs. C30 + C200 
Reference: 
Cell lines Up- Down- Down regulated* 
regulated regulated 
13: 6 cisplatin-resistant cell 
JUN {t) and pairs, including A2780 and IFITM1 (,l,) MRC2 (,l,) CP70 
14: A2780 and oxaliplatin- FER1L3 (t), LIPA (t), SOC2 (,l,), MID1 (,l,), MMP3 (t), SPARC (t), IFITM1 (t), NMI (t) TFPI (,l,), MMRN (,l,), FER1l3 (t), TM4SF1 (,l,), resistant C10B 
and ALCAM (t) CCR, (,l,) and NID2 (t) CRIM1 (,l,) and PEG10 (,l,) 
16: 4 oxaliplatin-resistant cell TIMP2 (t), COTL1 (t), NFE2L1 (t), IFITM, (,l,) TIP120B (t) IL1R1 (t), SPARC (t) pairs, including A2780 and R4 and SLC4A2 (,l,) 
15: A2780, cisplatin-resistant S100A11 (,l,) and PEG10 (t), TMSB4X (,l,) 
ACR6 and ACRP SLC25A6 (,l,) and COLsA2 (,l,) 
The arrows behind the genes indicate whether the gene was up- (t) or down- (,l,) regulated in the cisplatin/ 
oxaliplatin-resistant subline(s) compared to the cisplatin/oxaliplatin-sensitive parental cell line according to 
microarray or SAGE data of other groups. * The genes selected from factor 2 that were also described in litera­
ture were all downregulated in C30 + C200 compared to CP70. 
Based on this predefined hypothesis two latent factors coinciding with differences 
in cisplatin-resistance between four ovarian cancer cell l ines were easily identified. 
The first factor retrieved during the fist step of FA represented the common variation 
of arrays and the fi rst two factors retrieved during the second step represented dif­
ferences between arrays. The variation of the arrays is generally explained by only a 
smal l  number of factors, of which the first (the major source of variation) represents 
variation the arrays have in common 18•20•24•26•27• One of the two factors that represented 
differences between arrays was interpreted as the contrast between the cisplatin-sen­
sitive A2780 cel ls and the cisplatin-resistant CP70, C30 and C200 cel ls. The other factor 
was explained as the contrast between the mi ld cisplatin-resistant CP70 cel ls and the 
extreme cisplatin-resistant C30 and C200 cells. From the fi rst factor 199 genes and 
from the second factor 152 genes were selected and 36 genes were shared by both 
gene sets. Th is overlap makes it very plausible that the two retrieved factors are in­
deed biologically meaningfu l .  It is biologically plausible that genes that are important 
for the difference between cisplatin-sensitive cel l s  and cisplatin-resistant cel ls  are a lso 
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Table 3 
Comparison of the main Gene Ontology categories among the gene lists 
A2780 vs. CP70 + 
CP70 vs. C30 + C200 
Gene Ontology: Level 3 C3o + C200 
No. of genes (%)' No. of genes (%)2 p 
Biological Process 
Cellular physiological process 60 (81) 39 (78) 0.82 
Metabol ism 43 (58) 29 (58) 
Regulation of cellular process 24 (32) 15 (3o) 0.85 
Organismal physiological process 23 (31) 10 (20) 0.22 
Regulation of physiological process 22 (30) 16 (32) 0.84 
Cell communication 20 (27) 13 (26) 
Localization 18 (24) 10 (20) o.66 
Response to stress 13 (18) 5 (10) 0,30 
Response to biotic stimulus 10 (14) 5 (10) 0.78 
Cell adhesion 10 (14) 3 (6) 0.36 
Negative regulation of biological process 9 (12) 5 (10) 0.78 
Response to external stimulus 9 (12) 3 (6) 0.36 
Morphogenesis 7 (9) 3 (6) 0.73 
Organ development 6 (8) 5 (10) 0.75 
Molecular Function 
Protein binding 33 (40) 24 (40) 
Ion binding 27 (33) 15 (25) 0.35 
Nucleic acid binding 18 (22) 12 (20) 0.84 
Transferase activity 14 (17) 3 (5) 0.04 (1)3 
Transcription factor activity 8 (10) 3 (5) 0.36 
Receptor activity 7 (9) 11 (18) 0.12 
Nucleotide binding 7 (9) 4 (7) 0.76 
Hydrolase activity 6 (7) 9 (15) 0.17 
Enzyme inhibitor activity 6 (7) 4 (7) 
Receptor binding 5 (6) 5 (8) 0.74 
' 74 genes with Gene Ontology annotation for biological process and 82 for molecular function; ' 50 genes 
with Gene Ontology annotation for biological process and 60 for molecular function; 3 FDR adjusted P-value. 
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By using SVD for the computation of the latent factors underlying the microarray data, 
we obta in uncorrelated (i.e. orthogonal) factors. Therefore, the outlier genes selected 
from each factor are not necessarily the same. The expected number of outlier genes 
common to both factors under the hypothesis of no relation is 1 .6, which is much 
lower than the actually found number of 36. Comparison of selected gene sets from 
biologica l ly relevant factors between arrays may, thus, be an important tool to vali­
date that the factors are indeed biologica l ly meaningful .  The biological relevancy of 
the factors was a lso supported by the finding that the loadings of the expression data 
of the ovarian cancer cel l  l ines on the two contrasts differed which could a lso be at­
tributed to the differences in the levels of cisplatin-resistance of the cell l ines. Further­
more, the FA data were supported by RT-PCR results for 16  genes and l iterature 13 16• 
Analyzing microarray data with CFA has several advantages. With only one a lgorithm, 
that is ava ilable in any standard statistical software package, both stages of microarray 
data ana lysis can be performed. By applying FA, variation in microarray data caused by 
biologica l d ifferences can be separated from variation related to the microarray tech­
nique. By using SVD, we assumed that some latent factors are expected to be corre­
lated with biological processes and others with experimental artifacts. So, applying FA 
to microarray data a lso means that to select differential ly expressed genes between 
different classes of samples, the classes do not have to be defined a priori. 
An advantage of using ULS as fitting method is that no assumption about the dis­
tribution of the microarray data has to be made. Other microarray ana lysis methods 
often assume that the gene expression data fol low normal distribution, but in rea lity 
the distribution is not necessarily symmetric and its tai ls  can differ in size and shape. 
A random process leading to non-normal distributions wil l  l i kely affect a l l  extracted 
factors (biological and non-biological) to an equal degree. Therefore, the statistical 
distribution of the gene expression data can be estimated from the factors that most 
l ikely represent noise. 
The problem of scale dependency was solved by performing the analyses on the 
correlation structure instead of the covariance structure. In this analysis we were not 
hindered by the difficulty that for ULS no formal tests are avai lable. I nstead the fa lse 
discovery rates for genes selected from biological factors were calculated as indicators 
for their qual ity. In addition, there was no rea l  need to assess the fit of the model as the 
retrieved factors reflected the design of the study, and the fa lse discovery rate was cal­
culated being an ind icator for the qual ity of our proposed cisplatin-resistant genes. 
The identification of biolog ical ly mean ingfu l  factors is uniquely dependent on the 
data and cannot be guaranteed. By randomization and balancing of possible con­
founders of microarray experiments, such as the order of processing (during one of 
the many steps of m icroarray experiments), the systematic (biological and instrumen­
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tor ana lysis structure is eventually possible and wil l not resu lt in a substantial decrease 
in the amount of variance expla ined. 
Another disadvantage may be that to use CFA the design of the two-color microar­
ray study ideal ly should include ·selfSelf" hybridizations, dye swaps and independent 
replications, which may not a lways be the most efficient design  due to the increas­
ing number of arrays. Biological factors are not easily identified when FA is applied to 
designs not including orthogonal contrasts, i.e. without "SelfSelf" hybrid izations or dye 
swaps, necessary to predefine the structure of the relationships among the variables 
(e.g. a rrays) . Examples of such designs not including orthogona l contrast are balanced 
block designs or loop designs 30•3'. 
Conclusion 
I n conclusion, our resu lts show that FA is an efficient method to analyze two-color 
microarray data provided that there is a predefined hypothesis reflected in an orthog­
onal design. 
�ethods 
Sample preparation and microarray experiments 
Total RNA was isolated from the ovarian cancer cell l ines A2780, CP70, C30 and C200 
(kind ly provided by TC Hami lton, Fox Chase Cancer Center, Phi ladelphia, US) in three 
independent experiments by guanidine isothiocyanate treatment and subsequent 
purification by cesium chloride u ltracentrifugation. After DNAse treatment, the RNA 
was l inearly amplified according to the T7 ampl ification protocol of the Centra l Micro­
array Facil ity of the Netherlands Cancer Institute 32. Each ampl ified RNA (cRNA) sample 
was then independently labeled with Cy3 (green) and Cys (red). 
The labeled samples were hybrid ized to the -18K cDNA microarrays produced at the 
Central Mlcroarray racil ity of the Netherlands Cancer I nstitute (NCI, Amsterdam, the 
Netherlands) according to the balanced reference design described in Table 1 and 
Figure 1 ;  Al l  four ovarian cancer cell l ines, A2780, CP70, C30 and C200 were hybrid ized 
against A2780 (common reference). Dye swaps were performed for a l l  experiments, 
except for the "SelfSelf" hybridization of A2780. This design was used for the 3 inde­
pendent RNA isolations from the cel l  l ines (3 independent cel l  cultures). In addition, 
one extra "SelfSelf"was performed in the second replication of the design, resu lting in 
a total of 22 hybrid izations 3'. 
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Table 4 
Primer sequences and PCR conditions 
Gene Primer sequences T" ((O) Cycles 
GAPDH F: 5'-caccaccatggagaaggctgg-3' 65 30 
R: 5'-ccaaagttgtcatggatgacc-3' 
COL3A1 F: 5'-agcctccaactgctccta-3' 56 30 
R: 5'-gtccgggtctacctgatt-3' 
ENO2 
F: 5'-gtctgctgctcaaggtcaac-3' 54 30 
R: 5'-tccaggcaagcagaggaatc-3' 




R: 5'-gcacatgccacttgatac-3' C LHX2 F: s'-tgaaggacagcctggtctac-3' 56 30 
R: s'-gagctgcttcaagtccttgg-3' 
MEIS, F: s'-gctgttccagcatctaacac-3' so 30 C R: 5'-tgttgctgaccgtccattac-3' 
MEIS2 F: s'-gatcacgccgttatgttgcc-3' 49 30 
R: s' -gctggagttcgagtgatgag-3' C PBX3 F: s'-caggaagcaggacatcgg-3' 56 30 R: s'-ttggctctgtaatctgagtgtt-3' 
PDGFRL F: 5'-gtggagctaccctgcgtatc-3' 60 35 C R: 5'-ctgggagaaggtacaaagagttc-3' 
PRICKLE, F: 5'-aggtacggtattgccagtctt-3' 60 35 
R: 5'-cgaacactgcaacttcacctc-3' 
C SAT F: s' -tcactcgccgaggttccttg-3' 53 30 R: s'-acagcagcactcctcactcc-3' 
SHB 
F: s'-gtttaatggcaacgagaagcg-3' 
60 35 0 R: s'-tcctcacagccacgggatag-3' F: 5'-ggaaacgacatttatggcaacc-3' TIMP2 
R: s'-acccagtccatccagaggc-3' 
60 30 
TLX1 F: 5'-acctcactggcctcaccttc-3' 57 30 0 R: s'-cagaccacggctgcagattc-3' 
TOP, 
F: s'-gaaggaacagctagcagatg-3' so 30 
54  R: s'-agaactctgcctcttgagac-3' UACA F: s'-cactgaatgacacgttagcca-3' 60 35 
R: 5'-atcctgcacctttctcatgct-3' 
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Fluorescent images of the microarray sl ides were obtained with the Affymetrix GMS428 
scanner (Santa Clara, CA). For both fluorophores, signal intensities for each spot were 
quantified by ded icated IMAGENE s.6 software (Biodiscovery, Marina Del Rey, CA). 
Reverse transcription-polymerase chain reaction (RT-PCR) 
Sixteen of the differentia l ly expressed genes were further assessed in the 4 ovarian 
cancer cell l ines by RT-PCR. cDNA was synthesized from s µg total RNA using ol igo dT 
primers and MMLV transcriptase. The primer sequences and PCR conditions for the 
genes are described in Table 4. PCR products were electrophorized in a 1 .2% agarose 
gel in 1x Tris-borate EDTA buffer. 
tiene Ontology (tiO) annotation 
FatiGO was used to annotate the genes with GO terms (biological process and mo­
lecular function) and to compare the distribution of the main GO terms between the 
gene list selected from the first and second factor 17• 
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Abstract 
Purpose and methods 
Three amino-acid loop extension (TALE) homeobox proteins MEIS and PBX are cofactors for 
HOX-class homeobox proteins, which control growth and differentiation during embryogen­
esis and homeostasis. We showed that MEIS and PBX expression are related to cisplatin-resis­
tance in ovarian cancer cell lines. Therefore, MEIS,, MEIS2 and PBX expression were investigated 
immunohistochemically in a tissue microarray (N=232) of ovarian cancers and ovarian surface 
epithelium (N=1s). Results were related to cl inicopathologic characteristics and survival. 
Results 
All cancers expressed MEIS,, MEIS2 and PBX in nucleus and cytoplasm. MEIS, and 2 only stained 
nuclear in surface epithel ium. Nuclear MEIS2 was negatively related to stage, grade and overall 
survival in univariate analyses. Additionally, MEIS and PBX RNA expression in ovarian surface 
epithel ium and other normal tissues and ovarian cancer versus other tumor types using public 
array data sets were studied. I n  ovarian cancer, MEIS, is highly expressed compared to other 
cancer types. 
Conclusion 
In conclusion, MEIS and PBX are extensively expressed in ovarian carcinomas and may play a 
role in ovarian carcinogenesis. 
Introduction 
HOX homeobox proteins are transcription factors involved in growth control and dif­
ferentiation during embryogenesis as wel l  as homeostasis '. HOX genes, when de­
regulated, play important roles in oncogenesis. Their expression and function in can­
cers seems to be tissue-specific 2•1. Three amino-acid loop extension (TALE) homeobox 
proteins MEIS and PBX function as cofactors for HOX proteins. All vertebrate model 
organisms seem to have three functional MEIS genes. Human MEIS, and MEIS2 genes 
have been reported in vivo, while the MEIS3 gene has only been identified in s i l ico. 
Furthermore, there are four human PBX genes 9-,4_ 
In a recent study using cDNA m icroarrays and reverse transcription-polymerase chain 
reaction, we have shown that the three amino-acid loop extension (TALE) homeobox 
genes MEIS,, MEIS2 and PBX3 were downregulated in  3 cisplatin-resistant subl ines of 
the cisplatin-sensitive parental ovarian cancer cell l ine A2780 15. I n  add ition, the M EIS, 
gene has been shown to be ampl ified and overexpressed in ovarian cancers com­
pared to normal ovarian surface epithel ium and is part of an ovary-specific gene ex­
pression profile distinguishing primary lung, colon and ovarian adenocarcinomas 16 18• 
As protein  expression data on the HOX cofactors in ovarian cancer are lacking, the 
aim of the present study was to investigate MEIS,, MEIS2 and PBX protein expression 
in a large set of ovarian cancers. To discover the effect of chemotherapy on MEIS and 
PBX proteins in  ovarian cancers, their expression levels were also compared between 
paired pre- and post-chemotherapy tumor samples. The results were related to cl in­
icopathologic characteristics and survival. Final ly, to compare MEIS and PBX RNA ex­
pression between normal ovarian surface epithel ium and various other normal tissues 
and between ovarian cancer and various other tumor types the public Affymetrix data 
sets N353 and XPO1026 were studied 19•20• 
�aterials and methods 
Tissue microarray 
Since the early 1980s, a l l  cl in icopathologic and fol low-up data of ovarian cancer pa­
tients referred to the Department of Gynecologic Oncology at the University Medical 
Center Groningen (Groningen, the Netherlands) were prospectively col lected during 
standard treatment and fol low-up and stored in a computerized database. Interna­
tional Federation of Gynecology and Obstetrics (FIGO) staging was performed. The 
patients were treated according to regional guidelines on the diagnostic work-up, 
surgical and medical treatment and fol low-up 21• The surgical guidelines largely re­
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num-based chemotherapy early 1980s, debu lking surgery at the end of 1980s and 
platinum/paclitaxel chemotherapy since 1996. Clinical response to chemotherapy 
was determined according to standard WHO criteria ,i_ Optimal and suboptimal de 
bulking were defined as the largest tumor lesions having a diameter :s:;2 cm or >2 cm, 
respectively. Progression free surviva l and overa ll surviva l were calcu lated from the 
date of primary surgery to the date of progression/relapse or last follow-up/death 
due to ovarian cancer, respectively. The database a lso contained information on the 
avai labil ity of tumor samples. Patients had given informed consent for collection and 
storage of tissue samples in  a tissue bank for future research. Tumor samples were ob­
tained at the time of surgery and embedded in paraffin blocks and/or frozen in l iquid 
nitrogen and stored at -80 °C. 
For the present study, the database was searched for consecutive patients treated for 
epithelial ovarian cancer between 1985 and 2002 and of whom paraffin-embedded tu­
mor was avai lable. Al l re levant data were retrieved from the database and transferred 
into a separate anonymous database. In this separate password-protected database, 
patient identity was protected by study-specific, unique patient codes. The true iden­
tity of patients was only known to two ded icated data managers, who also have daily 
responsibil ity for the larger database. In case of uncertainties with respect to cl inico­
pathologic and fol low-up data, the larger databases cou ld only be checked through 
the data managers, thereby ascertain ing the protection of patients' identity. Owing to 
these precautions, accordi ng to Dutch law no further IRB approva l was needed. 
Eight tissue microarrays (TMAs) were constructed from tu mor samples of 232 ovarian 
cancer patients. Of 44 patients paired tumor samples before and after first-l ine chem­
otherapy were available. Post-chemotherapy samples were col lected at surgery after 
three or six cycles of chemotherapy (N=26) or at surgery for recurrent disease (N=20). 
TMAs were constructed as described in a previous study '4• Four separate cores of o.6 
mm were retrieved from each tumor sample (Tissue Arrayer, Beecher I nstruments, 
Silver Spring, MD, USA). Each TMA conta ined d upl icate cores of 10 internal controls to 
ensure simi larity of stain ing between the sl ides. As internal controls 6 tumor samples 
(serous, mucinous, endometrioid, clear cell and und ifferentiated ovarian carcinoma, 
and an ovarian cystadenoma) and 4 normal tissue samples (fal lopian tube, endome­
trial, endocervica l and cervical tissue) were present on each TMA. As controls apart 
from the TMAs, 15 paraffin blocks containing normal ovarian epithel ium tissue (pre­
(N=5) and post-menopausa l (N=5) ovaries, and ovaries prophylactical ly removed from 
women with a BRCA1 (N=2) and BRCA2 mutation (N=3)), 2 blocks contain ing prol iferat­
ing endometria l tissue and 2 blocks containing non-prol iferating endometria l tissue 
were used ,;_ 
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lmmunohlstochemlstry 
For immunohistochemistry 4 µm sections were cut from the ovarian cancerTMAs and 
paraffin blocks containing norm a I ovaries or endometria I t issue and mounted on 3-am i­
no-propyl-ethoxy-si lane coated glass sl ides (Sigma-Aldrich, Diesenhofen, Germany). 
All sl ides were stained with in two weeks from sectioning. After the sections had been 
dewaxed in xylene, antigen retrieva l was performed by autoclave treatment; 3 t imes 
s min at 115 °C in blocking reagent (2% block + 0.2% sod ium dodecyl sulfate in ma leic 
acid, pH 6.o; Boehringer Mannheim, Mannheim, Germany). Endogenous peroxidase 
activity was blocked by incubating the sl ides in hydrogen peroxide. For MEIS1 and 
MEIS2, endogenous avidin and biotin activity was also blocked using Blocking kit 
(Vector laboratories, Burl ingame, CA, USA). All primary antibodies were purchased 
from Santa Cruz B iotechnology (Santa Cruz, CA, USA): MEIS1/2 (sc-10599), MEIS2 
(sc-10600) and PBX1/2/3/4 (sc-28313). MEIS1, MEIS2 and P BX antibodies were d i luted 
1 :25 and sections were incubated overnight at 4 °C. For MEIS1 and MEIS2 the sl ides 
were pre-incubated with 1 -5% normal rabbit serum for 1 h at room temperature. For 
a l l  washings and d i lutions o.os M Tris-buffered sal ine conta ining 0.1% Tween-20 was 
used for MEIS1 and PBX, and PBS containing 1% bovine serum a lbumin was used for 
MEIS2. For negative controls the primary antibodies were omitted. PBX was detected 
using a goat anti-mouse/rabbit secondary antibody conjugated with a peroxidase 
labeled polymer (DAKO EnVision+ system; DAKO, Cambridgeshire, UK). Biotinylated 
rabbit anti-goat lgG ((H+L), Southern Biotechnology, Birmingham, AL, USA) served as 
a secondary antibody (1:300 for 30 min at room temperature) for MEIS1 and MEIS2. For 
MEIS2, 1% normal rabbit serum was added to the di lution of the secondary antibody. 
ABComplex/HRP (DAKO) was appl ied for 30 min and 3, 3'-d iaminobenzidine was used 
to visual ize a l l  antigen-antibody reactions. 
Two observers (APGC and KAH) independently scored immunohistochemica l sta in­
ings at a double-headed microscope without prior knowledge of the cl inicopathologic 
information. The cases with a discrepant score were re-examined with a gynecologic 
pathologist (HH) until consensus was reached. At least two of the four core biopsies 
representing each whole tumor sample had to be avai lable for scoring. Nuclear and 
cytoplasmic immunoreactivity for the MEIS and PBX antibodies was graded as weak 
(0-1), moderate (2) or strong (3). Stain ing intensity was assessed by visual scoring. The 
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Statistical analysis 
lmmunohistochemlstry data analysis 
Statistica l ana lysis was performed using the SPSS 12.0 software package (SPSS I nc., 
Chicago, I L). The relationship between nuclear and cytoplasmic expression of MEIS1, 
MEIS2 and PBX proteins in paired pre- and post-chemotherapy tumor samples was 
assessed by the Wi lcoxon signed rank test. To assess the relation between nuclear 
MEIS1, MEIS2 and PBX protein expression and cl inicopathologic characteristics univari­
ate logistic regression analyses were performed, using MEIS1, MEIS2 and PBX as de­
pendents, respectively. The cut-off point for nuclear MEIS1 (weak/moderate or strong), 
MEIS2 (weak or moderate/strong) or PBX (weak/moderate or strong) expression was 
decided a priori. As independent cl inicopathologic characteristics were included; age 
(>59 or �59 years), stage (stage I l l/IV or stage 1/11), histology (serous or non-serous), 
grade (grade 3/und ifferentiated or g rade 1/2) and residual d isease (>2 cm or �2 cm). 
For MEIS2 also mu ltivariate logistic regression analysis was performed adjusted for 
the variables stage, grade and histology. To study whether nuclear MEIS1, MEIS2 and 
PBX protein  expression were predictive for overa l l  survival a nd progression free sur­
viva l, survival curves were ca lculated using Kaplan-Meier ana lysis with assessment of 
statistical significance using the log-ran k  test. Subsequently, to investigate whether 
MEIS1, MEIS2 and PBX were independent prognostic factors, multivariate overa l l sur­
vival and progression free survival analyses were performed using Cox proportional 
hazard regression models adjusted for stage and residual tumor. P-values of 0.05 were 
considered significant. 
Public Affymetrix data set analysis 
Affymetrix data for human norma l tissues (N353) and severa l cancer types (XPO1026 
(https://expo.intgen.org/expo/publ ic)) were retrieved from publ ic GEO (Gene Ex­
pression Omnibus) data sets on the NCBI website 19·20• CEL data from the Affymetrix 
GeneChip Human Genome U133 Plus 2.0 array data sets were downloaded and inten­
sity values and their accompanying P-va lues assigned to ME/51, MEIS2, MEIS3 (in silica 
identified sequence) and PBX1-4 probe sets with GCOS software using the MASS5.o 
algorithm. Annotations for the tissue samples analyzed are ava i lable from http://www. 
ncbi.nlm.nih.gov/geo/query/ thru thei r GEO ID: GSE3526 9 a nd GSE210 for the N353 
and XPO1026 data sets, respectively. 
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Results 
�flS and PBX protein expression in normal ovarian sur­
face epithelium, primary and paired pre- and post-chemo­
therapy ovarian tumors 
In norma l  ovarian surface epithel ium MEIS and PBX protein expression were clearly 
visible (Figure 1) . MEIS1 and MEIS2 stained exclusively nuclear, while PBX sta in ing was 
also cytoplasmic. There were no obvious differences in staining patterns for the three 
proteins neither in normal ovarian surface epithel ium from pre-menopausal women, 
post-menopausal women or women with fami l ia l  ovarian cancer. 
The clin icopathologic data of the 232 primary cancers present on the TMA are sum­
marized in Table 1 .  The median fol low-up time of the patients was 26 months (range: 
0-213 months) and the 5-year overa l l  survival rate was 31% (118 patients died because 
of ovarian cancer). 
MEIS1, MEIS2 and PBX protein expression were identified in ovarian cancers (Figure 1) .  
Tumors showed nuclear as well as cytoplasmic staining. Al l tumor sections whol ly and 
homogeneously stained for MEIS 1 and 2 and PBX. The percentage ovarian cancers 
per staining category for each protein are presented in Table 2. Nuclear MEIS1 and 
PBX expression were strong in most of the cancers (in 90% and 74%, respectively). 
Cytoplasmic MEIS1 and PBX expression were moderate in 81% and 660/o of the cancers, 
respectively. Nuclear MEIS2 expression was weak in about half of tumors and moder­
ate/strong in the other half. Cytoplasmic MEIS2 expression was weak in 330/o and mod­
erate in 62% of the cancers. 
To study whether chemotherapy influenced MEIS 1 and 2 and PBX expression levels, 
as observed in the isogenic ovarian cancer cisplatin-resistance cell l ine model, their 
expression levels were compared between paired pre- and post-chemotherapy sam­
ples of 44 patients 15. Table 3 shows that nuclear and cytoplasmic expression of MEIS1, 
MEIS2 and PBX were not different between pa ired pre-chemotherapy samples and 
samples obta ined after 3 or 6 courses of first-l ine chemotherapy, nor between paired 
pre-chemotherapy samples and samples obtained at surgery for recurrent disease. 
From the un ivariate logistic regression ana lyses (Table 4) it appeared that moderate/ 
strong nuclear MEIS2 expression was related with early stage (odds ratio 0-46 (0.25-
0.87)) and grade 1 or 2 tumors (odds ratio 0-47 (0.26-0.85)). There seemed to be a relation 
between strong nuclear MEIS1 (odds ratio 0.38 (0.13-1.07)) or moderate/strong MEIS2 
expression (odds ratio 0-59 (0.34-1.03)) and non-serous ovarian cancers. The multivari­
ate logistic regression analysis for MEIS2 showed that stage (odds ratio 0.61 (0.26-1.44)), 
grade (odds ratio 0.65 (0.32-1.33)) and histology (odds ratio 0.90 (0-46-1.79)) were not 
independently related with MEIS2 expression. Moderate/strong nuclear MEIS2 expres­
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Figure 1 
MEIS1, MEIS2 and PBX protein expression in ovarian tumor tissue and normal ovarian surface epithelium. 
A. Nuclear MEIS1 expression in normal ovarian surface epithelium; B. Nuclear ME/52 expression in normal 
ovarian surface epithelium; C. Nuclear and cytoplasmic PBX expression in normal ovarian surface epithe­
lium; D. Nuclear and cytoplasmic ME/51 expression in ovarian tumor tissue; E. Nuclear and cytoplasmic 




Clinicopathologic characteristics of the ovarian cancer patients 
All stages Stage 1/11 Stage I l l/IV 
Characteristic (N==232) (N==64) (N==166) 
N (%) N (%) N (%) 
Age 
Median 59 54 60 
Range (21-89) (23-83) (21-89) 
Stage (FIGO) 
I 45 (20) 
I I 19 (8) 
Ill 133 (58) C IV 33 (14) Unknown 2 
Grade C 1 39 (18) 29 (48) 9 (6) 
2 52 (25) 22 (37) 29 (20) 
3 104 (sol 7 (12) 97 (66) C Undifferentiated 14 (7) 2 (3) 12 (8) Unknown 23 4 19 
Histologic subtype 0 Serous 128 (ssl 13 (20) 115 (69) 
Mucinous 27 (12) 18 (28) 8 (sl 
Endometrioid 33 (14) 19 (30) 14 (8) 0 Clear Cell 17 (7) 6 (9) 10 (6) Other 27 (12) 8 (13) 19 (12) 
Debulking status 0 Optimal s2 cm 111 (sol 61 (97) 48 (31) 
Suboptimal >2 cm 109 (sol 2 (3) 107 (69) 
Unknown 12 11 64  First-line chemotherapy 
None 36 (16) 25 (40) 11 (7) 
0 Platinum-based 171 (76) 34 (ssl 136 (84) Non-platinum-based 17 (8) 3 (sl 15 (9) 
Unknown 8 2 4 
Chemotherapy-response 0 CR'/PR' 82 (71) 3 79 (70) 
SD3/PD• 34 (29) 34 (3o) 
0 ' CR, complete response; ' PR, partial response;' SD, stable disease; • PD, progressive disease. 
0 
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Table 2 
Nuclear and cytoplasmic MEIS and PBX protein expression in ovarian cancer 
samples 
N NE' weak moderate strong 
Nuclear MEIS1 
Primary 232 25 (11%) 2 (1%) 18 (8%) 187 (80%) 
After 3/6 cycles chemotherapy 26 6 (23%) 0 (0%) 2 (8%) 18 (69%) 
Recurrent disease 20 1 (5%) 0 (0%) 1 (5%) 18 (90%) 
Cytoplasmic MEIS, 
Primary 232 25 (11%) 27 (12%) 167 (72%) 13 (5%) 
After 3/6 cycles chemotherapy 26 6 (23%) 0 (0%) 19 (73%) 1 (4%) 
Recurrent disease 20 1 (5%) 1 (5%) 17 (85%) 1 (5%) 
Nuclear MEIS2 
Primary 232 29 (13%) 105 (45%) 88 (38%) 10 (4%) 
After 3/6 cycles chemotherapy 26 6 (23%) 16 (62%) 4 (15%) 0 (0%) 
Recurrent disease 20 2 (10%) 8 (40%) 10 (50%) 0 (0%) 
Cytoplasmic MEIS2 
Primary 232 29 (13%) 66 (28%) 126 (54%) 11 (5%) 
After 3/6 cycles chemotherapy 26 6 (23%) 9 (35%) 10 (38%) 1 (4%) 
Recurrent disease 20 2 (10%) 5 (25% 13 (65%) 0 (0%) 
Nuclear PBX 
Primary 232 25 (11%) 11 (5%) 42 (18%) 154 (66%) 
After 3/6 cycles chemotherapy 26 6 (23%) 2 (8%) 8 (31%) 10 (38%) 
Recurrent disease 20 2 (10%) 0 (0%) 5 (25%) 13 (65%) 
Cytoplasmic PBX 
Primary 232 25 (11%) 47 (20%) 136 (59%) 24 (10%) 
After 3/6 cycles chemotherapy 26 6 (23%) 7 (27%) 10 (38%) 3 (12%) 
Recurrent disease 20 2 (10%) 4 (20%) 12 (60%) 2 (10%) 
All tumor sections wholly and homogeneously stained for MEIS and PBX. ' NE, not-evaluable. 
PBX (p=o.ss) expression showed no relation with surviva l .  Figure 2 shows the Kap­
lan-Meier overal l  su rvival curves calculated for MEIS2. The m u ltivariate Cox regression 
analyses adjusted for stage and residual tumor (Table s) showed that MEIS 1 and 2 and 
PBX were not independent prognostic factors for overa l l  survival. The data for progres­
sion free survival were comparable to the resu lts for overa l l  survival (not shown). 
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Table 3 
Comparison of MEIS1, MEIS2 or PBX expression between 
paired ovarian pre- and post-chemotherapy tumor samples 
N Ties' P' 
After 3/6 cycles chemotherapy 26 
Nuclear MEIS, 20 17 0.56 
Nuclear MEIS2 20 16 1.00 
Nuclear PBX 20 12 0.61 
Cytoplasmic MEIS, 20 15 0.66 
Cytoplasmic MEIS2 20 10 0.78 
Cytoplasmic PBX 20 10 0.53 
Recurrent disease 20 
Nuclear MEIS, 19 18 0.32 
Nuclear MEIS2 17 6 0.76 
Nuclear PBX 18 8 0.53 
Cytoplasmic MEIS, 19 13 1.00 
Cytoplasmic MEIS2 18 9 0.32 
Cytoplasmic PBX 18 5 0.32 
'Ties: similar expression of ME/51, ME/52 or PBX between paired ovarian pre-and post-
chemotherapy tumor samples; ' Compared with primary ovarian cancer samples, 
Wilcoxon paired test. 
�tl5 and PBX gene expression in public human ..\ffymetrix 
data sets of normal (N353) and tumor (XP01026) tissue 
of different origins 
The average expression of the MEIS1, MEIS2, MEIS3 ( in sil ico identified sequence), PBX1, 
PBX2, PBX3 and PBX4 genes in normal tissue ranges from 53-1249, 60-1792, 15-333, 1 62-
2580, 62-303, 99-774 and 7-364, respectively (see Table 6). In normal ovary average ex­
pression of MEIS1 (559, standard error (SE): 93) and MEIS2 (489, SE: 72) is comparab le. 
Furthermore, PBX1 (898, SE: 60) and PBX3 (747, SE: 183) seem to be wel l  expressed in 
normal ovarian tissue compared to PBX2 (248, SE: 34) and PBX4 (ss, SE: 36). 
The average expression of MEIS1, MEIS2, MEIS3, PBX1, PBX2, PBX3 and PBX4 in cancer 
ranges from 86-1018, 178-865, 34-147, 299-899, 64-228, 72-927 and 24-95, respectively 
(Table 7). In ovarian cancer average MEIS1 expression (902, SE: 111)  is much higher than 
average MEIS2 expression (353, SE: so). Additional ly, of the four  PBX genes PBX1 has the 
highest expression (685, SE: 46). Moreover, the average expression of MEIS1 in ovarian 
and uterine cancer, neuroblastoma and medu l loblastoma is high compared to the 
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Table 4 
Results of the univariate logistic regression analysis for nuclear MEIS,, MEIS2 
and PBX protein expression and clinicopathologic characteristics in ovarian 
cancer (odds ratios (OR) and 95% confidence intervals (Cl)) 
Nuclear MEIS, Nuclear MEIS2 Nuclear PBX 
Clinicopathologic (strong or weak/ (moderate/strong (strong or weak/ 
characteristic moderate) or weak) moderate) 
OR 95% CI OR 95% CI OR 950/o CI 
Age 
> or :;; median age 1.25 0-49-3.20 1.18 0.68-2.06 1,53 0.81-2.89 
Stage 
I l l/IV or VII 0.42 0.12-1.48 0-46 0.25-0.87' 0.67 0.33-1-40 
Histologic type 
Serous or non-serous 0.38 0.13-1.07 0-59 0.34-1.03 o.85 0-45 1 ,60 
Grade 
3/undiff or 1/2 0.84 0.33-2.16 0-47 0.26-0.85' O.S7 2.91-1.12 
Residual disease 
>2 cm or :;;2 cm 0.86 0.33-2,22 0.92 0.52-1.62 0,96 o.so-1.84 
'p<o.02. 
Discussion 
This study shows that in ovarian carcinomas MEIS1, MEIS2 and PBX proteins are exten­
sively expressed, both nuclear and cytoplasmic. I n  normal ovarian surface epithel ium, 
however, MEIS, and 2 only stained nuclear. Additiona l ly, MEIS, RNA is much higher 
expressed in ovarian cancer compared to other tumor types. 
These specific find ings in ovarian cancer are of interest as M EIS, and 2 and PBX could 
be important in ovarian oncogenesis by potentiating the function of aberrantly ex­
pressed HOX proteins s.26 28• When a HOX protein  forms a complex with a MEIS and 
a PBX protein, they show powerfu l downstream target promoter regulation as their 
DNA-binding affinities and specificities are increased sign ificantly 29.3°. Co-activation 
of HOXA9 and MEIS, in mouse bone marrow cel ls has been reported to rapidly in­
duce acute myeloid leukaemia, an effect not observed with overexpression of these 
homeobox genes alone 3'. In ovarian carcinomas the effect of co-activation of HOX, 
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The Kaplan-Meier overall survival curves calculated for MEIS2. Moderate/ 
strong nuclear MEIS2 expression (-) was related with a better overall 
survival (p=o.036) in ovarian cancer patients (all stages). Weak nuclear 
MEIS2 expression: (---) curve. 
MEIS and PBX has not yet been investigated, although aberrant expression of HOX 
RNA and proteins has been demonstrated. In ovarian cancer the HOXA9-11 proteins 
are expressed accord ing to a subtype-specific pattern, whereas they are absent in 
normal ovarian surface epithel ium. The abi l ity of HOXA9-11 to induce differentiation 
along their respective pathways was shown to be promoted by HOXA7 26• Addition­
al ly, HOXB7 and HOXB13 genes were found to be overexpressed in ovarian cancer cell 
l ines and cancers compared to whole normal ovaries and invasive characteristics of 
the ovarian cancer SKOV3 cel ls were found to be suppressed by the expression of anti­
sense HOXB7 and HOXB13 mRNA 28. As we have shown that MEIS and PBX proteins are 
frequently expressed in ovarian carcinomas they may potentiate the effect of these 
aberrantly expressed HOX genes on their target genes. 
Moreover, there is evidence that HOX, MEIS and PBX genes are involved in oncogenic 
processes, such as chromatin bind ing, cel l cycle control, prol iferation, apoptosis, ang­
iogenesis and cel l-cel l  communications 3•7•25•28•32 39• It has been shown that in the normal 
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Table 5 
Results of multivariate Cox regression overal l  survival 
analysis for nuclear MEIS,, MEIS2 and PBX protein 
expression in ovarian cancer adjusted for stage and 
residual tumor (hazard ratio (HR) and 95% Cl) 
TALE protein  
Nuclear MEIS, 
(strong or weak/moderate) 
Nuclear MEIS2 
(moderate/strong or weak) 
Nuclear PBX 
{strong or weak/moderate) 
Overall  survival 
HR 95% CI 
1.00 0-54-1 .83 
0.87 0.60-1.26 
0.89 0-59-1.34 
and was absent throughout the rest of the cycle, suggestive of a function in prol ifera­
tion for MEIS1 25• Furthermore, after exposure of the ovarian surface epithel ium cell l ine 
MCV152 to fol l icle-stimu lati ng hormone, cel l prol iferation was increased and MEIS1 ex­
pression was upregulated 37• Constitutive overexpression of MEIS, may thus promote 
tumor growth in endometria l and ovarian cancer. This is supported by the finding that 
MEIS, RNA is highly expressed in these cancer types. 
In Drosophi la, MEIS protein is necessary for nuclear loca l ization of PBX, which is ex­
ported to the cytoplasm in the absence of MEIS, and this mechanism was initial ly 
confirmed in mammal ian cel ls for both MEIS1 and MEIS2 40A'. A later report however, 
indicates that nuclear loca l ization of PBX, can a lso be regulated independently of 
MEIS proteins 42• I nterestingly, in normal endometria l epithel ium cel ls in the develop­
ing female genital tract, PBX, can be cytoplasmic even in the presence of MEIS, pos­
sibly in correlation with the cell cycle 43. It is therefore d ifficult to speculate whether 
our finding that the loca lization of MEIS1 and 2 in ovarian cancers is both nuclear and 
cytoplasmic compared to nuclear in normal ovarian surface epithel ium is important 
for their function as wel l  as the function of PBX. Further research has to elucidate the 
mechanisms and mean ing of MEIS and PBX local ization in both normal and tumor 
tissues of the female genital tract. 
In the present study, MEIS1 and PBX RNA and protein were higher expressed than 
MEIS2, indicating that these are the main HOX cofactors present in ovarian cancers. 
Univariate analysis showed that moderate/strong nuclear MEIS2 protein expression 
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Table 6 
Average gene expression of MEIS and PBX in  various normal tissues (N353 Affymetrix data set) 
MEIS, MEIS2 MEIS32 PBX, PBX2 PBX3 PBX4 
Tissue type N' Exp• SE• Exp SE Exp SE Exp SE Exp SE Exp SE Exp SE 
Adipose tissue 3 140.7 64.S 241.3 54-9 43-7 18.7 411.1 20.2 121.S 32.0 185-4 30.1 39.0 21.6 
Adipose omental tissue 4 467.3 15.6 464.9 21.7 40.1 9.6 873-8 71.1 146.6 10.9 149-7 13-3 19.3 5-3 
Adipose subcutaneous tissue 3 96.s 20.1 184.2 37.6 62.5 20.S 485.1 65.9 109.8 16.8 167.6 5-3 42.7 17.1 
Adrenal gland cortex 4 8o4.o 94-3 1161-4 105-4 38-4 12.7 954,oB 116.3 120.3 14-7 590.8 65.5 7.1 1.1 
Bone marrow 5 89-4 17.8 59.S 3.0 58.5 14.S 201.7 38.7 298.2 48-4 130.2 5-7 16-4 2.0 
Bronchus 3 377,6 70.0 268-4 43-3 100.0 19.0 413.9 57.7 155.3 43.6 174.3 10.0 61.3 6-4 
w I Cerebellum 9 408.8 28.7 263.7 13.9 56.3 14.1 416.0 26.3 164.4 16.8 131.7 15.0 25-4 5-4 w 
Cerebral cortex 9 112.0 19.S 410-4 36.9 118.1 19.8 595.2 33-3 171.2 18-4 124.3 19.4 21.1 6.1 
Cerebrum 143 134_9 6-4 505.3 41.7 93-7 8.o 514.2 11 7 163.S 4.6 233-5 10.5 26.0 1.6 
Cervix 4 1208.5 107.0 749.S 79,7 98.1 11.9 1n3.3 149-7 179 9 14.3 449-4 45,9 29.9 8.3 
Colon coecum 3 398.2 74.S 392.6 91.5 32.5 8.S 645.8 100.0 149.3 8.6 246.9 56.0 49-5 16 6 
Coronary artery 3 110.0 6.6 559-9 48.8 63.3 11.0 546.1 45.0 302.7 121.8 216.6 47,1 30.1 12.7 
Dorsal root ganglia 8 71.1 8.3 147.S 15.8 61.S 9.1 293.8 12-3 159_9 13.1 287-7 16.6 27.0 3.2 
Endometrium 4 1210-4 166.5 737-7 4o8.o 209.8 63.0 1424.0 487,0 274-9 61.2 171-4 45.0 43-5 13.8 
Oesophagus 4 524.2 68-4 352.6 48.3 50.3 17.0 888.6 113.6 150.3 26-4 264.2 38.8 33-4 5-4 
Heart atrium 4 26o.o 31-4 436.8 19.1 35.6 7-4 615,7 39-3 2o8.o 46.9 466.6 72-8 11.9 5-3 
0 0 0 0 0  0 0 0 0 0 0  
Table 6 continued • 
• ;s 
MEIS1 MEIS2 MEIS32 PBX1 PBX2 PBX3 PBX4 . ; 
Tissue type N' Exp• SE• Exp SE Exp SE Exp SE Exp SE Exp SE Exp SE = = 
Heart ventricle 3 197,2 40,1 6053 119,8 23.0 5.2 589.1 78.0 175.S 15.4 272.6 41,3 21.2 11.2 
Kidney cortex 98,7 18.0 629.0 29.6 98,7 12.6 4 372.3 24.0 20.4 1.0 132.3 19,1 30.2 10.2 = 
Kidney medulla 4 1443 21.6 509.8 53.2 28.3 8.4 625.3 65.S 120.1 11.7 136.2 13,9 67.8 5,9 
Liver 4 81.2 16.S 207,9 26.6 15.0 1.2 210.0 28.2 115,9 11.S 213.3 29,7 14,7 3.S 
= =-
Lung 453,8 263 3 20.7 407.S 19.S 39.0 13.9 425.3 37,7 154,2 35.1 230.0 51.2 23.7 'C 
Lymph nodes 4 283.6 184.8 515.7 162.9 48,3 10.3 460.2 167,7 168.0 14,3 272.0 94.S 91.0 30.2 a t;' w I = .i,. Mammary gland 3 146.4 14,1 3589 76.1 63.4 8.S 689.0 87,9 167.6 24.2 203.8 40,7 31.1 14.8 (II 
Myometrium 5 1249.1 199,8 1792.2 200.S 333,1 69.4 2580.0 272.8 296,9 93.2 252.3 29.2 16.2 5.S = 
Nipple cross-section 4 194,6 35.8 421.8 45,6 so.a 12.7 10339 88.1 215.3 39,0 185,7 12.3 43.4 6,5 
Nodose nucleus 8 243,9 17,0 269-4 22.S 32.8 6-4 368.1 
= 
19.2 172.6 19.3 368.7 25,9 11.6 2.7 = 
I') 
Oral mucosa 4 281.0 44.6 159-4 6.1 39,0 5,1 646.4 44 2 143,6 31.2 214.0 so., 38.0 11.0 = = 
Ovary 4 559.4 92,9 488.6 72.0 79.6 13,7 898-4 60.2 248.4 33,5 774.4 182.6 54,9 35.6 
Pharyngeal mucosa 4 463.8 81.8 392.7 51.2 48.8 9,8 379-4 31.1 117-4 10.3 99,1 15.7 44.2 10.0 
Pituitary gland 8 105,3 48.1 648,7 85.1 100.2 19.4 745.1 72.S 239.0 27,9 237,2 31.9 50.7 10.0 
Prostate gland 3 302.3 63-4 1347,0 70.S 84.6 12.S 893.8 102.6 134,8 22.3 436.S 14.4 39.6 9.7 
Salivary gland 4 648.5 55,6 1234,3 106.8 41.2 11.8 877,8 14,7 130.0 20.S 351.0 23.3 14.0 4.6 
Saphenous vein 3 106 1 16.1 446,3 113.4 55.4 9.0 652.4 65.3 179,8 26.2 192.0 33.0 12.2 1 .S 
Table 6 continued 
MEIS, MEIS2 MEIS32 PBX, PBX2 PBX3 PBX4 
Tissue type N' Exp3 SE• Exp SE Exp SE Exp SE Exp SE Exp SE Exp SE 
Skeletal muscle 5 98.4 12.2 90.7 13.2 36.3 9-4 588.1 37.2 128.1 22.5 101.8 15-3 17-4 3-9 
Spinal cord 8 191.0 9.8 365.3 14,6 52,0 7,3 493,1 32,5 111,9 14,1 412.0 17,5 26,4 7.3 
Spleen 4 245,3 26.6 309,4 60.9 36.1 9,9 338,4 39.8 162.0 23.2 240.9 24.8 60.1 8.o 
Stomach cardiac 3 491.9 306.7 370.3 1 50.2 25.8 7-7 792.0 228.0 197.S 16.2 328,7 88.o 46,8 11.6 
Stomach fundus 4 880-4 343.7 739.0 208.9 50.3 7.8 912.1 250.3 198.8 20.9 389.S 107-4 66.S 15.7 
Stomach pyloric 4 446.7 147.0 628.8 168.8 36.6 8.2 592.2 88.7 139.3 15,8 286,7 62.8 95,8 20.3 
Testes 3 64.6 4.6 65.0 6.1 80.3 13.0 162.0 21.2 73-4 18.0 143-4 10.9 131.6 8.o 
I Vl Thyroid gland 4 80.2 8.2 246.6 35,9 53,5 7,1 856.2 58,3 192,9 29,4 408,4 14.0 364,3 41.5 
Tongue main corpus 4 186.6 5,5 211.5 19,9 29.8 10.1 491.1 24,2 112.8 6-4 140.0 22.0 24.1 11.S 
Tongue superior part w/pap1llae 4 245,4 90.3 309.2 87.6 42.8 11.2 434,6 80.2 105,7 10.2 147.1 25.S 34.S 22.7 
Tonsil 3 148.3 25.3 160.3 28.6 40.2 7.S 275.6 44.1 157.0 27.1 131,1 28.3 104.7 16.6 
Trachea 3 477,9 25.9 312.2 25,3 58.3 6.o 546.1 66,3 122.2 19.8 170,4 19,9 39,8 5,6 
Trigem,nal ganglia 8 53.0 8.8 197.2 20.4 64.6 8-4 299-9 24.7 165.1 16.0 282.5 23.7 26.2 4,4 
Urethra 3 469.1 29,3 826.27 54,2 70,4 16.1 858,1 59,5 131.6 26.2 182.8 7.3 34,1 3,6 
Vagina 4 905,7 116.1 790.1 199.8 45-4 11.1 1131.6 220.7 180.1 31.9 501.8 50.8 25.6 7,4 
Vulva 4 422,4 59.5 377 3 21.2 56,1 8.8 528,3 33.S 244,6 18.0 275,4 30.1 31.0 9.0 
'N, number of normal tissue samples; ' In silica identified MEIS3 sequence;' Exp, average expression;• SE, standard error. 
0 0 0 0 0  0 0 0 0 0 0  
Table 7 
Average gene expression of MEIS and PBX in various tumor types (XP01026 Affymetrix data set) 
• J; 
MEIS, MEIS2 MEIS31 PBX1 PBX2 PBX3 PBX4 . ; = = 
Tumor type N' Exp' SE• Exp SE Exp SE Exp SE Exp SE Exp SE Exp SE =-
Bladder 8 149-7 21.2 274.0 59.S 40.6 8-4 396.8 85.7 172-9 31.2 201.7 28-9 53.8 9-7 � 
=' 
Breast 207 105.1 6.9 197.6 11.6 68.9 2.6 898.7 35.7 167.9 4.8 204.6 8.8 29.8 1.3 = 
Cervix 10 206.6 40-7 288-4 32.0 50.9 13-4 576.0 130.2 183.8 23.2 204.6 24.6 46-4 10.0 = 
Colon 146 177.7 23.3 190-4 9.9 39.7 2-4 349-4 12-4 151.0 4.8 154.8 5.3 48.S 1.8 a -= 
Corpus uteri 7 517 9 221.0 691.6 270.2 67-4 26.2 792.7 80.8 152.9 48.7 249-7 108 0 37.16 12.7 i � I Endometrium 63 772.9 61.5 457.6 50.9 51.5 5-3 703.8 583 179-4 9-4 112.2 19.0 37.2 2.S = OI (II 
Kidney 112 116.s 8.o 349.S 34.1 37 3 3.0 310.7 12-4 196.9 6.1 138.6 5-3 37-4 2.3 = 
Liver 16 142.8 35.1 177.8 46.0 41.9 7.3 342.2 52.7 172.9 17.3 173.S 16,6 46.8 3.6 
Lung 74 157.2 9.6 268.0 32.6 46 0 3-9 386.7 29.1 177.1 8-4 212.2 15.2 42.1 2.6 = = 
Medulloblastoma 51 384.9 109.5 715.7 74- 130.9 5.8 298.9 55-9 64.2 20,3 123.S 10.3 95.0 3.9 
t":I = = 
Neurob astoma 110 965-4 76-4 864.8 40.7 147.0 4.2 452.2 36.6 120-4 10.0 401-4 13.1 40.3 2.6 t":I 
Omentum 36 1018.2 24.6 429.0 76.0 57.S 5-4 692.2 47.5 227.6 10 3 147-4 33.5 47.9 2-4 
Ovary 98 902.0 110.8 353-3 50-4 42.0 7,1 685.1 45.6 193.1 10-4 177-4 19.1 42.7 4.2 
Prostate 20 198.9 39-4 671.7 47-9 41.2 8-4 564.7 49-7 173-3 15.8 475_0 33-3 23.5 10.9 
Table 7 continued 
MEIS, MEIS2 MEIS32 PBX, PBX2 PBX3 PBX4 
Tumor type N' Exp• SE• Exp SE Exp SE Exp SE Exp SE Exp SE Exp SE 
Rhabdomyo-sarcoma 9 282.7 26.0 427.7 49.8 61-4 7-4 464-4 78.7 61.7 28.9 138.0 36.7 140.6 8-4 
Rectosigmoid 19 274.6 103.6 224.2 189.5 41.9 12.1 400.8 245.0 182.7 14.9 153.S 61.6 36-4 12.0 
Rectum 19 150.2 87-2 188-4 306.0 48.2 9.1 335-9 132.8 158.7 23-4 169-4 58.7 64-4 12.8 
I ....., Renal pelvis 8 132.6 284 327.9 58.9 35.1 5.S 453.7 65.5 194-4 30.3 132.6 353.7 61.8 18.9 
Small intestine 10 267.2 43-7 59.23 83-9 57.2 11.1 678.S 98.0 202.7 14.6 280.7 59-9 50.7 6 7  
Stomach 6 375-4 82.3 609.9 75.6 344 8.3 522.2 74.8 155.6 20.9 252.3 12-4 45.9 3.S 
Thyroid 14 86.S 21.2 246.7 59-5 35-9 8-4 588.8 85.7 182.8 31.2 927.2 28.9 81.1 9-7 
Urinary bladder 7 200.3 6.9 382.6 11.6 62.8 2.6 746-4 35.7 141.0 4.8 228.3 8.8 49-7 1.3 
Uterus 14 679.1 40.7 535.8 32.0 40.2 134 615.9 130.2 177.1 23.2 71.5 24.6 28.8 10.0 
'N, number of tumor samples; ' In si/ico identified ME/53 sequence;• Exp, average expression;• SE, standard error. 
0 0 0 0 0  n n n n n n  
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Bar diagram showing average ME/51 RNA expression in ovarian tumors and various other tumor types 
based on analysis of the public human Affymetrix data set XP01026. The hashed bars correspond to the 
average ME/51 expression in ovarian cancer (omentum and ovary). The error bars represent the standard 
error of ME/51 expression. The average expression of ME/51 in ovarian cancer is high compared to most 
other tumor types. 
was related to early stage and non-serous cancers and a lso associated with better 
overa l l  survival. An explanation for the lack of relation between nuclear MEIS1 and PBX 
and cl inicopathologic characteristics or survival may be the similar expression pattern 
in al l  ovarian cancers. 
Ana lyses of pai red samples before and after chemotherapy showed that, the expres­
sion of al l three proteins was not influenced by preceding first- l ine chemotherapy 
and not d ifferent at the time of recu rrence in paired cancers. In our microarray study 
of four ovarian cancer cel l  l ines, MEIS1 and 2 and PBX3 gene expression were associ­
ated with cisplatin-resistance '5• This may be due to the fact that avai labi l ity of paired 
patient samples only occurs in the case of residua l  and resistant disease. 
Targeting of MEIS1 or 2 or PBX may impair the oncogenic function of various aber­
rantly expressed HOX proteins at once. Although targeting of homeobox proteins 
with d rugs is momentarily not possible, targeting MEIS1 or 2 or PBX in vitro with siRNA 
138 
is an option. As MEIS, appears to be so highly expressed in ovarian cancers compared 
to other cancer types especia l ly this gene seems the most interesting cand idate for 
targeted therapy. 
It is important in future research to discover aberrantly expressed HOX genes in ovar­
ian cancer and how their function is enforced by their cofactors MEIS, and 2 and PBX. 
This could lead to insight in how oncogenic HOX function would be abolished by 
targeting MEIS, and 2 and PBX. 
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1) to identify molecular markers underlying acquired chemotherapy-resistance in ovarian can­
cer and 2) to assess the association of pathways and transcription factors with acquired che­
moresistance. 
Methods 
To avoid noise caused by d istinct genetic backgrounds of individual patients 10 paired ovarian 
cancer samples, obtained before and after chemotherapy, were profi led using -35K 70-mer 
ol igonucleotide microarrays (-35,000 probes). Paired t-test (p<o.001) was appl ied to identify 
differentially expressed genes. Furthermore, a functional class scoring analysis was used to as 
sess pathways/transcription factors for thei r association with acquired chemoresistance. 
Results 
Comparison of paired pre- and post-chemotherapy samples revealed 53 differentially expressed 
genes. H ierarchical clustering based on this gene subset showed that pre- and post-chemo­
therapy samples were segregated. Additionally, 18 KEGG pathways and 15 TRED transcription 
factors associated with acquired chemoresistance were identified. 
Conclusion 
Our study provides new clues to genes, pathways and transcription factors which may con­
tribute to acqu i red chemoresistance in ovarian cancer and may be exploited in designing new 
treatment strategies. 
Introduction 
I ntrinsic and/or acq uired resistance to platinum-based chemotherapy is a major ob­
stacle to overcome in the treatment of patients with advanced stage ovarian can­
cer. Platinum-resistance is thought to cause treatment fai lure and death in 80-90% 
of patients ' .  I ntrinsic and/or acqu i red resistance to platinum-drugs is l i kely regu lated 
by the coordinated alteration of molecu lar pathways 2• Nowadays, there is increas­
ing recognition of the va lue and the possibi l ity of comprehensive approaches for the 
molecular characterization of platinum-resistance. U nderstanding of the mechanisms 
of platinum-resistance should u ltimately result in improved treatment of advanced 
stage ovarian cancer. 
In ovarian cancer extensive tumor tissue is usual ly avai lable at diagnosis, but access to 
post-chemotherapy samples is l im ited, as most patients currently do not routinely u n­
dergo second-look surgery following chemotherapy. Tumor samples obta ined shortly 
fol lowing chemotherapy may well be enriched in resistant cells and/or clones and 
are l ikely to display the molecu lar signature associated with acqu i red chemoresist­
ance. Comparing pre- and post-chemotherapy samples from the same patients in  
theory provides the possibil ity to specifically study the effect of  the selective pressure 
of chemotherapy, while noise caused by distinct genetic background of individual pa­
tients is avoided. So far, only one study has compared the gene expression profi les of a 
very heterogeneous group paired pre- and post-chemotherapy ovarian tumors 3• 
In the present study we have therefore profiled a homogeneous group of 10 paired 
pre- and post-chemotherapy ovarian cancers using 70-mer oligonucleotide microar­
rays (-35,000 probes). The post-chemotherapy samples were obtained at interva l or 
second-look surgery shortly after 3 or 6 courses of first-l ine platinum-based chemo­
therapy. The a im of our study was: 1) to identify molecu lar markers underlying ac­
quired chemotherapy-resistance, and 2) to assess the association of pathways and 
transcription factors with acqu i red chemoresistance. 
�aterials and methods 
Patients and tumor samples 
The study population consisted of 10 patients with advanced stage ovarian cancer 
operated on at the University Medical Center Groningen (UMCG, Groningen, the 
Netherlands) or at surrounding hospitals in  the presence of a gynecologic oncologist 
from the UMCG in the period 1990-2003. All patients were treated accord ing to Dutch 
guidel ines on diagnostic work-up, surgical and medical treatment and fol low-up, that 
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(F IGO) 4 5• New chemotherapy treatment regimens were adopted as fol lows: platinum­
based chemotherapy at the beginning of the 1980s, and platinum/paclitaxel chemo­
therapy after 1996. Pre- and post-chemotherapy tumor samples were obtained dur­
ing surgery, flash frozen in l iqu id n itrogen and stored at -80 °C. Post-chemotherapy 
samples were defined as those samples obtained at the time of interval or second­
look surgery maxi mal ly 6 weeks after 3 or 6 cycles of fi rst-l ine platinum-based chemo­
therapy, respectively. Al l samples were confirmed to comprise tumor cel ls  as exam­
ined with hematoxyl in and eosin staining of frozen sections. The median percentage 
tumor cel ls in pre- and post-chemotherapy samples was 65% and 60%, respectively. 
Patients gave informed consent for col lection and storage of tissue samples in a tissue 
bank for future research. Al l relevant patient data were retrieved and transferred into 
an anonymous, password-protected, database. The patient's identity was protected 
by study-specific, unique patient codes and their true identity was only known to 
two ded icated data managers. According to Dutch law, these precautions meant no 
further institutional review board approva l was needed. 
RN..\ extraction and amplification 
Frozen tumor samples were homogen ized using the Micro-Dismembrator U (8. Braun 
Biotech International, Melsungen, Germany) and dissolved in guanidine isothiocy­
anate buffer ( lmmunoSource, Hal le-Zoersel, Belg ium). Total RNA from tumor samples 
was isolated with cesium ch loride density grad ient u ltracentrifugation (Roche, Al mere, 
the Netherlands). After total RNA samples had been given DNAse treatment (Megas­
cript T7 kit, Ambion, Huntingdon, U K) for 90 min at 37 °C, they were checked for re­
sidual DNA using a di nucleotide primer set D11S875 (F: 5'-ACTGTCCTCTCATCCTACTG-3' 
and R: 5'-TACAGAGCTGAGTTTGTAGC-3') specific for genomic DNA. For those samples 
for which a PCR product was obta ined the DNAse treatment was repeated 6• mRNA 
was l inearly ampl ified by in vitro transcription using T7 RNA polymerase (Megascript 
T7 kit, Ambion, Huntingdon, UK) on 4 µg tota l RNA 7• Qual ity/integrity of total RNA 
and a mplified mRNA (cRNA) was checked by spectrophotometer ana lysis, UV 260/280 
ratio >1.8, and/or agarose gel electrophoresis. 
cRN.c\ labeling and hybridization 
Two randomly selected cRNA samples were hybridized together on the arrays for 
intensity-based instead of ratio-based analysis of the microarray data 8• All cRNA 
sam ples (1.s µg) were labeled with ULS-Cys and U LS-Cy3 label (B IOKE, Leiden, the 
Netherlands) and hybrid ized at 42 °C for 18 h to 70-mer two-color ol igonucleotide 
microarrays (-35,000 Operon v3.o probes), manufactured by the Netherlands Cancer 
I nstitute (Amsterdam, the Netherlands) 7• As each tumor sample was profiled once 
with Cys and once with Cy3, there was one repl icate of the whole experiment. Sam­
ples were hybrid ized according to a randomized design to prevent systematic biases 
146 
such as those caused by batch effects 9 11• After we had randomized the processing 
order of the arrays from different batches, Cys- and Cy3-labeled cRNA samples were 
randomly placed onto the arrays. Arrays were scanned with the Affymetrix GMS428 
scanner (Affymetrix, Santa Clara, CA). Expression va lues were ca lcu lated by B lueFuse 
software (BlueGnome, Cambridge, UK). 
Data analysis and statistics 
Quanti le normal ization was appl ied to 1092 transformed Cys and Cy3 intensities 12• 
Principal components analysis was performed for qual ity control. Samples with a fac­
tor loading with the first principal components of less than 2 times the standard devia­
tion from the mean were excluded as their hybridizations were considered to be of 
low qual ity '3·'4. Operon V3.o probe identifiers (-35,000) were converted to official gene 
symbols. Expression values of multiple probes targeting the same gene were averaged, 
resulting in a total of 15,909 unique genes for further ana lysis. Cys and Cy3 expression 
data of the same tumor were averaged. Microarray analyses were performed with the 
software package BRB Array Tools 3.6.0, developed by the Biometric Research B ranch 
of the US Nationa l Cancer Institute (http:/ /l inus.nci.nih.gov/BRB-ArrayTools.html). 
Comparison between pre- and post-chemotherapy samples 
To identify significant differential ly expressed genes, paired t-test was appl ied with a 
sign ificance threshold of p<o.001. Average l inkage hierarch ica l clustering was appl ied 
according to the centered Pearson distance measure to compare the gene expression 
profiles of the pa ired pre- and post-chemotherapy samples across the generated l ist 
of differentia l ly expressed genes. 
Pathway and transcription factor analysis 
Functional gene set enrichment analysis was performed as described by Pavlidis et a l  
to indicate which gene sets contained more genes differential ly expressed between 
pre- and post-chemotherapy samples than would be expected by chance •s. As in­
put for gene set enrichment analysis a l l  15,909 unique genes were used. Fi rst an uni­
variate Cox proportional hazards P-va lue was computed for al l  genes. Then P-va lues 
of a subset of genes belonging to a functional set were summarized by the LS and 
KS summary statistics. For a set of N genes, the LS statistic is defined as the mean 
negative natural logarithm of s ingle gene P-values. The KS statistic is defined as  the 
maximum difference between i/N and p, where P, is the i'h smal lest P-value. This i s  the 
Kolmogorov-Smirnov statistic for testing if the P-values are of uniform distribution. 
The statistical sign ificance of a functional gene set containing N genes is evaluated by 
computing the empirica l d istribution of these summary statistics in random samples 
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of Genes and Genomes database (KEGG) and 111 as reported in the Transcriptional 
Regulatory Element Database (TRED) were analyzed 16·17• 
Results 
Patient characteristics 
The clinicopathologic characteristics of the 10 patients included in  this study are 
presented in Table 1. Tumors were predominantly of stage I l le, serous histology and 
grade 3. All patients had residual tumor lesions with a diameter of >2 cm after first 
laparotomy. Furthermore, patients were mostly treated with carboplatin/cyclophos­
phamide combination chemotherapy. I nterval or second-look surgery was performed 
6 weeks after the third or sixth course of first-l ine chemotherapy. The median age of 
the patients was 57 (range, 42-66). The median progression  free and overa l l  survival 
times were 19 months (range, 4-18 months) and 14 months (range, 6-21 months), re­
spectively. 
Differentially expressed genes between paired pre- and 
post-chemotherapy samples 
Table 2 shows 53 genes differential ly expressed between the 10 paired pre- and post­
chemotherapy tumors (p<o.001) with fold d ifferences ranging from o.s to 1 .8. Cluster­
ing of the samples based on differential ly expressed genes between pre- and post­
chemotherapy samples showed that pre- and post-chemotherapy samples were 
segregated, except for 1 pre-chemotherapy sample (Figure 1) . 
Pathways and transcription factors associated with ac­
quired chemotherapy-resistance 
Eighteen KEGG pathways were identified associated with acqu ired chemotherapy-re­
sistance (see Table 3). The 15 transcription factors associated with acqu ired chemore­
sistance are shown in Table 4. 
Discussion 
In the present study 53 d ifferentia l ly expressed genes between pai red pre- and post­
chemotherapy ovarian cancer samples were identified. I n  addition to individua l genes, 
we were also able to identify 18 KEGG pathways and 15 TRED transcription factors as­
sociated with acqu ired chemoresistance. 
Nine other microarray studies have tried to identify genes related to resistance to first­
line platinum-based chemotherapy in ovarian cancer :ps·is. However, only two studies 
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Table 1 








































' CC, carboplatin/cyclophosphamide;' CP, cisplatinlcyclophasphamide; 
' TC, carboplatin/paclitaxel. 
have investigated chemoresistance using post-chemotherapy samples. Jazaeri et a l  
compared 15  post-chemotherapy samples with 21  unpaired primary chemosensitive 
and 24 unpaired primary chemoresistant tumors, respectively, using -7.sK cDNA micro­
arrays. The post-chemotherapy tumors had been obtained at interval debulking fol low­
ing neoadjuvant chemotherapy or at second-look surgery. They found that more genes 
were differential ly expressed between post-chemotherapy and chemosensitive (N=759) 
than between post-chemotherapy and chemoresistant tumors (N=229) 21 • L'.Esperance 
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Table 2 
Differentially expressed genes between paired pre- and post-chemotherapy 
tumors (p<o.001) 
Gene 
Description p FD' 
symbol 
HAL histidine ammonia-lyase 1.sE-06 1.8 
VIP vasoactive intestinal peptide 6.9E-06 1 ,4 
CLEC12A C-type lectin domain family 12, member A 5,45E-os 0.7 
NEK8 NIMA (never in mitosis gene a)- related kinase 8 5.97E-05 1.4 
SDCCAG3 serologically defined colon cancer antigen 3 8.o8E-os o.8 
DOK1 docking protein 1, 62kDa (downstream of tyrosine kinase 1) 0.000112 1,2 
TARSL1 threonyl -tRNA synthetase 2, mitochondrial (putative) 0.000128 0,7 
XPOs exportin s 0.000141 0,7 
TCHH trichohyalin 0.000149 0,7 
FAM129A family with sequence similarity 129, member A 0.000158 1.6 
DPAGT1 
dolichyl-phosphate (UDP-N-acetylglucosamine) N acetyl 0.000165 0.7 glucosaminephosphotransferase 1 (GlcNAc 1 P transferase) 
C17orfso chromosome 17 open reading frame so 0.000181 1.8 
ABHD14B abhydrolase domain containing 14B 0.000245 o.8 
BYSL bystin-like 0.000249 o.8 
OR10S1 olfactory receptor, fa mily 10, subfamily S, member 1 0,000249 1,5 
VPS13C vacuolar protein sorting 13 homolog C (5. cerevisiae) 0.000282 OB 
NXFs nuclear RNA export factor s 0.000293 1,4 
SEPX1 selenoprotein X, 1 0.000301 1.4 
RAP2B RAP2B, member of RAS oncogene family 0.000379 1.8 
SPSB1 splNryanodine receptor domain and SOCS box containing 1 0.000381 0.7 
NCBP2 nuclear cap binding protein subunit 2, 20kDa 0.000385 1,4 
ILF3 interleukin enhancer binding factor 3, 9okDa 0.000390 o.8 
LHB luteinizing hormone beta polypeptide 0.000424 o.6 
ZC3H6 zinc finger CCCH-type containing 6 0.000426 1,5 
ENPP6 ectonucleotide pyrophosphatase/phosphodiesterase 6 0.000450 0.7 
ZNF154 zinc finger protein 154 0.000470 1.7 
SPRR2F small praline-rich protein 2F 0.000480 0.7 
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Table 2 continued 
Gene 
Description p FD' symbol 
COL23A1 collagen, type XX/II, alpha , 0.000554 o.s 
PABPC3 poly(A) binding protein, cytoplasmic 3 0.000567 o.6 
CCDC87 coiled-coil domain containing 87 0.000569 0.7 
FTL FTL 0.000593 1.2 
CNKSR1 connector enhancer of kinase suppressor of Ras , 0.000595 0.8 
TRPV2 transient receptor potential cation channel, 0.000617 1.6 0 subfamily V, member 2 
KIAA1467 KIAA1467 0.000629 0.7 
CXorf56 chromosome X open reading frame 56 0.000632 1.3 0 
C20orf78 chromosome 20 open reading frame 78 0.000664 0.6 
ABCD2 ATP-binding cassette, sub-family D (ALO), member 2 0.000698 1-4 0 KCNIP3 Kv channel interacting protein 3, calsenilin 0.000701 0.8 
LOC285847 hypothetical protein LOC285847 0.000716 1.7 0 KCNAB2 potassium voltage-gated channel, shaker-related subfamily, 0.000720 o.8 beta member 2 
MGAT3 mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosami- 0.000763 0.8 0 nyltransferase 
MYEOV myeloma overexpressed gene (in a subset of t(11;14) positive 0.000766 0.7 multiple myelomas) 
7t  BLOC1S2 biogenesis of lysosome-related organelles complex-,, 0.000775 1-4 subunit 2 
TMPRSS7 transmembrane protease, serine 7 0.000788 1-4 0 ANKRD34 ankyrin repeat domain 34 0.000807 1-4 
SDCBP SDCBP 0.000869 1.7 
0 OGG1 8-oxoguanine DNA glycosylase 0.000869 0.8 
(14orf102 chromosome 14 open reading frame 10 0.000892 o.s 
0 ATP284 ATPase, Ca++ transporting, plasma membrane 4 0.000920 0.7 
PRPH peripherin 0.000925 0.7 
ITGA1 ITGA1 0.000965 14 0 EGR2 early growth response 2 (Krox-20 homolog, Drosophila) 0.000977 o.8 
DENND2C DENN/MADD domain containing 2C 0.000993 o.s 0 
' FD, fold difference in paired samples of post-chemotherapy compared to pre-chemotherapy tumors. 
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Dendrogram for clustering experiments, 













Supervised hierarchical clustering of the 10 paired pre- and post-chemotherapy tumors 
using centered Pearson correlation with average linkage. 
ferential ly expressed genes (t-test, p=o.05). From those genes a l ist of 175 genes was 
derived that commonly differentiated more than two-fold between pai red pre- and 
post-chemotherapy samples 3• None of the 175 genes were among the 53 genes that 
were d ifferential ly expressed in our study. However, comparison of studies is d ifficult 
because of differences in patients. In contrast to our study population the group of 
patients profiled by L'.Esperance et a l  was rather heterogeneous in clinicopathologic 
characteristics. The study included 5 stage I l l/IV serous tumors and 1 stage I clear cell 
tumor. Al l patients had received platinu m/paclitaxel chemotherapy, but a variable 
number of regimens, ranging from 1 to 3, between their first and second laparotomy. 
In addition, time between last chemotherapy and the next surgery during which the 
post-chemotherapy samples were obtained was variable with a range from 3 to 40 
months 3• 
Our study did not suffer from noise caused by distinct genetic background of individual 
patients. We assume that the observed differentially expressed genes may truly rep­
resent molecu lar changes associated with acquired chemoresistance, as the pre- and 
post-chemotherapy samples were obtained within maximal ly 6 weeks after 3 or 6 cy­
cles of first-l ine platinum-based chemotherapy. The post-chemotherapy ovarian cancer 
samples therefore were asserted to be enriched in chemoresistant cells/clones '6. 
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Table 3 
KEGG pathways with more genes d ifferentially expressed between 
pre- and post-chemotherapy samples than expected by chance 
KEGG Pathway Pathway description No. of genes 
hsao4080 Neuroactive ligand-receptor interaction 276 
hsaoo190 Oxidative phosphorylation 101 
hsaoo230 Purine metabolism 136 
hsao1430 Cell communication 104 
hsao4020 Calcium signaling pathway 165 
hsao4060 Cytokine-cytokine receptor interaction 225 
hsa04110 Cell cycle 104 
hsao4310 Wnt signaling pathway 141 
hsa04360 Axon guidance 117 
hsa04510 Focal adhesion 178 
hsa04514 Cell adhesion molecules (CAMs) 108 
hsa04530 Tight junction 105 
hsa04630 Jak-STAT signaling pathway 135 
hsao4650 Natural killer cell mediated cytotoxicity 101 
hsao4670 Leukocyte transendothelial migration 104 
hsao4810 Regulation of actin cytoskeleton 193 
hsa04910 Insulin signaling pathway 122 
hsa04020 MAPK signaling pathway 255 
Pathways shown in bold are also associated with overall survival in our microarray study of 157 
advanced stage serous ovarian cancers (data not shown here). 
Among the genes associated with acqu i red resistance (Table 2) there are several 
genes known to be potential ly involved in ovarian carcinogenesis. Among the up­
regulated genes in post-chemotherapy samples integrin a lpha 1 (ITGA1), vasoactive 
intestinal peptide (VIP) and member of RAS oncogene family 2B (RAP2B) are of inter­
est. ITGA1 has been demonstrated to be over expressed in a clonal isolate of oxa l ipla­
tin-resistant ovarian carcinoma cel l  l ine A2780/C10 compared to the parental cel l l ine 
using Affymetrix HG-U95Av2 oligonucleotide arrays 27• It has been shown that the VI P 







fiene expression profiling of paired ovarian cancers ••• 
Table 4 
Transcription factor gene sets with more genes 
differentia l ly expressed between pre- and post­
chemotherapy samples than expected by chance 
Factor name Accession no. No. of genes 
C/EBPalpha Too1os 141 
CREB Too163 162 
E2F-1 To1542 390 
E2F-2 To1544 122 
E2F-4 To1546 201 
c-Ets-1 Too112 144 
JUN Tooo29 201 
c-Myb Too137 143 
CTF1 Too176 101 
NF-kappaB(-like) Too591 182 
Sp1 Too759 289 
AP-2alphaA Tooo35 282 
P53 Too671 248 
POU5F1 Too652 15 
HOXD9 To1424 2 
Transcription factor gene sets shown in bold are also associated with 
overall survival in our microarray study of 157 advanced stage serous 
ovarian cancers (data not shown here}. 
ovarian cell carcinoma xenografted into nude mice 28• Furthermore, RAP2B very l i kely 
plays a role in the phosphol ipase (-epsilon pathway. The Phospholipase (-epsilon 
pathway is activated by Epac1 which catalyses GTP-loading on RAP2B, which leads to 
Phospholipase (-epsilon activation. In ovarian carcinoma cel ls (OVCAR-3 cel ls) RAP 
was demonstrated to mediate the stimu latory action of Epac on cel l adhesion 29• Mo­
mentari ly, there are Epac-selective cAMP ana logs, but there is no specific antagon ist 
of Epac 30. However, other components of the Phosphol ipase (-epsilon pathway may 
be more drugable. Among the genes downregu lated in post-chemotherapy samples 
early growth response 2 (EGR2) is of potentia l importance. EGR2 has been shown to 
1 54 
be decreased in ovarian tumors compared with corresponding normal tissues and ap­
pears to be a mediator of the PTEN growth-suppressive signal ing pathway 31•32• 
Although individual genes such as those described above may prove to be relevant 
for tumor behavior, it is often not known in ovarian cancer and other cancers whether 
large fold changes in individual genes wil l have more biological importance com­
pared to smaller but coordinated fold changes in  a set of genes along a single path­
way. Analysis of our microarray data by integrating genes into functional gene sets 
according to pathways or transcription factors enabled us to consider all avai lable 
genomic information rather than genes passing a certa in significance threshold, thus 
providing extra clues to which signal ing pathways and transcription factors contrib­
ute to acquired chemoresistance. 
With this approach several interesting signaling pathways and transcription factors 
(Table 3 and 4) were identified previously reported to be impl icated in ovarian cancer. 
The cell cycle, Wnt, Jak-STAT and MAPK pathways, playing a role in apoptosis, prol ifera­
tion, differentiation and/or cel l  cycle were identified and aberrant signaling of these 
pathways has been proposed as a contributing factor in ovarian carcinogenesis 33 37• 
Additional ly, the transcription factors AP-2a lpha and c-Ets-1 have been suggested to 
be associated with poor prognosis in ovarian cancer 35•40• Similar, E2F transcription fac­
tors, members of the C/EBP fa mi ly and CREB were demonstrated to play an important 
role in ovarian carcinogenesis 41 44. Moreover, 17/18 KEGG pathways and 1 2/15 TRED 
transcription factors associated with chemoresistance in the present study were also 
found to be associated with survival in our microarray study of 157 advanced stage 
serous ovarian cancers. 17/18 pathways and 11/15 transcription factors were a lso asso­
ciated with overal l  survival in a publicly avai lable data set of 118 well-defined primary 
serous ovarian cancers profiled by Dressman et al (data not shown here) 25• 
A l imitation of functional gene set enrichment analysis as performed in our study is its 
inabil ity to assess the activation status of identified pathways in an individual tumor 
sample. Such a d isadvantage might be overcome by a strategy recently described 
by Bild et a l  25A5• I ndividual (oncogenic) pathways were activated in quiescent cel ls 
to identify the effects of single pathway activation on global gene expression. Gene 
expression profi les were then generated, reflecting the activation of specific signaling 
pathways. Identification of relevant pathways in ovarian cancer by gene set enrich­
ment analysis as performed in our present study should be followed by the strategy of 
Bild et al, enabling us to assess activation of identified relevant pathways in individual 
ovarian cancers 45• Subsequently, in the future pathway activation ana lysis in individual 
tumor may gu ide the choice of targeted drugs in ovarian cancer patients 46• 
I n  conclusion, our study provides new insights in molecular changes, both at the sin­
gle gene level as wel l  as at the level of signaling pathways and transcription factor 
gene sets that are relevant for acquired resistance to chemotherapy in ovarian cancer 
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To evaluate if serum cytokine levels could be used as diagnostic or prognostic markers in ova­
rian cancer. 
Methods 
A cytokine bead array was done to simultaneously analyze 14 cytokines in the sera of 187 ova­
rian cancer patients with complete clinicopathologic data and fol low- up, 45 patients with be­
nign ovarian tumors, and so healthy controls. Serum levels of the wel l-known serum tumor 
marker CA-125 were routinely measured in all patients. 
Results 
Serum levels of CA-125, i nterleukin 6 (IL-6), IL-7 and IL-10 were elevated in ovarian cancer pa­
tients compared with patients with benign ovarian tumors. Analyzing the cytokines in combi­
nation with CA-125 showed that a combination of IL-7 and CA-125 serum levels could accurately 
predict 69% of the ovarian cancer patients, without falsely classifying patients with benign 
pelvic mass. The cytokines IL-6, IL-7, IL-8, IL-10, monocyte chemotactic protein-, (MCP-1), and 
IP-10  and CA-125 were associated with disease free and overal l  survival in univariate analysis. In 
multivariate analysis, IL-7 and IP-10 were independent predictors of overal l  survival, although 
after inclusion of the cl ininopathologic parameters, only stage and residual disease remained 
as independent predictors of survival. 
Conclusion 
IL-7 levels were found to be strong ly associated with ovarian cancer and could be used in com­
bination with CA-125 to d istinguish between malignant and benign ovarian tumors. 
Introduction 
Ovarian cancer is the most frequent cause of death among gynecologic mal ignancies. 
It represents the fifth leading cause of death from a l l  mal ignancies in women. Despite 
standard treatment, cytoreductive surgery fol lowed by platinum/paclitaxel-based 
chemotherapy, the overal l  survival for ovarian cancer is only 35% '. This high death 
rate is related to the difficu lty of detecting ovarian cancer at an early stage as wel l  as 
the lack of effective therapies for advanced disease. 
Ovarian cancer often only gives vague and nonspecific symptoms, as a result of which, 
most patients have advanced stage d isease at diagnosis. Hence, markers for screening 
and diagnosis are needed. However, rel iable markers with high sensitivity and spe­
cificity have not yet been identified. An often used marker is serum CA-125, which is 
elevated in more than Bo% of the patients with advanced epithel ial ovarian cancer. 
Elevated CA-125 levels are a lso found in 10/o of healthy women and 60/o of patients with 
benign ovarian d isease; therefore, CA-125 a lone is not sensitive and specific enough 
for screening or diagnosis of ovarian cancer 2•3• 
The majority of patients presenting with advanced stage disease wi l l  have relapse of 
disease after initia l treatment, which is mostly incurable. "Classic" predictors of survival 
in ovarian cancer are cl inical parameters, such as tumor stage, age, residual tumor 
after surgery, histology, preoperative ascites, and CA-125 levels 4• To further individual­
ize treatment, additional prognostic markers that predict the clin ical course of the 
disease have to be found. 
Serum cytokine levels have been investigated as d iagnostic and prognostic markers 
in ovarian cancer. Cytokines are produced by a variety of hemopoietic and non-he­
mopoietic cel l  types and mediate and regulate immunity, inflammation, and hemo­
poiesis. Ovarian cancer cel l  l ines and primary ovarian cancer cel l  cultures seem to 
produce tumor-promoting cytokines l ike interleukin 6 (IL-6) and IL-8 5•6• The interaction 
between tumor and immune system and the production of cytokines by the tumor 
itself can result in different local and systemic levels of cytokines in cancer patients 7• 
Previous studies showed that most cytokines are not independent prognostic mark­
ers, and individual cytokines are not specific enough for screening purposes 3.8.9. 
Lately, a new technique, the cytokine bead array, has been developed for s imu lta­
neous analysis of multiple cytokines in serum samples. Serum levels of epiderma l  
growth factor (EGF), monocyte chemotactic protein-1 (MCP-1), CA-125, vascular en­
dothelial growth factor (VEGF), IL-6, and IL-8 showed significant differences between 
early stage ovarian cancer and control groups based on this cytokine bead array. A 
panel of these cytokines resulted in a higher sensitivity and specificity than CA-125 
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this study, serum cytokines were only investigated as a screening tool for early stage 
ovarian cancer and not for use as d iagnostic or prognostic tool. 
In the present study, the cytokine bead array was used to analyze 14 cytokines in pro­
spectively collected sera from ovarian cancer patients with complete c l inicopatho­
logic data and adequate fol low-up. The a im of this study was to evaluate if levels of 
cytokines can distinguish patients with ovarian cancer from patients with benign 
ovarian tumors or healthy controls. The second a im was to determine whether cy­
tokines can be used as prognostic markers in ovarian cancer. 
�aterials and methods 
Patients 
Pretreatment and fol low-up serum samples are routinely obtained of ovarian cancer 
patients treated at the Department of Gynecologic Oncology of the University Medica l 
Center Groningen (Groningen, the Netherlands) .  After col lection, serum is stored at -
80 °C in our serum bank until use. Serum markers l i ke CA-125 are routinely determined 
in al l patients suspected of ovarian cancer. I n  addition, extra serum is obtained after 
informed consent for future {research) use. The present study is part of an institutional 
review board-approved protocol (UMCG 2002/219). Patients who underwent surgery 
followed by chemotherapy at our department between January 1985 and July 2004 
and of whom sufficient serum was sti l l  avai lable were selected. Serum samples of 187 
ovaria n  cancer patients before surgery and 3 to 6 months after chemotherapy were 
selected. Tumors are staged according to the International Federation of Gynecology 
and Obstetrics classification. Al l stages a nd histologic types are represented in this 
patient group and are a reflection of the regular  population of ovarian cancer patients 
(Table 1). Data concerning age, tumor histology, tumor stage, differentiation grade, 
historical CA-125 values (al l  analyzed with the same assay), type of chemotherapy, re­
sponse to chemotherapy, resid ual tumor, ascites, and cl inical outcome were retrieved 
from our database (see next section). The mean observation period of ovarian cancer 
patients was 3.9 years (range 0-17.7 years). Preoperative sera of 45 patients with be­
nign ovarian tumors and sera of so age-matched healthy fema les were ana lyzed as 
controls. 
Institutional review board approval 
All c l inicopathologic and histologic data of patients referred to the Department of 
Gynecologic Oncology of the University Medica l Center (Groningen, the Netherlands) 
are prospectively col lected and stored in a com puterized database. All fol low-up data 
are obtained during standard treatment and follow-up. For the present study, al l rel­
evant data were retrieved from our computerized database and transferred into a 
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separate anonymous database. I n  this separate password-protected database, patient 
identity was protected by study-specific, unique patient codes. The true identity of 
patients was only known to two dedicated data managers, who also have daily re­
sponsibil ity for the larger database. In  case of uncerta inties with respect to clin ico­
pathologic and fol low-up data, the larger databases cou ld only be checked through 
the data managers, thereby ascertaining the protection of patients' identity. 
Selection of cytoklnes 
For selection of cytokines to be measured, initia l ly, preoperative serum of 26 ovarian 
cancer patients, post-chemotherapy serum of 20 ovarian cancer patients, and serum 
of 12 patients with benign ovarian tumors and 8 healthy controls were ana lyzed for 21 
cytokines [I L-,a, IL-1 J3, I L-2, IL-4, IL-5, I L-6, IL-7, IL-8, I L-10, IL12p70, I L -13, IL-15, IL-17, I FN-y, 
granu locyte colony-stimulating factor (G-CSF), granu locyte macrophage colony-stim­
ulating factor GM-CSF, tumor necrosis factor-a (TNF-a), eotaxin, MCP-1 , macrophage 
inflammatory protein-,a (MIP-,a), and IP-10] by cytokine bead array. Cytokines with 
very low or undetectable concentrations in al l patients in this group were excluded 
from further analyses. Serum samples of our entire patient popu lation were subse­
quently analyzed for 14 cytokines with a customized LINCOp/ex kit. 
Cytokine bead array 
For the s imultaneous measurement of mu ltiple cytokines in a smal l volume of serum, 
a LINCOp/ex kit was used according to manufacturer's protocol (Linea research, St. 
Charles, MO, USA). The serum samples were randomly assigned to the p lates to avoid 
assay bias. Two serum samples were analyzed on every p late to determine interassay 
differences. A fi lter-bottom, 96-well microplate was blocked for 10 min with provided 
assay buffer. A standard curve (ranging from 3.2 to 10,000 pg/ml) was made by 5-fold 
di lutions of the human cytokine standard cocktai l in the provided buffer. Standards, 
controls and patient sera were pipetted at 25 µI per wel l  in dupl icate. About 25 µI of 
serum di luent was added to the standards and controls, and 25 µI of provided assay 
buffer was added to the serum samples. After adding 25 µI of the bead mixture, the 
microplate was incubated for 1 h on a microtiter shaker in the dark at room tempera­
ture. Wel l s  were washed twice usi ng a vacuum man ifold. A cocktail of biotinylated 
secondary antibod ies was added, and the microplate was incubated for 30 min in the 
dark on a microtiter shaker. After 30 min of incubation with streptavidin-phytoeryth­
rin, the microplate was washed twice. Sheath flu id was added to each wel l, and sam­
ples were ana lyzed using the Biop/ex system (Bio-Rad Laboratories, Hercules, CA, USA). 
Data were ana lyzed using a five-parametric-curve fitting. As a control for freeze-thaw 
effects, serum was frozen and thawed up to seven times before analysis. No changes 
in  cytokine concentrations were detected after these multip le freeze-thaw cycles. 
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Statistical analysis of data 
Differences in cytokine levels between ovarian cancer patients, patients with benign 
ovarian tumors, and healthy controls were determined with a Mann-Whitney U test. 
To analyze differences in cytokine levels before operation compared with cytokine 
levels after primary treatment (surgery fol lowed by chemotherapy), a Wilcoxon signed 
rank test was done. Tumor and cl inica l parameters were correlated with cytokine lev­
els in ovarian cancer patients using a Mann-Whitney U test. Receiver operator curves 
(ROC) were created to determine the predictive va lue of the cytokines to distinguish 
between ovarian cancer patients and control groups. Statistical differences in progres­
sion free survival and overal l  survival for prognostic markers were determined by the 
log-rank test and Kaplan-Meier survival curves were made. Overal l  survival was de­
fined as the time since primary surgery until death due to ovarian cancer or the date 
of last fol low-up. Progression free survival was defined as the time from primary sur­
gery until the date of progression or relapse of the d isease. Mu ltivariate analysis was 
done using the Cox proportional hazards model. Statistical significance was defined 
as p<o.os. SPSS (SPSS 1202, Inc., Ch icago, I L) was used for al l ana lyses. 
Results 
Selection of cytoklnes 
Sera of a smal l  group of ovarian cancer patients, patients with benign ovarian tumors, 
and healthy controls  were analyzed for a panel of 21 cytokines by cytokine bead array. 
Serum concentrations of IL-1�, I L-s, IL-12p70, I L-13, I L-17, TNF-a, and IFN-y were low or 
undetectable in a l l  patients in th is group and therefore not ana lyzed in the complete 
patient group. Subsequently, serum samples of a l l  patients were analyzed for I L-m, 
IL-2, I L-4, I L-6, I L-7, I L-8, I L-10, I L-15, G-CSF, GM-CSF, eotaxin, MCP-1, MIP-1a, and IP-10. 
Cytoklne and CA-12  S concentrations in pretreatment 
sera of ovarian cancer patients and control groups 
Median serum levels of CA-125, I L-6, I L-7, I L-8, I L-10, and MCP-1 were higher in ovar­
ian cancer patients compared with healthy controls (p<o.001 to p<o,03; Table 2). Sera 
of ovarian cancer patients had lower levels of G-CSF than healthy controls (p<o.01) .  
Serum levels of CA-125, I L-6, I L-7 and IL-10 were higher in  ovarian cancer patients com­
pared with patients with benign ovarian tumors (p<o.001 to p<o.02). 
To find markers for the early detection of ovarian cancer, analyses were a lso done for 
stage 1/11 ovarian cancer patients only. Levels of IP-10 were lower in stage 1/11 ovarian 
cancer patients than in healthy controls (p=o.006). As expected, serum concentrations 
of CA-125 were higher in  stage 1/1 1 ovarian cancer patients compared with healthy con­
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Table 2 
Median concentrations (pg/ml) of serum cytokines in  ovarian cancer pa-
tients (N=187), stage 1/11 ovarian cancer patients (N=67), stage 1 1 1/IV ovarian 
cancer patients (N=119), patients with benign ovarian tumors (N=45) and 
healthy controls (N=so) 
Ovarian 




340· 1 42.0· 1 980" ' 16 7,5 
(59.0-1660) (17.0-140.0) (295-2117) (8 o 37,0) (5.0-13.0) 
IL-6 
15.1· 1 7.01 23.8· 1 70 6.6 
{4,7-44,2) (0.0-22.6) (8.3-52,1) (0,47-25,4) (0.3-32,3) 
IL-7 
5.3· t 3.S 7,6
° 
I 2.0 2.9 
{2,3-10.6) (1,4·6.1) (3.2 11 .0) (0-4 6) (0,9-4.7) 
IL-8 
13.2' 7-4* 16.3" t 7.S 7,1 
(5,7-37,7) (2,4-24.3) (8.0-40.6) (2.9-32.5) (3.1-18.8) 
IL 10 
8.2" I 3.2' 12 5· 1 2.1 2.7 
(2,4-217) (0.0·8.9) (5.1-26.6) (o 7.Sl (0-8.1) 
G-CSF 
0.01 o.o' o' 0 1,7 




I 229,4 218.3 
(193,7-336.0) (150.9-295,9) (213,7-385,5) (148.6-298.8) (169.1-286.8) 
Eotaxin 
79,8' 63.S 84,7' 102.6 70.0 
(37.7-130.2) (27.6-107,9) (44,4-139,4) (45,9-145,1) (23.9-139,9) 
!P-10 
110.s' 47,8" I 1S4,9' I 77,5 81.9 
(45.1-236.2) (27.1-110.5) (82.6-278.7) (57,1-129.0) (52,79-140.8) 
Results are given as median concentrations and interquartile range. P-values were calculated with the Mann­
Whitney U test. · Comparison between ovarian cancer patients and patients with benign tumors, (p<o.05); ' 
Comparison between ovarian cancer patients and healthy controls, (p<o.05); 1 Not significant. 
patients compared with patients with benign ovarian tumors (p=o.01 to p=o.02). Se­
rum concentrations of CA-125 and IL-7 were increased in stage 1/1 1  ovarian cancer pa­
tients compared with patients with benign ovarian tumors (p=o.04). Stage I l l/IV ovar­
ian cancer patients had higher serum levels of CA-125, IL-6, IL-7, IL-8, IL-10, MCP-1, and 
IP-10 and lower levels of G-CSF compared with healthy controls (p<o.001 to p<o.01). 
Serum levels of CA-125, I L-6, IL-7, IL-8, IL-10, MCP-1 ,  and IP-10 were elevated in stage I l l/IV 
ovarian cancer patients compared with patients with benign ovarian tumors (p<o.001 
to p<o.02; Table 2). 
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Pretreatment serum cytokine concentrations in relation 
to clinicopathologlc parameters 
Table 3 shows that serum levels of CA-125, I L-6, I L-7, I L-8, IL-10, eotaxin, MCP-1, and IP-10 
were related with more advanced disease and presence of ascites (p<o.001 to p<o.04). 
CA-125, I L-6, I L-7, I L-8, I L-10, MCP-1, and IP-10 were related with residual tumor after 
surgery (p<o.001 to p<o.02). Serum CA-125, I L-8, I L-10, eotaxin, MCP-1, and IP-10 were 
higher in patients with serous tumors versus non-serous tumors (p<o.001 to p<o.04). 
CA-125, I L-8, I L-10, eotaxin, and IP-10 were related with higher grade tumors (p<o.001 
to p<o.03). I L-6, I L-8, I L-10 eotaxin, MCP-1, and I P-10 were related with increasing age 
(p<o.001 to p<o.02). 
Serum levels of ovarian cancer patients before operation and after chemotherapy 
were compared as wel l, showing decreases in levels of CA-125, I L-6, I L-7, I L-8, and IL-10 
after chemotherapy (p<o.001; data not shown). 
Predictive value of serum cytokines for ovarian cancer 
versus control groups 
ROC were created to determine the predictive va lue of serum cytokines distingu ish­
ing ovarian cancer patients from control groups. Serum levels of cytokines ( IL-6, I L-7, 
and IL-10) and CA-125 elevated in serum of ovarian cancer patients compared with 
patients with benign ovarian tumors were ana lyzed for their predictive value. Areas 
under the ROC for CA-125, I L-6, I L-7, and IL-10 were 0.881, 0.609, 0.721, and 0.695 respec­
tively (p<o.001 to p<o.03; Figures 1A and B). CA-125 discriminated between benign 
ovarian tumors versus cancer with a sensitivity of 81.1% and a specificity of 80%. For 
I L-6, I L-7, and IL-10, the area under the curve was low, resulting in sensitivities and 
specificities between 60% and 700/o. Serum levels of CA-125, I L-6, I L-7, I L-8, I L-10, and 
MCP-1 were significantly higher in  ovarian cancer patients versus healthy controls and 
were analyzed for their d iagnostic va lue. For ovarian cancer versus healthy controls 
the areas under the curve for CA-125, IL-6, I L-7, I L-8, I L-10, and MCP-1 were 0.952, 0.602, 
0.660, 0.618, 0.681, and 0.615 respectively (p<o.001 to p<o.03). CA-125 had a sensitivity 
of 90.9% and a specificity of 85.3% for d istinguishing between cancer and healthy 
controls. CA-125 levels above the upper l imit of normal (35,000 un its/L) accurately 
classified 82% of the ovarian cancer patients, but a lso wrongly classified 27% of the 
patients with benign tumors as mal ignant. For the other cytokines, sensitivities and 
specificities between 55% and 70% were reached. 
None of the cytokine markers alone were able to distinguish between ovarian cancer 
and benign ovarian tumors. Therefore, the predictive values of d ifferent cytokines in  
combination with CA-125 were analyzed to improve the accurate detection of  ovarian 
mal ignancy. Patients with missing values for the analyzed cytokine or CA-125 were 
excluded from this ana lysis. The combination of IL-7 and CA-125 could predict ovarian 
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Table a 
Median concentration (pg/ml) of cytokines in sera of ovarian cancer patients 
that correlated significantly with cl inicopathologic features 
Clinical 
CA-125 IL-6 IL-7 IL-8 IL-10 Eotaxin MCP-1 IP-10 
characteristic 
Age 
s59 years 10,7 9,3 6.o 63.S 243.6 71-6 
>59 years 23.8 16.9 10,0 88.2 263.3 153,9 
Tumor stage 
Stage 1/11 42.0 7.0 3.5 7-4 3,2 63.5 220.S 47,8 
Stage Ill/IV 980 23.8 ].6 16.3 12.5 84.7 274.1 154.9 
Tumor grade 
Grade 1/2 112 11.0 6 0  59,5 65.1 
Grade 3/undlff 630 15,7 12.9 84.53 181-4 
Tumor histology 
Serous 1125 16 9 10.3 88.6 295,3 154.9 
Non-serous 73 10.7 6.0 69-4 235.0 69.3 
Residual tumor 
s2 cm 97 11.9 4,3 9.7 5.6 67.2 68.1 
>2 Cm 1030 24.1 7.5 19.8 12.6 89.3 167.S 
Ascites 
s1 L 68.o 6.7 3.9 8.6 3-7 65.8 229.5 70-4 
>1 L 1280 28.2 8.9 20.9 15-4 92.2 305.8 143.2 
-, no significant correlation. 
with benign ovarian tumors were included. The ROC curve showed that for I L-7 a cut­
off point of 3.8 pg/ml gave the highest accuracy to distinguish malignant from benign 
ovarian tumors. In patients with serum levels of I L-7 above the cut-off point of 3.8 pg/ml, 
a ROC for CA-125 was created to discriminate between malignant and benign cases. 
In this group, a cut-off point of CA-125 of 40,000 units/L gave a specificity of 1 00% 
for d istinguishing between malignant and benign pelvic mass. In this manner, 56% 
of the patients with ovarian cancer were detected. In patients with I L-7 levels below 
cut-off of 3.8 pg/ml, CA-125 levels above 300,000 units/L reached a specificity of 1 00% 
in predicting the presence of mal ignant pelvic mass, detecting another 1 3% of the 
patients with ovarian cancer. Hence, by combining cytokine levels of IL-7 and CA-125, 
69% of the patients with mal ignant pelvic mass were accurately classified, without 
falsely classifying patients with benign pelvic mass (Figu re 1C). 
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For stage 1/11 patients versus healthy controls the areas under the curve for CA-125 
and IP-10 were 0.875 and 0.352 (p<o.001 and p<o.06, respectively). For stage 1/11 ovar­
ian cancer patients versus patients with benign ovarian tumors the area under the 
curve for CA-125, IL-7, eotaxin, and IP-10 were 0.716, 0.615, 0.364, and 0.362, respectively 
(p<o.001 to p<o.04; data not shown). 
Serum cytokine levels as prognostic marker in ovarian 
cancer 
Univariate analysis of the cl inicopathologic parameters showed that age, histology, 
stage, grade, response to chemotherapy, residual tumor, and ascites were associated 
with progression free and overa l l  survival in ovarian cancer patients (Table 4). The type 
of chemotherapy that patients received (non-taxol containing chemotherapy versus 
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Serum cytokines for distinguishing between patients with malignant and benign ovarian tumors. 
A. ROC for CA-125 and B. ROC for IL-6 (- - -), IL-1 (-), and IL-10 (-) for ovarian cancer versus benign 
ovarian tumors; C. Combination of serum levels oflL-7 and CA-125 that can discriminate between pa­
tients with malignant or benign ovarian tumors. The markers with cut-off (picograms per milliliter for 
/L-7 and thousand units per liter for CA-125) are depicted, together with the percentage of the patients 














Serum cytoklne profiling In ovarian cancer ••• 
survival as determined by univariate ana lysis (p=o-33 and p=o.89, respectively). Serum 
levels of CA-125, IL-6, IL-7, IL-8, I L-10, MCP-1, and IP-10 above the median were asso­
ciated with a shorter progression free and overa l l  survival in the univariate analysis 
(Table 4). Kaplan-Meier curves of IL-7 and IP-10 are shown in  Figure 2, the other above­
mentioned cytokines gave simi lar resu lts. 
In stage 1/1 1 ovarian cancer patients, only tumor grade was associated with progres­
sion free survival .  The serum levels of CA-125, IL-7, eotaxin, and I P-10 did not correlate 
with progression free and overa l l  survival in the univariate analysis of stage 1/1 1 ovarian 
cancer (data not shown). 
In m u ltivariate ana lysis of the cl inicopathologic parameters, stage and tumor grade 
remained as independent predictors of progression free surviva l in ovarian cancer 
patients. Stage and residual tumor were independent predictors of overa l l  survival. 
Response to chemotherapy was eva luable in on ly 42% of the patients and therefore 
not included in the multivariate analysis. Mu ltivariate analysis of the cytokines that 
were associated with surviva l in the univariate analysis revea led that I L-7 and IP-10 
were independent predictors of overa l l  survival . CA-125 and I P-10 were independent 
predictors of progression free survival . However, when these cytokines were analyzed 
together with the clinicopathologic parameters, only stage and residua l tumor re­
mained independent predictors of progression free and overa l l  surviva l. 
Furthermore, d ifferent combinations of cytokines, which showed correlation with sur­
viva l in the univariate ana lysis, were analyzed. In the univariate ana lyses, a combina­
tion of CA-125, I L-7, and I P-10 with serum levels higher than the median gave the best 
association with overal l surviva l , with a hazard ratio of 5,77 [95% confidence interval 
(95% Cl), 2.88-11 .53]. Although the hazard ration of this panel of cytokines is higher 
than for the ind ivid ual cytokines, the panel of CA-125, IL-7, and I P-10 was not an inde­
pendent prognostic marker in the m ultivariate ana lysis. 
Discussion 
In our  study, serum levels of CA-125, I L-6, I L-7, and I L-10 were found to be elevated in 
ovarian cancer compared with patients with benign ovarian tumors. Moreover, deter­
mination of both IL-7 levels and CA-125 could classify 690/o of the ovarian cancer pa­
tients accurately, without fal sely classifying patients with benign ovarian tumors. We 
and others found that the commonly used tumor marker CA-125 was elevated (>35,000 
units/L) in 82% of the ovarian cancer patients 2• However, as has been shown by many 
previously, CA-125 was a lso elevated in part of the patients with benign tumors and 
therefore lacks sufficient sensitivity and specificity to be used solitarily for distinguish­
ing between mal ignant and benign pelvic mass 11• To our knowledge, IL-7 has never 
been investigated for use as a diagnostic tool in ovarian cancer. Xie et al reported 
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Table 4 continued 
Progression free survival Overall survival 
Hazard ratio (95% Cl} p Hazard ratio (95% Cl} p 
IL-10 
<8.15 1 1 





<253.28 1 1 





<110-51 1 1 
1,89 (1.89-4-57) 
<0,001 
2.95 {1 ,90-4.59) 
<0.001 
>110-51 
that IL-7 was found to be expressed in only 3% of the ovarian carcinoma tissues 12, 
ind icating that the increased serum levels of IL-7 probably a re produced by host im­
mune cel ls in response to tumor growth. In cervical and endometria l cancer, serum 
IL-7 was a lso elevated compared with healthy controls, but was not further investi­
gated for diagnostic or prognostic purposes 1�14• Our data suggest that IL-7 might be a 
good addition to CA-125 for d iagnosis of ma lignant versus benign ovarian tumors. A 
prospective, larger study should be done to evaluate the additional val ue of determin­
ing IL-7 in combination with CA-125 for d iscriminating between benign and malignant 
pelvic masses. Natural ly, in such a study, commonly used tools such as u ltrasound 
should a lso be included. 
In a variety of stud ies, IL-6 and IL-10 have a l so been reported to be elevated in serum 
or peritonea l fluids of ovarian cancer patients compared with patients with benign 
ovarian tumors 10-ws.16• IL-10 levels were measured to distingu ish ovarian cancer from 
benign ovarian tumors, but a low sensitivity and specificity were reported 15, compara­
ble to the data in the present study. 
The second goa l of the study was to determine if a single cytokine, or a combination 
of cytokines, cou ld be used as prognostic marker for ovarian cancer. In mu ltivariate 
ana lysis, IL-7 and I P-10 were shown to be significant predictors of overal l survival. How­
ever, after inclusion of the c l inicopathologic parameters in the multivariate ana lysis, 
only stage and residual tumor remained independently related to overa l l  survival, 
which is probably due to the relation between serum IL-7 and I P-10 levels and stage 
and residual d isease. Thus, I L-7 and IP-10 are correlated with the course of the disease, 
but the relation is not strong enough to use these cytokines as independent prognos­
tic marker in ovarian cancer. 
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Figure 2 
Kaplan-Meier curves of serum /L-7 levels (A) and serum /P-10 levels (BJ. The median /L-7 levels (5.3 pg/ml) and 
/P-10 level (110.s pg/ml) were taken as cut-off points. Kaplan-Meier curves of serum CA-125, IL-6, IL-8, /L-10, and 
MCP-1 showed similar results. 
IL-7 seemed to be one of the strongest prognostic markers of a l l  cytokines tested in our 
study. I n  breast cancer patients, aberrant expression of IL-7 and its signaling intermedi­
ates have also been related to a poor prognosis 17• It was suggested that IL-7 affects 
breast tumors by acting as a growth factor for both endothelial and breast cancer cells 
and by promoting lymphangiogenesis and metastasis '7·'8. In  contrast, transfection of 
IL-7 in an ovarian cancer cel l  l ine reduced tumorgenicity probably by activation of 
lymphokine-activated ki l ler cel ls 12• I n  colorectal cancer tissue and cel l  l ines IL-7, was 
found to be produced by tumor cel ls and was able to expand tumor-infi ltrating lym­
phocytes, thereby enhancing antitumor immunity '9• In ovarian cancer, further studies 
are required to address whether ovarian cancer cells a re able to produce I L-7 and if I L-7 
acts as a growth factor on ovarian cancer cel ls. 
The cytokine bead array has been used in one study before for the early detection of 
ovarian cancer. The levels of the cytokines measured were simi lar to the levels meas­
ured by ELISA or RIA 10• In their study the levels of CA-125, IL-6, IL-8, G-CSF, and MCP-1 
were reported to be significantly different in early stage ovarian cancer patients com­
pared with control g roups. We a lso found serum levels of CA-125, I L-6, IL-?, I L-8, IL-10, G­
CSF, and MCP-1 to be elevated in ovarian cancer patients of a l l  stages compared with 
healthy controls. Except for MCP-1, the concentration of these cytokines in healthy 
controls and patients with benign tumors were comparable to the concentrations as 














Serum cytokine profiling in ovarian cancer ••• 
I n conclusion, ll-7 was found to be strongly related to ovarian cancer and may be used 
in combination with CA-125 for diagnosis of ovarian cancer. Its role in the course of 
ovarian cancer needs to be further explored. 
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1) to develop a gene expression profile associated with overal l  survival in advanced stage se­
rous ovarian cancer, 2) to assess the association of pathways and transcription factors with 
overall survival, and 3) to val idate our identified profile and pathways/transcription factors in an 
independent set of ovarian cancers. 
Methods 
According to a randomized design, profiling of 157 advanced stage serous ovarian cancers was 
performed in duplicate us ing -35K 70-mer oligonucleotide microarrays. A continuous predic­
tor of overa l l  survival was bui lt taking into account well known issues in microarray analysis, 
such as multiple testing and overfitting. A functional class scoring analysis was uti l ized to as­
sess pathways/transcription factors for thei r association with overall survival. The prognostic 
value of genes that are part of our overal l  survival profile was val idated on a ful ly independent, 
publ icly available data set of 1 18  wel l-defined primary serous ovarian cancers. Fu rthermore, the 
functional class scoring analysis was also performed on this independent data set and results 
were compared. 
Results 
An 86-gene overal l  survival profile discriminated between patients with unfavorable and favo­
rable prognosis (median survival, 19 vs. 41 months, respectively; permutation P-value of log-rank 
statistic = 0,015) and maintained independent prognostic value in multivariate analysis. Genes 
that comprised the overa l l  survival profile were also able to discrim inate between the two risk 
groups in the independent data set. 16/17 pathways and 12/13 transcription factors identified in 
our data set were also associated with overa l l  survival in the independent data set. 
Conclusion 
This study provides new clues to genes, pathways and transcription factors which contribute 
to the clinical outcome of serous ovarian cancer and might be exploited in designing new 
treatment strategies. 
Introduction 
Ovarian carcinoma is the leading cause of death from gynecologic mal ignancies in  
the Western world '. Debulking surgery fol lowed by platinum-based chemotherapy i s  
considered standard care for patients with advanced stage ovarian cancer 2• Despite 
an in itial response rate of 65-80% to first-l ine chemotherapy, most women will relapse 
with drug-resistant d isease. Consequently, the 5-year survival rate of patients with ad­
vanced stage disease is only about 5-30% 3• 
To date, a variety of studies have employed gene expression profil ing to classify ovar­
ian carcinomas in cl in ica l ly relevant subtypes 4·9_ These studies provided va luable the 
first clues to molecular changes in serous ovarian cancer that might be exploited in 
new treatment strategies. However, most studies were of relatively l im ited size and 
the number of overlapping genes in the identified profi les was min imal. Although 
identification of gene expression profiles associated with clinical ly relevant subtypes 
in ovarian cancer is important, knowledge is now emerging rapidly on how genes 
interact in pathways, networks and complexes; this a l lows us to unravel cel lu lar path­
ways determining the biological behavior of ovarian cancer and these might be suc­
cessful ly targeted with drugs. 
The a im of our study was: 1) to develop a gene expression profile associated with 
overal l  survival in advanced stage serous ovarian cancer, 2) to assess the association of 
pathways and transcription factors with overa l l  survival, and 3) to validate our profile 
and identified pathways/transcription factors in a fu l ly independent, publ icly avai lable 
data set of serous ovarian cancers. 
�ethods 
Patients and tumor samples 
The study population consisted of 157 consecutive patients with advanced stage 
serous ovarian cancer operated on by a gynecologic oncologist from the Un iversity 
Medical Center Groningen (UMCG, Groningen, the Netherlands) in the period 1990-
2003. All patients were treated according to a Dutch gu idel ines, that were based on 
the International Federation of Gynecology and Obstetrics guidel ines (FIGO) '0·11 • New 
chemotherapy treatment regimens were adopted as fol lows: platinum-based chemo­
therapy at the beginning of the 1980s, and platinum/paclitaxel chemotherapy after 
1996. Tumor sam ples were obtained during surgery, flash frozen in l iquid nitrogen 
and stored at -Bo 0C. All samples were confirmed to comprise tumor cells (med ian 
percentage tumor cells: 70%, interquartile range: 50-80%), as examined after hema­
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lection and storage of tissue samples in  a tissue bank for future research. Al l  relevant 
patient data were retrieved and transferred into an anonymous, password-protected, 
database. The patient's identity was protected by study-specific, unique patient codes 
and their true identity was only known to two dedicated data managers. According 
to Dutch law, these precautions meant no further institutiona l review board approval 
was needed. 
RNA extraction and amplification 
Tota l RNA from tumor samples was pel leted through cesium ch loride density gra­
dient u ltracentrifugation (Roche, Almere, the Netherlands). After tota l RNA samples 
had been given DNAse treatment (Megascript T7 kit, Ambion, Huntingdon, UK), they 
were checked for residual DNA using a d inucleotide primer set D11S875 specific for 
genom ic DNA 12 . mRNA was l inearly ampl ified by in vitro transcription using T7 RNA 
polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) 13. Qual ity/integrity of total 
and a mplified mRNA (cRNA) was checked by spectrophotometer ana lysis, UV 260/280 
ratio >1.8, and/or agarose gel electrophoresis. 
�icroarray experiments 
Two randomly selected cRNA samples were hybrid ized together on the arrays for in­
tensity-based i nstead of ratio-based analysis of the microarray data 14• All cRNA samples 
(1 .s µg) were labeled with ULS-Cy5 and ULS-Cy3 label (BIOKt, Leiden, the Netherlands) 
and hybrid ized to -35K 70-mer two-color oligonucleotide microarrays (-35,000 Oper­
on v3.o probes), manufactured by the Netherlands Cancer Institute (Amsterdam, the 
Netherlands) 13• As each tumor sample was profi led once with Cy5 and once with Cy3, 
there was one repl icate of the whole experiment. Samples were hybridized accord ing 
to a randomized design to prevent systematic biases •s 11• After we had randomized 
the processing order of the arrays from d ifferent batches, Cy5- and Cy3-labeled cRNA 
samples were randomly placed onto the arrays. Arrays were scanned and expression 
values were ca lculated. 
Statistical methods 
Quantile normal ization was appl ied to 1092 transformed Cy5 and Cy3 intensities 18• 
Principal components analysis was performed for qual ity control. Samples with a fac­
tor loading with the first principal components of less than 2 times the standard de­
viation from the mean were excluded as their hybridizations were considered to be 
of low qual ity 19•20• Operon V3.o probe identifiers (-35,000) were converted to official 
gene symbols. Expression va lues of multiple probes targeting the same gene were 
averaged, resu lting in a tota l of 1 5,909 unique genes for further ana lysis. Subsequently, 
expression data obtained from Cy5- and Cy3-labeled samples of the same tumor were 
averaged (mean correlation 0.93 ± 0.04). Microarray analyses were performed with the 
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software package BRB Array Tools 3.6.0, developed by the Biometric Research B ranch 
of the US National Cancer Institute (http://l inus.nci.nih.gov/BRB-ArrayTools.htm l). 
Survival prediction 
An overa l l  survival profi le was bui lt  using the supervised principal components 
method 21• For each iteration of the complete cross-val idation, ten percent of the 
cases were omitted, and genes were selected that univariately correlated with overa l l  
survival at a significance level of p<o.001 for the remaining cases (pattern d iscovery). 
The first five principal components of the selected genes were computed and a Cox 
proportional hazards model was fitted to the data (with 10% of cases omitted) using 
the principal components as pred ictors. The fitted model was used to classify omitted 
cases as high or low risk based on whether their predictive index of the fitted model 
was above or below the median of the predictive indices for the 90% of cases in  the 
"training set''. This entire procedure was repeated, leaving out a d ifferent 10% of cases 
until each case had been omitted exactly once and the cross-va l idated risk g roups 
were determined for a l l  cases. Kaplan-Meier survival curves were plotted for the pre­
dicted overal l  survival risk classes and the log-rank statistic computed. To asses the 
significance of the log-rank statistic, a phenotype permutation test based on 1,000 
permutations was performed. Multivariate analysis for confounding prognostic fac­
tors was carried out using Cox proportional hazards regression. For this analysis, our  
overa l l  survival profile was considered a binary category (low risk, h igh risk). 
Pathway and transcription factor analysis 
Functional gene set enrichment analysis was performed as described by Pavl idis et al 22• 
Predefined gene sets were ana lyzed to indicate which gene sets contained more 
genes correlated with overal l  survival than would be expected by chance. First an uni­
variate Cox proportional hazards P-va lue was computed for a l l  15,909 unique genes. 
Then P-va lues of a subset of genes belonging to a functional set were summarized by 
the LS and KS summary statistics. For a set of N genes, the LS statistic is defined as the 
mean negative natural logarithm of single gene P-values. The KS statistic is defined as 
the maximum difference between i/N and P;, where P; is the ith smal lest P-va lue. This is 
the Kolmogorov-Smirnov statistic for testing if the P-va lues are of uniform distribution. 
The statistical s ignificance of a functional gene set conta ining N genes is eva luated by 
computing the empirical d istribution of these summary statistics in random sam ples 
of N genes. A total of 1 67 functional gene sets as reported in the Kyoto Encyclopedia 
of Genes and Genomes database (KEGG) and 111 as reported in the Transcriptional 
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External validation 
Expression and survival data publ icly avai lable from an independent set of serous 
ovarian cancers profi led by Dressman et a l was used to validate the genes that com­
prise our overal l  survival profi le 4•9•25• Probe set identifiers from the Affymetrix HU133A 
microarray were converted to official gene symbols. Converting HU133A probe set 
identifiers to official gene symbols enabled us to select probe sets targeting genes 
comprising our overa l l  survival profi le. The surviva l prediction method as described 
above was appl ied, except that genes part of our overal l surviva l profi le were prese­
lected in the independent data set from Dressman et al and not selected using pat­
tern d iscovery. Furthermore, functional c lass scoring ana lysis for pathways and tran­
scription factors as described above was a lso performed on this independent data set 
to compare resu lts 22• 
More detai led information on these methods is provided in the supplementary data 
(see supplementary methods). 
Results 
Patient characteristics 
Cl inicopathologic characteristics of the 157 platinum-treated patients with serous 
ovarian cancer are summarized in Table 1. For the whole group the median overa l l  sur­
vival time was 21 months (range 1-234) and the s-year overa l l  surviva l rate was 27%. 
<iene expression profile associated with overall survival 
Eighty-six genes were found to correlate with overal l survival by univariately fitting 
Cox proportional models at an a lpha of 0.001. In Table 2 each gene is l isted with its 
P-value, hazard ratio (HR) and description. Figure 1A shows the Kaplan-Meier surviva l 
curves for the patients pred icted to have above or below median risk of death due to 
ovarian cancer. The low risk group had a median survival of 41 months, whereas the 
high risk group had a median su rvival of 19 months (p=o.0014, log-rank) . The permuta­
tion P-va lue of the log-rank  test statistic between the two risk groups based on 1,000 
permutations was p=o.015. Table 3 shows the distribution of several prognostic factors 
as a function of risk assignment based on ou r 86-gene overal l survival profile. Age, 
stage, grade, debulking status and chemotherapy regimens showed no difference 
in distribution between the predicted low- and high-risk g roup. In addition to our 
overal l  survival profi le, on ly amount of residual tumor after primary surgery (p=o.0003; 
HR=2.340) showed prognostic va lue for overa l l  survival in un ivariate analysis. In mul­
tivariate ana lysis our overa l l  survival profi le (p=o.002; HR=1 .876) and debulking status 
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Figure 1 
Kaplan-Meier survival curves 
for the patients predicted to 
have above or below median 
risk of death due to ovarian 
cancer in: A. Present study, 
median survival of 19 months 
vs. 41 months (p=o.0014, /og­
rank), permutation P-value = 
0.015; 8. Dressman et of, me­
dian survival of 33 months vs. 
108 months (p<o.0001, log­
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Table 1 






























































All patients received platinum-based chemotherapy post­








Description symbol ratio 
AAK1 0.000645 0.476 AP2 associated kinase 1 
ACSM1 0.000361 0.274 acyl-CoA synthetase medium-chain family member 1 
AGPAT7 0.000418 0.331 1-acylglycerol-3-phosphate O-acyltransferase 7 (lysophospha· tidic acid acyltransferase, eta) 
AIPL1 0.000989 0.378 aryl hydrocarbon receptor interacting protein-like 1 
ATP5D 0.000133 0.521 ATP synthase, H+ transporting, mitochondrial F, complex, delta subunit 
BAX 0.000964 0.388 BCL2·associated X protein C BRSK1 0.000981 0.634 BR serine/threonine kinase 1 
c,oorfao 0.000407 0.352 chromosome 10 open reading frame Bo C C14orf121 0.000105 0.263 chromosome 14 open reading frame 121 
C1orfi51 0.000116 0.582 chromosome 1 open reading frame 151 
C C1orfi59 0.000228 0.296 chromosome 1 open reading frame 159 
C1orfi9a 0.000785 1 .606 chromosome 1 open reading frame 198 
C1orf68 0.000348 0.471 chromosome 1 open reading frame 68 g �  
C1QTNF3 0.000106 1.75 C1q and tumor necrosis factor related protein 3 
C20orf:32 0.000699 0.582 chromosome 20 open reading frame 32 C 
CACNA1B 0.000027 0.318 calcium channel, voltage-dependent, N type, alpha 1B subunit 
CACNG6 0.000154 0.402 calcium channel, voltage-dependent, gamma subunit 6 C CCDC135 0.000232 0.304 coiled-coil domain containing 135 
CCL28 0.000749 1-477 chemokine (C·C motif) ligand 28 C CDH19 0.000493 0.449 cadherin 19, type 2 
CDYL2 0.000987 0.489 chromodomain protein, Y·like 2 C CES2 0.000256 0.389 carboxylesterase 2 (intestine, liver) 
CNTFR 0.000710 0.451 ciliary neurotrophic factor receptor 
C CPE 0.000651 1.415 carboxypeptidase E 
CRYBB1 0.000473 0-339 crystallin, beta B, 
C DDB2 0.000937 0.641 damage-specific DNA binding protein 2, 48kDa 
FEZ, 0.000451 2.2 fasciculation and elongation protein zeta 1 (zygin i) 
FGFBP1 0.000525 0.729 fibroblast growth factor binding protein 1 C 
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Description symbol ratio 
FGFR1OP2 0.000428 1 .77 FGFR1 oncogene partner 2 
FKBP7 0.000042 2.903 FK506 binding protein 7 
GCM1 0.000638 0-414 gl ial cel ls missing homolog 1 (drosophila) 
GNAZ 0.000256 0.324 guanine nucleotide binding protein (G protein), alpha z 
polypeptide 
HIPK1 0.000440 0.195 homeodomain interacting protein kinase 1 
ITG87 0.000023 0.387 integrin, beta 7 
JAK2 0.000811 0-409 Janus kinase 2 (a protein tyrosine kinase) 
KDELR2 0.000566 1.73 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein reten-
tion receptor 2 
KIAA0141 0.000283 o.sos KIAA0141 
KLF12 0.000450 2.707 Kruppel-l ike factor 12 
KLHL7 0.000842 2,486 kelch-like 7 (drosophila) 
KRT10 0.000802 1.797 keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et 
plantaris) 
KYNU 0.000342 0,49 kynureninase (L kynurenine hydrolase) 
LIN28 0.000089 2.124 lin-28 homolog (C. elegans) 
LRRC17 0.000691 1 .506 leucine rich repeat contain ing 17 
LRSAM1 0.000397 0.381 leucine rich repeat and sterile alpha motif containing 1 
METTL4 0.000828 0,463 methyltransferase like 4 
MFAP2 0.000198 1.774 microfibrillar-associated protein 2 
MUTYH 0.000619 0.337 mutY homolog (E. coli) 
MXD1 0.000057 0.398 MAX dimerization protein 1 
NANOS1 0.000275 1 .804 nanos homolog 1 (drosophila) 
NCR2 0.000425 0.349 natural cytotoxicity triggering receptor 2 
ODF4 0.000094 0,43 outer dense fiber of sperm tails 4 
OR10A3 0.000023 0,491 olfactory receptor, family 10, subfamily A, member 3 
OR2AG1 0.000435 0,412 olfactory receptor, family 2, subfamily AG, member 1 
OR4C15 0.000931 0,401 olfactory receptor, family 4, subfamily C, member 15 
OR5185 0.000620 0,472 olfactory receptor, family 51, subfamily B, member 5 
OR51l1 0.000042 0.627 olfactory receptor, family 51, subfamily I, member 1 
OR6F1 0.000866 0.398 olfactory receptor, family 6, subfamily F, member 1 
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Description symbol ratio 
OR9G9 0.000512 0-45 olfactory receptor, family 9, subfamily G, member 9 
OSGEPL1 0.000443 2.046 O-sialoglycoprotein endopeptidase-like 1 
OSM 0.000645 0.618 oncostatin M 
PKHD1 0.000882 0.316 polycystic kidney and hepatic disease 1 (autosomal recessive) 
PPAP2B 0.000695 1.392 phosphatidic acid phosphatase type 2B 
PPCDC 0.335 phosphopantothenoylcysteine decarboxylase 0.000021 
PRELP 0.000430 1.336 praline/arginine-rich end leucine-rich repeat protein 
PTCH2 0.000200 0-433 patched homolog 2 (drosophila) C 
PTPRN2 0.000265 0-433 protein tyrosine phosphatase, receptor type, N polypeptide 2 
RIN1 0.000285 0-44 Ras and Rab interactor 1 C 
RIT1 0.000282 1-908 Ras-like without CAA"X 1 
SC02 0.000263 0-456 SCO cytochrome oxidase deficient homolog 2 (yeast) C SEPN1 0.000093 0-404 selenoprotein N, 1 
SIGLEC8 0.000838 0-477 sialic acid binding lg-like lectin 8 g4  sphingomyelin phosphodiesterase 2, neutral membrane (neu-SMPD2 0-472 0.000049 tral sphingomyelinase) 
SPATA13 0.000631 0-459 spermatogenesis associated 13 C 
SPATA18 0.000139 0.38 spermatogenesis associated 18 homolog (rat) 
SYT11 0.000838 1.69 synaptotagmin XI C TMEM150 0.000425 0.304 transmembrane protein 150 
TMEM45A 0.000288 1-49 transmembrane protein 45A C TRO 0.000051 2.165 trophinin 
TRPV4 0.000999 0 525 transient receptor potential cation channel. subfamily V, C member 4 TUBB4 0.000710 0-433 tubulin, beta 4 
WDR7 0.000086 0.261 WD repeat domain 7 C WNT16 0.000828 0-478 wingless-type MMTV integration site family, member 16 
ZBTB8 0.000324 2.256 zinc finger and BTB domain containing 8 C ZNF12 0.000588 2.051 zinc finger protein 12 
ZNF521 0.000281 1.504 zinc finger protein 521 
C ZNF569 0.000197 2-491 zinc finger protein 569 
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Table 3 
Association between the overal l  survival profile and cl inicopathologic 
characteristics 
Low Risk High Risk 
Characteristic (N=74) (N=83) 
N (%) N (%) p 
Age 
Median (years) 74 83 0-416 
Stage (FIGO') 
IIIA 2 (2.7) o (o.o) 
1118 1 (1.4) 5 (6.o) 
0.128 
IIIC 62 (83.8) 63 (75.9) 
IV 9 (12.2) 15 (18.1) 
Grade 
Well differentiated 9 (12.2) 5 (6.o) 
Moderately differentiated 16 (21.6) 29 (34_9) 
Poorly differentiated 43 (58.1) 39 (47.0) 0.104 
Undifferentiated o (o.o) 3 (3.6) 
Unknown 6 (8.1) 7 (8-4) 
Debulking status 
Complete debulking 12 (16.2) 1 0 (12.1) 
<2 cm 10 (13.s) 11 (13.3) 
�2 cm 48 (64.9) 52 (62.7) 0.237 
Positive, size unknown 1 (1-4) 8 (9.6) 
Unknown 3 (4.1) 2 (2-4) 
Chemotherapy 
Non-paclitaxel-based 44 (59.5) 58 (69.9) 0.115 
Paclitaxel-based 30 (40.5) 25 (30.1) 
Survival 
Median (months) 41 19 
P-values for stage, grade, debulking status and chemotherapy were derived from the Pearson Chi-
square test. P-value for age was derived from the t-test. ' FIGO, International Federation of Gynecology 
and Obstetrics. 
Independent validation of the overall survival profile 
Due to the different microarray platforms used, our model could not be directly tested 
on the independent serous ovarian cancer data set. Instead we identified 97 probes 
on the HU133A platform, targeting 57 out of the 86 unique genes from our overa l l  sur­
vival profile. These probes were used to bui ld a surviva l profi le  as described above. Fig-
190 
ure 1 B  shows the Kaplan-Meier survival curves for the patients from the independent 
data set predicted to have above or below median risk of death due to ovarian cancer. 
The low risk group had a median survival of 108 months, whereas the high risk group 
had a median surviva l of 33 months (p<o.0001, log-rank). The permutation P-va lue of 
the log-rank test statistic between the two risk groups, based on 1,000 permutations 
was p=o.007. 
Pathways and transcription factors associated with overall 
survival 
As input for the survival gene set ana lysis, sign ificance levels based on a univariate Cox 
proportional hazards regression of survival time versus the log expression level for a l l  
the 15,909 genes were used. KEGG pathways and transcription factors associated with 
overal l  survival in our data set and that of Dressman et a l  a re shown in Tables 4 and s, 
respectively. 16/17 pathways and 12/13 transcription factors found to be associated 
with overa l l  survival in our data set were also found to be associated with overal l  sur­
vival in the independent data set from Dressman et al .  
Discussion 
In this study on in a large series of advanced stage serous ovarian cancer patients, we 
identified a gene expression profi le, that reflects patient's overa l l  survival. Our overa l l  
survival profi le maintained independent prognostic significance in mu ltivariate ana ly­
sis. Moreover, expression of the genes that comprised our overal l  survival profile a lso 
held their prognostic value in an independent data set processed at a different insti­
tution using a d ifferent microarray platform. Finally, in addition to i ndividual genes, 
we were a lso able to reproducibly identify and val idate KEGG pathways and TRED 
transcription factors associated with overal l  survival. 
Limited overlap with respect to individual genes, as observed in comparable studies 
in other tumor types, was a lso found between our overa l l  survival profile and those 
reported in two previous ovarian cancer microarray studies 4•7• Non-reproducibi l ity of 
prognostic profiles between different microarray studies in the same tumor type can 
be attributed to a variety of methodological issues 26•27• Our study specifica l ly  pays 
attention to methodological principles such as randomization and replication. Thus, 
confounding effects are avoided and unbiased estimation of differential expression 
levels is provided. Furthermore, by using supervised principal components a nalysi s  
to bui ld prognostic profiles, we could consider survival as a continuous parameter 
patients were thus not forced into subgroups that might not be biologica l ly mean­
ingful .  Categorizing patients a priori i nto a "low risk" and "high risk" subgroup based on 
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Table 4 
KEGG pathways with more genes correlated with overal l  survival than 
expected by chance as identified in the present study and in the data set 
from Dresmann et a l  
KEGG Pathway Pathway description 
Present Dresmann 
study et al 
hsaos210 Colorectal cancer X 
hsaoo190 Oxidative phosphorylation X X 
hsaoo230 Purine metabolism X X 
hsaoo240 Pyrimidine metabolism X 
hsaoo380 Tryptophan metabolism X 
hsaoos64 Glycerophospholipid metabolism X 
hsao1030 Glycan structures biosynthesis ,  X 
hsao1430 Cell Communication X X 
hsao3010 Ribosome X 
hsao3320 PPAR signaling pathway X 
hsao4020 Calcium signaling pathway X X 
hsao4060 Cytokine-cytokine receptor interaction X X 
hsao4070 Phosphatidylinosltol signaling system X 
hsao4080 Neuroactive ligand-receptor interaction X 
hsao4110 Cell cycle X X 
hsao4210 Apoptosis X 
hsao4310 Wnt signaling pathway X X 
hsao4350 TGF-beta signaling pathway X 
hsao4360 Axon guidance X X 
hsao4370 VEGF signaling pathway X 
hsao4510 Focal adhesion X X 
hsao4512 ECM-receptor interaction X 
hsao4514 Cell adhesion molecules (CAMs) X X 
hsao4520 Adherens junction X 
hsao4530 Tight junction X X 
hsao4540 Gap junction X 
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Table 4 continued 
KEGG Pathway Pathway description 
Present Dresmann 
study et al 
hsao4612 Antigen processing and presentation X 
hsao4620 Toll-like receptor signaling pathway X 
hsa04630 Jak-STAT signaling pathway X X 
hsao4640 Hematopoietic cell lineage X 
hsa04650 Natural killer cell mediated cytotoxicity X X 
hsao4662 B cell receptor signaling pathway X 
hsao4670 Leukocyte transendothelial migration X X 
hsao4720 Long-term potentiation X 
hsao4730 Long-term depression X 
hsa04810 Regulation of actin cytoskeleton X X 
hsao4910 Insulin signaling pathway X X 
hsao4912 GnRH signaling pathway X 
hsao4920 Adipocytokine signaling pathway X 
hsaos120 Epithelial cell signaling in Helicobacter pylori infection X 
hsaoo670 One carbon pool by folate X 
hsaoo6Bo Methane metabolism X 
hsaoo604 Glycosphingolipid biosynthesis - ganglioseries X 
hsaoo6o3 Glycosphingolipid biosynthesis - globoseries X 
hsao4340 Hedgehog signaling pathway X 
hsa01031 Glycan structures - biosynthesis 2 X 
hsao1s10 Neurodegenerative Disorders X 
hsao4140 Regulation of autophagy X 
hsao4020 MAPK signaling pathway X 
Pathways that are significant at the nominal 0.005 level of the LS permutation test or KS permutation test are 
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Table 5 
Transcription factor gene sets with more genes correlated with 
overall survival than expected by chance 
Factor name Accession no. 
Present Dressman 
study et al 
ATF-1 Too968 X 
C/EBPalpha Too105 X X 
CREB Too163 X X 
E2F-1 To1542 X X 
E2F-4 To1546 X X 
Egr-1 Too241 X 
ER-alpha Too261 X 
c-Ets-1 Too112 X X 
PEA3 Too6Bs X 
HIF-1 To1609 X 
AP-1 Tooo29 X X 
c-Myb Too137 X X 
CTF-1 Too176 X X 
NF-kappaB(-like) Too591 X X 
POU2F1 Too641 X 
PPAR-gamma, To2736 X 
RAR-alpha1 Too719 X 
RAR-beta Too721 X 
RelA Too594 X 
Sp1 Too759 X X 
Sp3 To2338 X 
PU.1 To2068 X 
AP-2alphaA Tooo35 X X 
P53 Too671 X X 
USF1 Too874 X 
USF2 Too878 X 
NF-IL6-2 Too581 X 
E2F-2 T01544 X 
Transcription factor gene sets that are significant at the nominal 0.005 level of the LS per-
mutation test or KS permutation test are indicated with X. Transcription factor gene sets 
shown in bold are associated with survival in both data sets. 
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be suspect when u nderlying, u nidentified, biologically d ifferent subgroups have con­
siderable overlap in survival t imes. 
Our overa l l  survival profi le comprises several interesting genes (Table 2) that offer po­
tential insight into mechanisms associated with tumor behavior. High expression of the 
proapoptotic BAX gene was associated with improved prognosis in our study. Previous 
studies have suggested a correlation of BAX expression with response to chemotherapy 
and overa l l  survival in ovarian cancer 9.29 30• Likewise, high expression of Ras inhibitor 1 
(RIN1) and low expression of Ras-like without CAAX1 (RIT1) a re associated with better 
overa l l  survival, which agrees with previous work showing that activated Ras contrib­
utes to the maintenance and growth of ovarian carcinomas 31• Furthermore, OSM, JAK2 
and CNTFR are components of the Jak-STAT signaling pathway, which can stimu late 
cel l prol iferation, differentiation, cel l  migration and apoptosis 32• OSM has individua l ly 
been identified as a potent suppressor of tumor cell prol iferation and inducer of dif­
ferentiation in multiple tissues 31. FGFBP1 and FGFR1 interact with fibroblast growth fac­
tors FGF1 and FGF2 and it has been suggested that the fibroblast growth factors cou ld 
serve as the angiogenic switch in human cancer 34 36. 
Although individual genes such as those described above may prove to be relevant 
for tumor behavior, it is often not known in ovarian cancer and other cancers whether 
large fold changes in i ndividual genes will have more biological relevance compared 
to smaller but coordinated fold changes in a set of genes along a single pathway. 
Analysis of our microarray data by integrating genes into functional gene sets accord­
ing to pathways or transcription factors enabled us to consider a l l  ava i lable genomic 
information rather than genes passing a certain sign ificance threshold, thus providing 
extra clues to which signal ing pathways and transcription factors contribute to the 
cl inica l outcome of ovarian cancer. With this approach, that has not been appl ied to 
ovarian cancer array data sets before, we identified several interesting signal ing path­
ways (Table 4) that, with total ly different approaches, were previously reported to play 
an important role in  (ovarian) carcinogenesis via effects on apoptosis, prol iferation, 
d ifferentiation and cell cycle 37•37 42• Evidence shows that there are many cancers with a 
misba lance in the apoptotic control mechanism that favor cell survival 38. I nhibiting or 
correcting this apoptotic mechanism may not only cause d i rect cancer cel l  death but 
could a lso serve to enhance sensitivity to chemotherapy. Furthermore, human mal ig­
nant tumors are characterized by abnormal proliferation resulting from a lterations in 
cell cycle-regulatory mechanisms and several genes have been implicated in  ovarian 
cancer 37• In the present study, the cel l cycle, Wnt, Jak-STAT and MAPK pathways, play­
ing a role in apoptosis, prol iferation, differentiation and/or cell cycle, were identified 
and aberrant signal ing of these pathways has been proposed as a contributing factor 
in ovarian carcinogenesis 37•39·42_ 
Therapeutic options are currently being explored that act on several signal ing path­
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cancer 39 41 . For example farnesyltransferase inhibitors (R115777 and SCH66336) prevent­
ing Ras signal ing and Raf-1 kinase inhibitor BAY 43-9006 39· 41_ FKBP7 with the highest 
HR in our study is of interest as FKBPs can be targeted with the immunosuppressant 
drugs FK506 and rapamycin 43. I t  is further noteworthy that the data set of Dressman 
et a l  i ndicated an impact of the VEGF signa ling pathway on survival in  ovarian cancer, 
since the anti-VEGF monoclonal antibody, bevacizumab, recently showed significant 
antitu mor effect in ovarian cancer 44As_ We also identified, again with a total ly different 
approach, several tanscription factors (table s) previously reported to be impl icated 
in ovarian cancer. For instance, AP-2alpha and c-Ets-1 have been suggested to be as­
sociated with poor prognosis in ovarian cancer 46 48. Similar, E2F transcription factors, 
members of the C/EBP fami ly, and CREB were demonstrated to play an important role 
in ovarian carcinogenesis 49 si. 
As mentioned before in ovarian cancer microarray studies, there is usual ly only l im ited 
overla p  with respect to ind ividual genes between the prognostic profi les previously 
publ ished 53. I n  contrast, integrating genes in functional gene sets according to path­
ways a nd transcription factors in this study resulted in considerable overlap between 
our data set and the independent data set. Th is result va lidates the use of functional 
gene set enrichment analysis as a tool to investigate mechanisms of tumor behavior 
and suggests that determination of coord inated expression of several signaling path­
ways is more rel iable and reproducible than expression of individual genes. 
A l im itation of functiona l gene set enrichment ana lysis as performed in our study is its 
inabil ity to assess the activation status of identified pathways in an individual tumor 
sample. This gap is interestingly potential ly fil led by the strategy recently described by 
Bi ld et al 9·'5. I ndividual (oncogenic) pathways were activated in quiescent cel ls to iden­
tify the effects of single pathway activation on g lobal gene expression. Using principa l  
components ana lysis gene expression profi les were then generated, reflecting the 
activation of specific signal ing pathways. Identification of relevant pathways in ovar­
ian cancer by gene set enrichment analysis as performed in our present study shou ld 
be fol lowed by the strategy of Bi ld et a l ,  enabl ing us to assess activation of identified 
relevant pathways in individua l ovarian cancers 54• Momentarily, it is not possible to 
use the data of Bi ld et al to accurately define pathway activation status in our ovar­
ian tu mor samples. When principa l components analysis would be appl ied on the 
combined cel l  l ine data of Bi ld et al with our ovarian tumor profi les, the top principal 
components would primari ly be driven by the systematic variation (tissue origin and/ 
or platform differences) and not by the oncogene-activated pathway status. 
In conclusion, our study provides new, va lidated, insights in molecular changes rel­
evant for ovarian cancer behavior, which might therefore be exploited in the search 
for new treatment strategies. In the future, pathway activation analysis in ind ividual 
tumors may guide the choice of targeted drugs in ovarian cancer patients ss.s6• 
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Patients and tumor samples 
The study population consisted of 157 consecutive patients with advanced stage 
serous ovarian cancer operated on by a gynecologic oncologist from the Un iversity 
Medica l Center Groningen (UMCG, Groningen, the Netherlands) in the period 1 990-
2003. All patients were treated according to Dutch gu idel ines on diagnostic work-up, 
surgical and medical treatment and follow-up, that are based on the International 
Federation of Gynecology and Obstetrics guidelines (FIGO) ,.,_ New chemotherapy 
treatment regimens were adopted as fol lows: platinum-based chemotherapy at the 
beginning of the 1980s, and platinum/paclitaxel chemotherapy after 1996. Tumor sam­
ples were obta ined during surgery, flash frozen in l iquid nitrogen and stored at -80 °C. 
Al l  samples were confirmed to comprise tumor cel ls (median percentage tumor cells: 
70%, interquartile range: 50-80%), as examined after hematoxyl in and eosin sta in ing 
of frozen sections. Patients gave informed consent for collection and storage of tissue 
samples in a tissue bank  for future research. Al l  relevant patient's data were retrieved 
and transferred into an anonymous, password-protected, database. The patients' iden­
tity was protected by study-specific, unique patient code and their true identity was 
only known to two ded icated data managers. According to Dutch law, these precau­
tions meant no further institutional review board approval was needed. 
l!NA extraction and amplification 
Frozen tumor samples were homogenized using the Micro-Dismembrator U (B. B raun 
Biotech International, Melsungen, Germany) and dissolved in guanidine isothiocy­
anate buffer ( lmmunoSource, Halle-Zoersel, Belgium). Tota l RNA from tumor samples 
was subsequently pelleted through cesium chloride density gradient u ltracentrifuga­
tion (Roche, Al mere, the Netherlands). After total RNA samples had been given DNAse 
treatment (Megascript T7 kit, Ambion, Huntingdon, UK) for 90 min at 37 °(, they were 
checked for residual DNA using a d inucleotide primer set D11S875 (F: 5'-ACTGTC­
CTCTCATCCTACTG-3' and R: 5'-TACAGAGCTG-AGTTTGTAGC-3') specific for genomic 
DNA. For those sam ples for which a polymerase chain reaction product was obtai ned 
DNAse treatment was repeated 3. mRNA was l inearly amplified by in vitro transcription 
using T7 RNA polymerase (Megascript T7 kit, Ambion, Huntingdon, UK) on 4 µg total 
RNA 4• Qual ity/integrity of total and ampl ified mRNA (cRNA) was checked by spectro­
photometer ana lysis, UV 260/280 ratio >1 .8, and/or agarose gel electrophoresis. 
�icroarray experiments 
All cRNA samples (1 .s µg) were labeled with U LS-Cy5 and ULS-Cy3 label (BIOKE, Leiden, 
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color ol igonucleotide microarrays (-35,000 Operon v3.o probes), manufactured by the 
Netherlands Cancer Institute (Amsterdam, the Netherlands) 4• We performed inten­
sity-based ana lysis, instead of ratio-based analysis of the two-color ol igonucleotide 
microarrays, circumventing the need for a reference sample that occupies half of the 
hybrid ization capacity. This enabled us to create one repl ication of the whole experi­
ment, as each tumor sample was profiled once with U LS-Cys and once with U LS-Cy3. 
It was demonstrated by 't Hoen et al that for long-ol igonucleotide microarrays the 
signal intensity of the cRNA samples was not influenced by the presence of a target 
labeled with a different color 5• Thus, two cRNA samples labeled with d ifferent colors 
were hybrid ized together on the arrays for intensity-based ana lysis of the microarray 
data, a l lowing a more efficient and flexible hybrid ization design. 
Samples were hybridized according to a randomized design to prevent systematic 
biases such as those caused by batch effects or technical variation which can be in­
troduced during label ing, hybridization and scanning (see Figure 1) 6 8• Using a random 
number generator the order of processing of the microarray experiments was rand­
omized: the order of processing arrays of d ifferent batches was randomized and sub­
sequently Cys- and Cy3-labeled cRNA samples were randomly placed onto the arrays. 
In this way Cys-labeled samples were randomly paired with Cy3-labeled samples and 
the order of label ing, hybridizing and scann ing of the tumor samples was random, 
thereby preventing hidden biases. 
Arrays were scanned with the Affymetrix GMS428 scanner (Affymetrix, Santa Clara, CA). 
Expression values were calculated by BlueFuse software (BlueGnome, Cambridge, UK). 
Statistical methods 
Quantile normalization was appl ied to log2 transformed Cys and Cy3 intensities 9• The 
goa l of the quanti le normal ization is to make the distribution of expression va lues for 
each array in  a set of arrays the same: 1) Sort expression va lues of each microarray, 2) 
Compute median intensity in each rank across the m icroarrays, 3) Replace each ex­
pression va lue by the median intensity at its rank. 
Principa l components analysis was performed for q ual ity control. It has been shown 
that the most significant principal component for a gene expression data matrix is 
frequently a constant pattern, which dominates the data 10• So, the fi rst principal com­
ponent explaining the largest part of the variation, could be considered as variation 
the arrays have in common 11•12• Next, for each individual a rray correlation with the first 
principal component is ca lculated (factor load ing). Factor loadings of the first prin­
cipal component for an ind ividual a rray can be seen as a qual ity index, as arrays of 
lesser qual ity would have lower or d istinctly different correlations than arrays of good 
qual ity. Samples with a factor load ing with the fi rst principal components of less than 
2 times the standard deviation from the mean were excluded as their hybrid izations 
were considered to be of low qua l ity. 
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Figure 1 
Operon V3.o probe identifiers (-35,000) were converted to official gene symbols us­
ing probe annotations provided by the Netherlands Cancer I nstitute (http://micro­
arrays.nki.nl/ /download/files/operon_hs_o60614.xls). A description of the annota­
tion methodology util ized by the Netherlands Cancer Institute is provided on their 
website (http://microarrays.nki .n l/services/blastdata.html). We have only used those 
ol igonucleotides that specifica l ly BLAST with a single h it on a gene. Expression va lues 
of mu ltiple ol igonucleotide probes targeting the same gene (identical gene symbol) 
were averaged, resu lting in a total of 15,909 unique genes for further ana lysis. Subse­
quently, expression data obtained from Cys- and Cy3-labeled samples of the same 
tumor were averaged, as these were considered to be replicates (mean correlation 
0-93 ± 0.04). M icroarray analyses were performed with the software package BRB Ar­
ray Tools 3.6.0, developed by the Biometric Research Branch of the US National Cancer 
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Survival prediction 
An overa ll survival profi le was bui lt using the supervised principal components 
method 13• For each iteration of the complete cross-va l idation, ten percent of the cases 
were omitted, and genes were selected that un ivariately correlated with overa l l  sur­
vival at a significance level of p<o.001 for the remaining 900/o of cases (pattern discov­
ery). The first five principal components of the selected genes were computed and a 
Cox proportional hazards model was fitted to the data (with 10% of cases omitted) us­
ing the principa l components as predictors. The fitted model was used to classify the 
omitted cases as h igh or low risk based on whether thei r predictive index of the titted 
model was above or below the median of the pred ictive ind ices for the 900/o of cases 
in the "training set''. This entire procedure was repeated, leaving out a d ifferent 100/o of 
cases unti l each case was omitted exactly once and the cross-va l idated risk groups 
were determined for al l cases. Kaplan-Meier survival curves were plotted for the pre­
dicted overa l l survival risk classes and the log-rank statistic computed. To assess the 
significance of the log-rank stati stics a phenotype permutation test based on 1,000 
permutations was performed. Survival data is randomly shuffled among the cases 
and the entire cross-va l idation process described above is repeated. For each random 
re-shuffl ing, the process is repeated, new cross-va l idated Kaplan-Meier survival curves 
created, and the log-rank statistic for the random shuffling i s computed. This provided 
a nu l l-distribution of the log-rank statistic. The tai l area of th is nu l l  d istribution beyond 
the log-rank statistic obta ined from the real data is the permutation significance level 
for testing the nu l l  hypothesis that there is no relation between the expression data 
and overal l surviva l. Mu ltivariate ana lysis for confounding prognostic factors was car­
ried out using Cox proportional hazards regression . For this analysi s, our overal l sur­
vival profile was considered a binary category (low risk, h igh risk). 
Pathway and transcription factor analysis 
Functional gene set enrichment ana lysis was performed as described by Pavl idis et 
al '4• Predefined gene sets were ana lyzed to indicate which gene sets conta ined more 
genes correlated with overal l survival than would be expected by chance. First an uni­
variate Cox proportional hazards P-va lue was computed for a l l  1 5,909 un ique genes. 
Then P-values of a subset of genes belonging to a functional set were summarized by 
the LS and KS summary statistics. For a set of N genes, the LS statistic is defined as the 
mean negative natural logarithm of single gene P-val ues. The KS stati stic is defined as 
the maximum difference between i/N and P,, where p1 is the i
th smal lest P-va lue. This is 
the Kolmogorov-Smirnov statistic for testing if the P-values a re of un iform distribution. 
The statistical significance of a functional gene set containing N genes is eval uated by 
computing the empirical distribution of these summary statistics in random samples 
of N genes. A tota l of 167 functional gene sets as reported in the Kyoto Encyclopedia 
204 
of Genes and Genomes database (KEGG) and 111 as reported in the Transcriptional 
Regu latory Element Database (TRED) were analyzed 15•16• 
External  validation 
Expression and survival data publ icly avai lable from an independent set of serous ovar­
ian cancers profiled by Dressman et al was used to va l idate the genes that comprise 
our overa l l  survival profi le 17 19• Probe set identifiers from the Affymetrix HU133A m icro­
array were converted to official gene symbols using the most recent probe annota­
tions provided by Affymetrix (http://www.affymetrix.com/ Auth/analysis/downloads/ 
na23/ivt/HG-U133A.na23.annot.csv.zip). A description of the annotation methodology 
util ized by Affymetrix is provided on their website (http://www.affymetrix.com/sup­
port/technical/technotes/annot_method_technote.affx). Converting HU133A probe 
set identifiers to official gene symbols enabled us to select probe sets targeting genes 
comprising our overa l l  survival profile. The survival pred iction method as described 
above was applied, except that genes part of our overa l l  survival profi le were prese­
lected in the independent data set from Dressman et al and not selected using pattern 
discovery. Furthermore, functional class scoring ana lysis for pathways and transcrip­
tion factors as described above was a lso performed on this independent data set and 
results were compared 14• 
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Summary, general discussion and future perspectives ••• 
Summary 
I n  advanced stage ovarian cancer the cei l ing seems to be reached for conventional 
chemotherapeutic drugs and a lmost every imaginable combination of chemotherapy 
has been eva luated in cl inical tria ls. The 5-year overal l  survival rate (10-30%) has hardly 
improved the last decades '. Therefore, a paradigm sh ift is needed; instead of treating 
a l l  patients according to standard gu idelines, ind ividual ized molecular targeted treat­
ment should be a imed for. Ovarian cancer is a heterogeneous disease, both at the 
clinicopathologic and at the molecular level. This suggests that identification of prog­
nostic markers or profiles may yield potentia l ly new targets for drug development 
and thus may lead to more individual ized treatment. In this thesis several studies in 
ovarian cancer are described which focus on the identification of molecular markers 
(profiles), pathways and/or transcription factors associated with survival and/or chem­
oresistance using h igh-throughput techniques such as DNA, tissue and cytokine bead 
microarrays. There were various strateg ies for the identification of prognostic and/or 
predictive markers fol lowed, summarized below. 
In  chapter 2 meta-analyses of prognostic studies i n  ovarian cancer on the tumor sup­
pressor protein p53, detoxification protein g lutath ione S-transferase pi (GST-pi) and 
the epidermal growth factor receptors EGFR (HER-1) and HER-2 were performed. The 
results of the prognostic studies on each of these molecular markers are contradic­
tory, which is at least partly due to methodological variabil ity between the studies. 
Prognostic studies in ovarian cancer differ greatly with respect to type of study de­
sign, patient inclusion criteria, assays or methods used to determine a specific factor, 
determinations of factor cut-off points, and definition of cl inical study end point. I n  
add ition, many studies had a sma l l  sample size, which may lead to over- o r  underes­
timation of the relevance of the molecular marker. Our meta-analysis showed that 
patients with p53, EGFR, or HER-2 overexpression and/or amplification had lower odds 
of surviving s years, while there seemed to be a trend for a decreased probabi l ity of 
s-year survival for patients with overexpression of GST-pi in their tumors 2• Agents tar­
geting these molecular markers, thus, might have therapeutic potential .  
In  chapter 3 a review is given of drugs targeted at components of molecu lar pathways 
of potentia l importance in ovarian cancer. Enhancement of the apoptotic pathway 
and inhibiting prosurvival pathways and angiogenesis appear to be attractive strat­
egies. There probably is no single dominant oncogenic pathway in ovarian cancer. 
Therefore, to maximize anticancer efficacy, it seems necessary to intervene simu ltane­
ously in multiple pathways. Recently, agents that inhibit multiple targets have been 
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carefu l selection of therapeutic targets and the thoughtfu l appl ication of novel com­
bination strategies (incl uding combinations with chemotherapy) has the potentia l to 
significantly improve the treatment and prognosis of women with ovarian cancer in  
the futu re 1. 
Both in chapter 2 and chapter 3 DNA microarray studies in ovarian cancer are sum­
marized. Particula rly, the chal lenges of performing prognostic microarray studies are 
discussed 2-1• Most microarray studies in ovarian cancer were executed to identify 
diagnostic markers by comparing ovarian carcinomas or ovarian cancer cell l ines to 
norma l ovarian epithel ium. Furthermore, many microarray studies aimed to discover 
genes associated with "classic" cl lnical prognostic factors or drug-resistance to pick 
up clues to treatment and prognosis. Only a minority of studies has tried to identify 
prognostic factors and/or prognostic profi les for personal ized prediction of disease 
outcome 2•1• The cl inical evidence of prognostic microarray studies (as wel l as prog­
nostic studies on sing le markers) only reaches level 3 or 4 evidence (smal l/large ret­
rospective studies) on a scale of s (low) to 1 (h igh) 4• Prognostic microarray studies 
suffer from the same methodological d ifficu lties as prognostic studies on single mo­
lecular  markers, described above. However, in m icroarray studies there are additional 
hurd les, which make it a cha l lenge to identify reproducible prognostic profi les. Each 
stage in the course of a microarray experiment is a possible source of error, but the 
most important problem, overfitting, can take place during the analysis of microarray 
data. Overfitting, i.e. finding a discriminatory pattern by chance, can occur when large 
numbers of potential predictors are used to discriminate among a smal l  number of 
outcome events 5. I nclusion of a sufficient number of tumors is especia l ly important 
in microarray research as the fold differences in expression may not be large between 
two classes of samples which makes it chal lenging to identify relevant genes from 
among the thousands of noise genes (low signal to noise) 6. Due to the relative rarity 
(and the heterogeneous nature) of ovarian cancer, the risk of overfitting is en larged 
in prognostic microarray studies in ovarian cancer. The incidence of ovarian cancer i s  
about 8 times lower than the incidence of breast cancer, making the inclusion of suf­
ficient numbers of patients d ifficult 7• 
I n chapter 4 the prognostic va lue of epidermal g rowth factor receptor 1 (EGFR/HER-1), 
phosphorylated EGFR (pEGFR), EGFR variant 3 (EGFRvlll, lacks exons 2-7), epidermal 
growth factor receptor 2 (HER-2), tumor suppressor gene PTEN (phosphatase and 
tensin homolog deleted on chromosome 10), oncogene AKT, phosphorylated AKT 
(pAKT) and phosphorylated MAP kinase ERK (pERK) in ovarian cancer was investigat­
ed. lmmunohistochemica l staining of these proteins was performed on 232 primary 
tumors using the tissue microarray technique and related to clinicopathologic char-
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acteristics and survival. In add ition, the expression of EGFRvl l l  was determined in 45 
ovarian cancers by reverse transcription-polymerase chain reaction (RT-PCR). 
Negative PTEN immunosta in ing was associated with stage 1/1 1 d isease (p=o.006), non­
serous tumor type (p=o.042) and in multivariate ana lysis with a longer progression 
free survival (p=o.015). Positive pAKT staining was associated with advanced stage 
disease (p=o.006). None of the tumors were positive for EGFRvl l l .  Other proteins were 
expressed only at low levels and were not associated with any cl inicopathologic pa­
rameter or survival. Thus, tumors showing negative PTEN staining could represent a 
subgroup of ovarian carcinomas with a relatively favorable prognosis. 
There are many statistical methods that can be used to ana lyze microarray data. I n  
chapter s, factor analysis was appl ied to the microarray data. Factor ana lysis i s  a meth­
od that can be used to make biological contrasts that underlie the many microarray 
data visible by representing the data in a reduced set of factors. Disadvantages of fac­
tor ana lysis are that biologica l contrasts do not necessarily coincide with single factors 
and that the biological factors are difficult to recognize. 
We therefore hypothesized that when the microarray hybridization design would 
contain contrasts, biological contrasts would be reflected by single factors that wou ld 
be easy identifiable (as the correlation structure of the factors with the arrays would 
reflect the design). This hypothesis was tested in a study exploring d rug-resistance 
markers that might be used to select which patients will benefit from chemotherapy. 
Factor analysis was appl ied to microarray data obtained by profi ling an ovarian cancer 
cel l  line model for cisplatin-resistance (A2780, CP70, (30 and C200) using -18K cDNA 
microarrays accord ing a hybrid ization design including "SelfSelf" hybridizations, dye 
swaps and independent replications. Two factors reflected the hybridization design 
and thus mirrored contrasts in cisplatin-sensitivity between the 4 cel l  l ines. From those 
factors 315 genes associated with cisplatin-resistance were selected. 199 genes were 
differential ly expressed between the cisplatin-sensitive parental cell l ine A2780 and 
the resistant subl ines CP70, C30 and (200. 152 genes differentiated the mild resistant 
cel l  l ine CP70 from the extreme resistant cel l  l ines C30 and (200. Both gene l ists had 36 
genes in common. The gene expression of 16 genes, col lagen type Il l alpha 1 (COL3A1), 
enolase 2 (ENO2), fi broblast growth factor 18 (FGF18), jun oncogene (JU N), LIM home­
obox 2 (LHX2), MEIS homeobox 1 (MEIS1), MEIS homeobox 2 (MEIS2), pre-B-cell leuke­
mia homeobox 3 (PBX3), platelet-derived growth factor receptor-l ike (PDGFRL), prickle 
homolog 1 (PRICKLE1), spermidine/spermine N1-acetyltransferase (SAT), Src homology 
2 domain conta ining adaptor protein B (SHB), T-cel l  leukemia homeobox 1 (TLX1), TIMP 
meta l lopeptidase inhibitor 2 (TIMP2), Topoisomerase 1 (TOP1) and uveal autoantigen 
with coiled-coil domains and ankyrin repeats (UACA), was val idated with reverse tran­
scription-polymerase chain reaction (RT-PCR). Thus, the rel iabi l ity of our ana lysis of the 














Summary, general discussion and future perspectives ••• 
Three amino-acid loop extension ( TALE) homeobox proteins MEIS and PBX are cofac­
tors for HOX proteins, which control growth and differentiation during embryogenesis 
and homeostasis. We have shown that the MEIS1, MEIS2 and PBX3 genes were down­
regulated in 3 cisplatin-resistant sublines of the cisplatin-sensitive parental ovarian 
cancer cel l  l i ne A2780 (chapter s) 8• In addition, the MEIS1 gene has been shown to be 
amplified and overexpressed in ovarian cancers compared to normal ovarian surface 
epithel ium and is part of an ovary-specific gene expression profile distinguishing pri­
mary l ung, colon, and ovarian adenocarcinomas 9 11• As protein expression data of the 
HOX cofactors in ovarian cancer are lacking, the aim of the study described in chapter 6 
was to investigate MEIS1, MEIS2 and PBX protein expression in ovarian cancers of 232 
patients arranged onto a tissue microarray. Of 44 patients there was al so a post-chem­
otherapy sample ava ilable on the tissue microarray. The protein expression levels of 
MEIS1 and 2 and PBX were furthermore investigated in the surface epithel ium of 1 5  
norma l ovaries. MEIS and/or PBX expression levels i n  primary cancers were related to 
cl inicopathologic characteristics and patient surviva l .  Additiona l ly, MEIS and PBX RNA 
expression levels were compared between normal ovarian surface epithel ium and 
various normal tissues and between ovarian cancer and various cancer tissues using 
publ ic array data sets. 
MEIS1 , MEIS2 and PBX proteins were extensively expressed in a l l  ovarian cancers, both 
at the nuclear and cytoplasmic level. In norma l ovarian surface epithel ium MEIS1 and 2 
on ly stained nuclear. When MEIS and/or PBX expression levels were related to clin­
icopathologic characteristics and patient survival it was found that nuclear MEIS2 ex­
pression was re lated to stage (p<o.02), grade (p<o.02) and overal l  survival (p=o.036) 
in univariate analyses. Analyses of the public array data sets revea led that in ovarian 
cancer the MEIS1 gene is very high ly expressed compared to other cancer types. 
These specific findings in ovarian cancer are of interest as MEIS1 and 2 and PBX could 
be important in ovarian oncogenesis by potentiating the function of aberrantly ex­
pressed HOX proteins '2 15• Co-expression of HOX, MEIS and PBX family members very 
l i kely l eads to greater effects on HOX target genes by increased DNA binding of the 
HOX-DNA complexes •M_ In  ovarian cancer various HOX genes and proteins are differ­
ential ly expressed compared to norma l ovarian surface epithel ium '2 '5. Moreover, there 
is evidence that HOX, MEIS and PBX genes are involved in oncogenic processes ,s.,a '6• 
Further research is needed to discover aberrantly expressed HOX genes in ovarian 
cancer and to elucidate how their function is enforced by their cofactors MEIS1 and 2 
and PBX. This cou ld lead to insight in how oncogenic HOX function would be abol­
ished by targeting MEIS1 and 2 and PBX. 
In chapter 7 10 paired pre- and post-chemotherapy ovarian tumors were profi led 
using -35K 70-mer oligonucleotide microarrays to identify molecular markers under-
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lying acquired platinum-resistance in ovarian cancer and to assess the association of 
pathways and transcription factors with acquired chemoresistance. Comparison of 
paired pre- and post-chemotherapy samples using a paired t-test (p<o.001) revealed 
53 differentia l ly expressed genes. H ierarch ical clustering based on this gene subset 
showed that pre- and post-chemotherapy samples were segregated. 
Among the up-regulated genes in post-chemotherapy samples integrin a lpha 1 
(ITGA1), vasoactive intestinal peptide (VIP) and member of RAS oncogene family 
2B (RAP2B) are of interest. ITGA1 has been demonstrated to be overexpressed in a 
clonal isolate of oxa l iplatin-resistant ovarian carcinoma cell l i ne A2780/C10 compared 
to the parental cel l l ine using Affymetrix HG-U95Av2 oligonucleotide arrays 29• It has 
been shown that the VIP antagonist JV-1-52 was able to inhibit growth and reduce 
tumorigen icity of UCl-107 ovarian cel l  carcinoma xenografted into nude mice 30• Fur­
thermore, RAP2B very l ikely plays a role in the phospholipase (-epsilon pathway. The 
Phospholipase (-epsi lon pathway is activated by Epac1 which catalyses GTP-load ing 
on RAP2B, which leads to Phosphol ipase (-epsilon activation. In ovarian carcinoma 
cel ls (OVCAR-3 cel ls) RAP was demonstrated to mediate the stimulatory action of Epac 
on cel l adhesion 3' .  Momentarily there are Epac-selective cAMP analogs, but there is 
no specific antagonist of Epac 32• However, other components of the Phosphol ipase 
(-epsi lon pathway may be more drugable. Among the genes downregu lated in post­
chemotherapy samples early growth response 2 (EGR2) is of potential importance. 
EGR2 has been shown to be decreased in ovarian tumors compared with correspond­
ing normal tissues and appears to be a mediator of the PTEN growth-suppressive sig­
nal ing pathway 33•34. 
Furthermore, 18 KEGG pathways and 15 TRED transcription factors were associated 
with acquired chemoresistance in this study. Several pathways and transcription fac­
tors were previously reported to be impl icated i n  ovarian cancer. The cell cycle, Wnt, 
Jak-STAT and MAPK pathways, playing a role in apoptosis, prol iferation, d ifferentiation 
and/or cel l  cycle were identified and aberrant signal ing of these pathways has been 
proposed as a contributing factor in ovarian carcinogenesis 3•35·:ia. Additional ly, the 
transcription factors AP-2a lpha, c-Ets-1, E2F, C/EBP and CREB, associated with acquired 
chemoresistance in our study, have been suggested to play a role in ovarian cancer 39 45• 
Moreover, 17/18 KEGG pathways and 12/15 TRED transcription factors associated with 
chemoresistance in the present study were also found to be associated with survival 
in our microarray study of 1 57 advanced stage serous ovarian cancers. 17/18 pathways 
and 11/12 transcription factors were also associated with overal l  survival in a publicly 
avai lable data set of 118 well-defined primary serous ovarian cancers profiled by Dress­
man et al (see chapter 9) 46• 
This study provides new clues to genes, pathways and transcription factors which 
may contribute to acquired chemoresistance in ovarian cancer and may be exploited 














Summary, general discussion and future perspectives ••• 
I n chapter 8 the cytokine bead array was used for the identification of serum cytokine 
levels suitable as diagnostic or prognostic markers in ovarian cancer. Simu ltaneously 
fourteen cytokines [interleu kin 10 (I L-10), I L-2, I L-4, I L-6, I L-7, I L-8, I L-10, I L-15, granulocyte 
colony-stimu lating factor (G-CSF), granulocyte macrophage colony-st imu lating factor 
(GM-CSF), eotaxin, monocyte chemoattractant protein-1 (MCP-1), macrophage inflam­
matory protein-,a (MIP-1a.), and IP-10] were ana lyzed In prospectively col lected sera 
of 187 ovarian cancer patients with complete cl inicopathologic data and fol low-up, 45 
patients with benign ovarian tumors and so healthy controls. Serum levels of the wel l­
known tumor marker CA-125 were a lso routinely measured in a l l  patients. Analyzing 
the cytokines in combination with CA-125 showed that a combination of IL-7 and CA 
125 serum levels could accu rately predict 69% of the ovarian cancer patients, without 
fa lsely classifying patients with benign pelvic mass. In multivariate analysis, I L-7 and 
I P-10 were independent predictors of overa l l  survival, a lthough after inclusion of the 
cl in icopathologic parameters, only stage and residual disease remained as independ­
ent predictors of survival. Therefore, I L-7 levels could be used in combination with 
CA-125 to distinguish between malignant and benign ovarian tumors. 
In chapter 9 we tried to identify a gene expression profi le predictive for overal l  survival 
by profil ing of 157 advanced stage serous ovarian cancers using -35K 70-mer ol igonu­
cleotide microarrays. An 86-gene overa l l survival profi le was built that d iscriminated 
between patients with unfavorable and favorable prognosis (median surviva l ,  19 vs. 
41 months, respectively; permutation P-va lue of log-rank statistic = 0.015) and main­
tained independent prognostic value in mu ltivariate analysis. Our overal l survival pro­
file comprises several i nteresting genes that offer potential insight into mechanisms 
associated with tumor behavior. High expression of the proapoptotic BAX gene was 
associated with improved prognosis in our study. Previous studies have suggested 
a correlation of BAX expression with response to chemotherapy and overa l l  survival 
in ovarian cancer 47 50• Likewise, high expression of Ras inhibitor 1 (R IN1) and low ex­
pression of Ras-li ke without CAAX1 (RIT1) are associated with better overal l survival, 
wh ich is which agrees with with previous work showing that activated Ras contrib­
utes to the maintenance and growth of ovarian carcinomas si_ Furthermore, OSM, JAK2 
and CNTFR are components of the Jak-STAT signa ling pathway, which can sti mulate 
cel l proliferation, differentiation, cell migration and apoptosi s 52• OSM has individual ly 
been identified as a potent suppressor of tumor cel l proliferation and inducer of d iffer­
entiation in mu ltiple tissues 53• I n addition, FGFBP1 and FGFR1 interact with fibroblast 
growth factors FGF1 and FGF2 and it has been suggested that the fibroblast growth 
factors could serve as the angiogenic switch in human cancer 54-56_ 
Furthermore, 17 KEGG pathways and 13 TRED transcription factors were found to be 
associated with overal l  survival in our data set. The cel l cycle, Wnt, Jak-STAT and MAPK 
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pathways were associated with survival in our study and aberrant signal ing of these 
pathways has been proposed as a contributing factor in ovarian carcinogenesis 3•35 38• 
Additional ly, the transcription factors AP-2alpha, c-Ets-1, E2F, C/EBP and CREB, associat­
ed with survival in our study, have been suggested to play a role in ovarian cancer 39 45• 
The survival predictor was validated on a com pletely independent, publ icly avai lable 
data set of118 well-defined primary serous ovarian cancers profi led by Dressman et al 46• 
Genes that comprised the overal l  survival profile were also able to discriminate be­
tween the two risk groups in the independent data set from Dresman et al (p<o.0001, 
log-rank). Furthermore, the functional class scoring analysis was also done on the in­
dependent data set and results were compared. 16/17 pathways and 12/13 transcrip­
tion factors identified in our data set were a lso associated with overal l  survival in the 
independent data set. 
Therapeutic options are currently being explored that act on several signaling path­
ways, which we and others revealed to be associated with overa l l  survival in ovarian 
cancer 3.35•36• For example farnesyltransferase inh ibitors (R115777 and SCH66336) prevent­
ing Ras signal ing and Raf-1 kinase inhibitor BAY 43-9006 3.3s.35_ FKBP7 with the highest 
HR in our study is of interest as FKBPs can be targeted with the immunosuppressant 
drugs FKso6 and rapamycin 57• It is further noteworthy that the data set of Dressman 
et al ind icated an impact of the VEGF signal ing pathway on survival in ovarian cancer, 
since the anti-VEGF monoclonal antibody, bevacizumab, recently showed sign ificant 
antitumor effect in ovarian cancer 58•59• 
In conclusion, our study provides new, validated, insights in molecular changes, both 
at a single gene as well as at a signal ing pathway and transcription factor analysis level 
that are relevant for ovarian cancer behavior, which m ight therefore be exploited in  
the search for new treatment strategies. 
Oeneral discussion and future perspectives 
With the rise of options for targeted drugs, a lso at the horizon in ovarian cancer, it is 
becoming more important that the choice of therapy or combination of therapies 
will be tai lored to the individual patient based on "classic" cl in icopathologic factors 
plus the molecu lar phenotype of the ovarian cancer. In this thesis we have identi­
fied molecular markers and profiles associated with chemoresistance and/or survival 
both in ovarian cancer cell l ines and cancers using several high-throughput profil ing 
techniques. The next step wil l  be to va l idate the prognostic value of the molecular 
markers and profiles, which should preferably be done in large independent sets of 
prospectively col lected ovarian cancers (such as in cl inical trials) to reach level 2 or 1 
c l in ical evidence 4• In add ition, identification of relevant pathways in ovarian cancer 














Summary, general discussion and future perspectives ••• 
lowed by a strategy such as recently described by Bi ld et al 60·61 . I nd ividual (oncogenic) 
pathways were activated in qu iescent cel ls to identify the effects of sing le  pathway 
activation on global gene expression. Using principal components ana lysis gene ex­
pression profi les were then generated, reflecting the activation of specific signa l ing 
pathways. Via such a strategy we would be able to assess the activation status of iden­
tified pathways in an individual tumor sample. Moreover, it wil l  be worth the effort to 
discover potential drugable targets among the identified prognostic molecu lar mark­
ers and pathways. In this search for drugable targets it wi l l  be important to investigate 
whol ly new molecular pathways, as they may play a role in ovarian carcinogenesis by 
mechanisms that are very different from our current paradigms. Furthermore, when 
in the future our knowledge on molecular regulatory networks is extended it may be 
worthwhile to re-analyse the microarray data to try to identify predictive (oncogenic) 
pathway profi les in  advanced stage ovarian cancer. I n  the end, identification of predic­
tive oncogenic pathway profiles might provide an opportun ity for treating individual 
patients with targeted and thereby hopefu l ly  the most appropriate therapy. 
In conclusion, the resu lts presented in this thesis may contribute to reaching the aim 
of patient-tailored therapy and thus increased su rvival for patients with advanced 
stage ovarian cancer. 
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Samenvatting 
De lange termijn overleving voor patienten met uitgezaa ide eierstokkanker is al een 
aantal decennia niet hoger dan 10-30% 1• Het plafond l ijkt bereikt te zijn wat betreft 
de effectiviteit van de momenteel ter besch ikking staande conventionele chemo­
therapie. Eierstokkanker is een heterogene ziekte, zowel kl inisch, pathologisch als 
moleculair. Het zou daarom mogelijk moeten zijn om patienten op basis van een 
genexpressieprofiel van de tumor in verschi l lende groepen te onderscheiden. Als er 
in de toekomst nieuwe medicijnen ter beschikking komen, dan kan er mogelijk  een 
ge"i"ndividualiseerde therapie gegeven worden. In d it proefschrift worden versch i l­
lende studies beschreven, die als doel hebben prognostische molecu laire markers of 
profielen te identificeren in eierstokkanker met behulp van verschi l lende microarray 
technieken, namelijk  DNA, tissue en cytokine bead arrays. 
I n  hoofdstuk 1 wordt, na een korte in leiding, een beschrijving gegeven van de ver­
schil lende studies d ie opgenomen zijn in d it proefschrift. 
In hoofdstuk 2 zijn meta-analyses verricht van studies die de prognostische waarde 
van het tumorsuppressor eiwit p53, het detoxificatie eiwit g lutathione S-transferase pi 
(GST-pi) en de epidermale g roeifactorreceptoren EGFR (HER-1) en HER-2 in patienten 
met eierstokkanker als onderwerp hadden. De resultaten van deze prognostische 
studies waren tegenstrijdig. Een verklaring hiervoor was onder andere gelegen in  
de methodologische verschi l len tussen de studies. Studies naar de prognose van 
patienten met eierstokkanker l iepen sterk u iteen met betrekking tot de studie opzet, 
de inclusiecriteria voor patienten, de gebru ikte technieken om de expressie van mo­
lecu laire markers te bepalen, de expressie afkappunten en de definities van kl inische 
eindpunten. Daarnaast was de studie omvang vaak klein, wat kan leiden tot onder- of 
overschatting van het belang van de molecu laire marker. 
De meta-analyses toonden aan dat patienten met een verhoogde p53, EGFR of HER-2 
expressie in eierstokkanker een geringere kans hadden s jaar te overleven. Verder leek 
de kans om te overlijden aan eierstokkanker hoger te zijn voor patienten met een 
verhoogde GST-pi expressie. Medicijnen gericht op deze molecu laire markers zouden 
wel l icht in de toekomst van therapeutische waarde kunnen zijn 2• 
In hoofdstuk 3 wordt een overzicht gegeven van de recente literatuur over molecu­
laire aangrijpingspunten in eierstokkanker, die specifiek geattaqueerd kunnen worden 
met medicijnen. Het stimuleren van de apoptose route en het remmen van pro-sur­
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Er is waarschijn l ijk n iet een dominante afwijkende molecu laire route in eierstokkanker­
cel l en. Om het antikanker effect te maxima liseren, l ijkt het noodzakelijk te zijn tege l ij­
kertijd meerdere afwijkende routes in de eel plat te leggen. Recent zijn er medicijnen 
ontwikkeld die erop gericht zijn meerdere verschi l lende routes tegel ijkertijd u it te 
schakelen. Een groat aanta l dergel ijke medicijnen wordt momenteel in kl inische stu­
dies getest. Als er in de toekomst nieuwe effectieve medicijnen komen die specifieke 
routes in de eel platleggen, l ijkt de behandel ing en dus de overleving van patienten 
met eierstokkanker mogel ijk verbeterd te kunnen warden. Het type medicijn voor 
patienten met eierstokkanker zou dan op grand van tumoreigenschappen geselec­
teerd kunnen warden 3• 
Zowel in hoofdstuk2  als 3 warden DNA microarraystudies in elerstokkanker samenge­
vat.Voora l de u itdagingen die erzijn op het gebied van het u itvoeren van prognostische 
microarraystudies warden bes pro ken 2·3. Het doel van de meeste microarraystudies is het 
identificeren van diagnostische markers door eierstokkankerweefsel of eierstokkanker­
cellijnen te vergelijken met oppervlakte-epitheel dat normale eierstokken bekleedt. 
Voorts probeert men in veel microarraystudies genen te ontdekken die geassocieerd 
zijn met "klassieke" kl in ische prognostische factoren of chemotherapie-resistentie. Het 
doel van slechts een beperkt aanta l studies was het identificeren van prognostische 
moleculaire markers of profielen zi. De kl inische waarde van prognostische microarray­
studies bereikt slechts niveau 3 of 4 (kleine/retrospectieve stud ies) op een schaa l van 
s (laag) tot 1 (hoog) 4• Prognostische microarraystudies hebben te ma ken met dezelfde 
methodologische problemen a l s  studies naar de prognostische waarde van enkele 
moleculaire markers, zoa ls beschreven in hoofdstuk 1 .  Daarnaast heeft men in prognos­
tische microarraystudies te ma ken met "overfitting"; wanneer een groat aantal poten­
tiele voorspellers gebruikt wordt om onderscheid te maken tussen een klein aantal 
uitkomsten, kan een discriminerend profiel gevonden warden dat op toeva l berust 
en dus n iet reproduceerbaar is '· Het is daarom belangrijk voldoende patienten met 
eierstokkanker te includeren in prognostische microarraystudies. Dit wordt bemoei lijkt 
door de relatieve zeldzaamheid van eierstokkanker, waarvan de incidentie ongeveer 
8 keer lager is dan de incidentie van borstkanker 6• 
In hoofdstuk 4 is onderzocht of de expressie van de epidermale groeifactorrecep­
tor 1 (EGFR/HER-1), gefosforyleerd EGFR (pEGFR), variant 3 van EGFR dat exonen 2-7 
mist (EGFRvl l l), de epidermale groeifactorreceptor 2 (HER-2), het tumorsuppressorgen 
PTEN (fosfatase en tensine homoloog gedeleteerd op chromosoom 10), het onco­
gen AKT, gefosforyleerd AKT (pAKT) en de gefosforyleerde MAP kinase ERK (pERK) 
prognostische waarde heeft voor patienten met u itgezaaide eierstokkanker. Een tis­
sue microarray met weefsel van 232 patienten met eierstokkanker werd immunohis­
tochemisch gekleurd op deze eiwitten . EGFRvl l l expressie werd oak in weefsel van 
226 
45 patienten met eierstokkanker bepaald met reverse transcription polymerase-chain 
reaction (RT-PCR). 
Negatieve PTEN kleuring was geassocieerd met stadium 1/1 1 ziekte (p=o,006), non­
sereuse tumoren (p=o,042) en was een onafhankel ijke voorspeller voor een langere 
progressie vrije overleving (p=o,015). Positieve pAKT kleuring was geassocieerd met 
u itgezaaide ziekte (p=o,006). Geen van de tumoren was positief voor EGFRvl l l  RNA 
of eiwit. De overige eiwitten kwamen al leen laag tot expressie in het weefsel  van 
patienten met eierstokkanker en waren niet geassocieerd met kl inische en patholo­
gische parameters of overleving. Patienten met tumoren met negatieve PTEN kleu­
ring zouden dus een subgroep van eierstokkankerpatienten kunnen representeren 
die een relatief gunstige prognose heeft. 
Er zijn veel versch il lende statistische methoden om de microarraydata te analyseren. 
In hoofdstuk s is factoranalyse toegepast op de microarraydata. Factoranalyse is een 
methode waarmee de biologische contrasten die achter de grate hoeveelheid m icro­
arraydata schu ilgaan zichtbaar gemaakt kunnen warden, door de microarraydata te 
verminderen tot een paar factoren. Nadelen van deze methode zijn dat een biolo­
gisch contrast niet hoeft samen te val len met een enkele factor en dat de factoren 
die biologische contrasten weerspiegelen moei l ijk  te herkennen zijn. Wij formuleerden 
de volgende hypothese: wanneer in het hybridisatieontwerp van de microarrays ook 
contrasten aangebracht warden, va l len de biologische contrasten samen met enkele 
factoren, die makkel ijk te herkennen zijn. Dit komt doordat de correlatiestructuu r  van 
de factoren met de arrays het hybridisatieontwerp weerspiegelt. Deze hypothese werd 
getoetst in een microarraystudie, die tot doel had genen te identificeren die geassoci­
eerd zijn in een eierstokkankercel l ijnmodel met cisplatine-resistentie. De A2780 cel l ijn 
en de daarvan afgeleide cisplatine-resistente cellijnen CP70, (30 en C200 werden ge­
hybridiseerd op -18K cDNA microrarrays vol gens een ontwerp dat "Zeltzelf" hybridisa­
ties, dye swaps en onafhankelijke replicaties bevatte. Na toepassing van factorana lyse 
op de microarraydata werden eenvoudig 2 factoren ge·i"dentificeerd, d ie contrasten in  
cisplatine-gevoel igheid tussen de 4 cel l ijnen weerspiegelden. De eerste factor bevatte 
het contrast tussen de cisplatine-gevoelige A2780 cel len en de daarvan afgeleide cis­
platine-resistente cel l ijnen en de tweede factor het contrast tussen de mild resistente 
CP70 cel len en de extreem resistente (30 en C200 cel len. U iteindelijk werden er 315 
genen geselecteerd die geassocieerd waren met cisplatine-resistentie in de 4 cel l ijnen. 
De expressie van 16 genen, collageen type I l l  a lpha 1 (COL3A1), enolase 2 (ENO2), fibro­
blast groeifactor 18 (FGF18), het oncogen jun (JUN), de homeobox transcriptiefactoren 
LIM homeobox 2 (LHX2), MEIS homeobox 1 (MEIS1), MEIS homeobox 2 (MEIS2), pre-B­
eel leukemie homeobox 3 (PBX3), en T-cel leukemie homeobox 1 (TLX1), het gen dat 
codeert voor een eiwit dat lijkt op de van bloedplaatjes afgeleide groeifactorreceptor 
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(SAT), Src homoloog 2 domein bevattende adaptoreiwit B (SHB), TIMP metal lopepti­
dase inhibitor 2 (TIMP2), topoisomerase 1 (TOP1) en het uvea le autoantigen met coi led­
coll domeinen en ankyrine herhalingingen (UACA), werd gevalideerd met RT-PCR. 
Hiermee werd oak de betrouwbaarheid van de analysemethode bevestigd '· 
De TALE (three amino-acid loop extension) homeobox eiwitten MEIS en PBX zijn co­
factoren voor HOX homeoboxeiwitten, die een belangrijke rol spelen bij groei regu la­
tie en differentiatie tijdens de embryogenese. In het eierstokkankercel l ijnmodel voor 
cisp latine-resistentie, beschreven in hoofdstuk 5, was de expressie van MEIS1 ,  MEIS2 
en PBX3 verlaagd onder invloed van chemotherapie. Daarnaast is aangetoond dat het 
MEIS1 gen geampl ificeerd was en verhoogd tot expressie kwam in eierstokkankers 
die werden vergeleken met oppervlakte-epitheel dat normale eierstokken bekleedt. 
Oak was MEIS1 onderdeel van een genexpressieprofiel, specifiek voor eierstokkanker, 
dat eierstokkanker op molecu la ir n iveau van long- en darmkanker kan onderschei­
den 8 '0. Aangezien er geen eiwitexpressie gegevens waren, is in hoofdstuk 6 een 
tissue microarray met tumorweefsel van de primaire operatie van 232 patienten met 
eierstokkanker immunohistochemisch gekleurd op de eiwitten MEIS1, MEIS2 en PBX. 
Van 44 patienten was er op de tissue microarray oak kankerweefsel besch ikbaar dat 
verkregen was na chemotherapie. Van 15 normale eierstokken is de enkele laag ep­
itheel die de eierstokken bekleedt oak gekleurd op deze eiwitten. Daarnaast is de 
expressie van MEIS en PBX genen vergeleken in oppervlakte-epitheel dat normale 
eierstokken bekleedt en andere normale weefsels en in eierstokkanker en andere 
kankersoorten met behu lp van publieke microarraydatasets. 
MEIS1 en 2 en PBX eiwitten kwamen zowel in de celkern a ls in het cytoplasma van 
eierstoktumoren tot expressie. Echter, in het oppervlakte-epitheel dat normale 
eierstokken bekleedt, kwamen MEIS1 en 2 eiwitten a I leen in de celkern tot expressie. In 
het gepaarde pre- en post-chemotherapie weefsel van patienten met eierstokkanker 
werd de expressie van MEIS1 en 2 en PBX eiwitten niet be·fnvloed door chemotherapie. 
MEIS2 eiwitexpressie in de kern was negatief geassocieerd met het stadium, de d iffe­
rentiatiegraad en de overleving. Echter, MEIS2 was geen onafhankel ijke prognostische 
marker. Analyse van de publ ieke microarraydata toonde aan dat MEIS1 RNA zeer hoog 
tot expressie komt in eierstokkankers vergeleken met andere kankersoorten. Dit zijn 
interessante resu ltaten aangezien MEIS en PBX eiwitten het effect van HOX eiwitten, 
die afwijkend in eierstokkankers tot expressie komen vergeleken met normaal opper­
vlakte-epitheel, op hun targetgenen zouden kunnen versterken. Bovendien is aange­
toond dat MEIS, PBX en HOX eiwitten een rol kunnen spelen in processen die leiden 
tot het ontstaan en onderhouden van kanker " »_ Het zou erg interessant zijn MEIS en 
PBX eiwitten met drugs uit te schakelen, aangezien men dan een omvangrijke route 
kan platleggen, die op verschi l lende manieren ingrijpt in het metabol isme en de over-
228 
leving van een kankercel. Uitschakeling van MEIS en PBX is op dit moment a l leen in 
vitro mogelijk met siRNA. 
In Hoofdstuk 7 hebben we geprobeerd voorspellende genen, routes en transcriptie­
factoren te identificeren door onderzoek naar verworven platinum-resistentie te doen. 
De hypothese is dattumorweefsel, verkregen kart na behandeling met platinum d rugs, 
voornamelijk uit chemotherapie-resistente cellen bestaat en dus het molecula ire 
profiel toont dat geassocieerd is met resistentie. Om het effect van selectieve druk van 
platinum drugs op het genexpressieprofiel van eierstokkanker te onderzoeken, heb­
ben wij 10 gepaarde pre- en post-chemotherapie tumorweefsels met elkaar verge­
leken middels -35K oligonucleotide microarrays. Er kwamen 53 genen verschi l lend 
tot expressie tussen pre- en post-chemotherapie tumoren (p<o,001). Na hierarch ische 
clustering werden de pre- en post-chemotherapie tumoren van elkaar gescheiden. 
Onder de 53 genen bevonden zich genen waarvan bekend is dat ze interessant zijn 
voor eierstokkanker. Bijvoorbeeld, integrine a lpha 1 (ITGA1), vasoactief intestinaal pep­
tide (VIP) en l id van de RAS oncogen fami l ie (RAP2B), d ie een hogere expressie hebben 
in post-chemotherapie tumoren. Met behu lp van Affymetrix HG-U95Av2 ol igonucle­
otide arrays is aangetoond dat ITGA1 tot overexpressie komt in de van A2780 afgeleide 
oxal ip latine-resistente cel l ijn, A2780/C10 vergeleken met de moedercel l ijn 23• De VIP 
antagonist JV-1-52 verminderde de gevoel igheid voor kanker in naakte muizen die 
een UCl-107 cel l ijn transplantaat hadden en remde de groei van de tumoren 24• De 
Phosphol ipase (-epsilon route wordt geactiveerd door Epac, die de GTP-lading op 
RAP2B katalyseert, wat leidt tot Phospholipase (-epsilon activatie. I n  eierstokkanker 
cel len (OVCAR 3 cel len) is aangetoond dat RAP een rol speelt in het stimu lerende ef­
fect van EPAC op celadhesie 25• Verder, van vroeg groei respons gen 2 (EGR2), dat een 
lagere expressie heeft in post-chemotherapie tumoren, i s  aangetoond dat de expres­
sie verlaagd is in eierstoktumoren vergeleken met normaal eierstokweefsel. EGR2 l ijkt 
bovendien een rol te spelen in de PTEN groei-onderdrukkende route 26•27. 
Naast de 53 genen zijn er 18 KEGG routes en 15 TRED transcriptiefactoren ontdekt die 
geassocieerd zijn met verworven platinum-resistentie. Van een aantal van deze routes 
en transcriptiefactoren is bekend dat zij een rol spelen in eierstokkanker. Bijvoorbeeld, 
in eierstokkanker zijn de celcyclus, Wnt, Jak-STAT en MAPK routes, welke in deze stu­
die met platinum-resistentie geassocieerd waren, afwijkend 3·28 31• Daarnaast is van de 
ge·1dentificeerde transcriptiefactoren AP-2alpha, c-Ets-1, E2F, C/EBP en CREB bekend 
dat ze een rol spelen in  eierstokkanker 32 38. Bovendien, zijn 17/18 KEGG routes en 12/15 
transcriptiefactoren ook geassocieerd met overleving in onze microarraystudie met 
157 patienten die uitgezaaid eierstokkanker hadden. 17/18 routes en 11/15 transcriptie­
factoren zijn ook geassocieerd met overleving in een publ ieke dataset van Dressman 
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Onze studie geeft dus nieuwe aanwijzingen welke genen, intracel lu la ire routes en 
transcriptiefactoren mogel ijk betrokken zijn bij verworven platinum-resistentie in 
eieistokkanker en als molecu la ire aangrijpingspunten zouden kunnen d ienen, die 
specifiek geattaqueerd kunnen worden met medicijnen. 
In hoofdstuk 8 is onderzocht of serum cytokinebepalingen diagnostische en prog­
nostische waarde hebben voor patienten met eierstokkan ker. Met behulp van een 
cytokine bead array zij n  in het serum van 187 patienten met eierstokkanker, van 45 
patienten met een goedaardige eierstoktumor en van so gezonde controle personen, 
tegel ijkertijd de waarden van 14 cytokines [interleukine ,a lpha ( I L-10), IL-2, I L-4, I L-6, IL-7, 
IL-8, I L-10, IL-15, de granulocyt kolonie-stimu lerende groeifactor (G-CSF), de granulo­
cyt en macrofaag kolonie-stimu lerende groeifactor (GM-CSF), eosinofiele granu locyt 
chemoattractieve prote·ine (eotaxine), monocyt chemoattractieve prote'ine-1 (MCP-
1), macrofage inflammatoire prote'ine-1a lpha (MIP-,a) en interferon-gamma geTn­
duceerd prote'ine-10 (IP-10)] bepaald. Daarnaast is in a l le serum monsters de tumor­
maker CA-125 gemeten. Een combinatie van IL-7 en CA-125 metingen kon 69% van 
de kwaadaard ige en 100% van de goedaardige eierstoktumoren correct voorspel len. 
B ij de analyse naar de onderl inge samenhang van atle cytokines, een zogenaamde 
multivariate analyse, waren IL-7 en IL-10 onafhankelijke voorspel lers voor overleving. 
Echter, wanneer in  de a nalyse ook de kl in ische en patholog ische variabe len werden 
meegenomen, waren a l leen stadium en de hoeveel heid resttumor na de operatie 
onafhankelijke voorspel lers voor overleving. 
Hetdoel van hoofdstuk9was hetontdekken van een prognostisch genexpressieprofiel 
voorspel lend voor overleving van patienten (N=157) met u itgezaaide eierstokkanker 
door middel van -35K ol igonucleotide microarrays. Daarnaast is onderzocht wel ke 
intracel lu laire routes en transcriptiefactoren geassocieerd zijn met overleving. Het 
gei'dentificeerde 86-genprofiel voor overleving presteerde beter dan toeval (p=o,015). 
Het prognostisch genexpressieprofiel bevat enkele interessante genen. Hoge expres­
sie van het pro-apoptotisch gen BAX is geassocieerd met een betere prognose in onze 
studie. In voorgaande studies is ook een verband aangetoond tussen BAX expressie 
en reacrie op chemotherapie en overleving in eierstokkanker 40 43• Hoge expressie van 
Ras inhibitor 1 (RIN1) en lage expressie van Ras-l ijkend zonder CAAX, (RIT7) zijn ook ge­
associeerd met een betere overleving, wat overeenkomt met eerdere studies die laten 
zien dat geactiveerd Ras bijdraagt aan het onderhouden en de groei van eierstoktu­
moren 44. Verder is beschreven dat OSM, JAK2, en CNTFR componenten zijn van de 
intracel lu laire Jak-STAT route, d ie celprol iferatie, d ifferentiatie, migratie en apoptose 
kan stimu leren 45• OSM is een krachtige onderdrukker van cel proliferatie en induceert 
differentiatie in meerdere weefseltypes 46. Daarnaast is bekend dat FGFBP1 en FGFR1 
een interactie aangaan met de fi broblast groeifactoren FGF1 en FGF2 en er wordt ge-
230 
suggereerd dat de fibroblast groeifactoren kunnen dienen als een angiogene switch 
in humaan kanker 47 49• Ons prognostisch genexpressieprofiel is geva l ideerd in een 
publ ieke dataset van Dressman et al met 118 primaire eierstoktumoren 39• Genen van 
het 86-genprofiel konden ook onderscheid maken tussen een laag- en hoog-riscico 
groep in deze onafhankel ijke dataset (p<o.0001, log-rank). 
Daarnaast waren in onze dataset 17 intracel lu la ire routes en 13 transcriptiefactoren 
geassocieerd met overleving. Er werden enkele interessante routes ontdekt waarvan 
eerder beschreven is dat ze een rol spelen in eierstokkanker, zoa ls de celcyclus, Wnt, 
Jak-STAT en MAPK routes 128 3'. Daarnaast, is ook getoond dat de transcriptiefactoren 
AP-2a lpha, c-Ets-1, E2F, C/EBP en CREB, die in onze studie geassocieerd zijn met ver­
worven chemoresistentie, betrokken zijn bij eierstokkanker 32 38. 16/17 routes en 12/13 
transcriptiefactoren ontdekt in onze dataset waren ook geassocieerd met overleving 
in de publ ieke dataset van Dressman et a l  39. 
Er warden momenteel therapeutische opties onderzocht die een aangrijpingspunt 
hebben in enkele ontdekte intracel lulaire routes 3•28•29• Voorbeelden zijn farnesyltrans­
ferase inhibitors (R115777 and SCH66336) die Ras signalering voorkomen en Raf-1 kinase 
inhibitor BAY 43-9006 3•28•29• Daarnaast is FKBP7 interessant aangezien het de hoogste 
hazard ratio heeft in onze studie en er medicijnen zijn zoals FKso6 en rapamycine, die 
specifiek gericht zijn tegen FKBPs 50• 
Concluderend, verschaft onze studie nieuwe geva l ideerde aanwijzingen welke mole­
culaire veranderingen van belang zouden kunnen zijn in eierstokkanker en specifiek 
geattaqueerd zouden kunnen warden met medicijnen. 
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